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After birth rapid metabolic adaptation is required to establish glucose homeostasis. 
Preterm birth disrupts normal timing of this physiological adaptation putting premature 
neonates at risk of hypo- and hyperglycaemia. 
A major barrier to conducting pharmacokinetic studies in neonates is the relatively 
large volume of blood required by most assays. The use of dried blood spots (DBS) has 
the potential to enable the use of smaller sample volumes and simplifies processing and 
handling. However, haematocrit in neonates varies significantly and can affect the 
accuracy of DBS assays.  
Insulin and C-peptide are secreted in equimolar amounts from the pancreas. C-peptide 
can be used as a biomarker for insulin secretion as, unlike insulin, it is not hepatically 
cleared and has a longer plasma half-life. Urinary C-peptide may give a non-invasive 
way of measuring insulin production in neonates. The insulin/C-peptide (I/CP) ratio 
gives an indication of relative insulin clearance in adults but normal ranges have not 
been reported in neonates. Premature neonates have significantly higher fasting levels 
of glucagon-like peptide-1 (GLP-1) than adults and are increased even further with 
feeding. 
Hyperglycaemia can often occur in extremely premature neonates and is associated 
with an increase in morbidity and mortality. Insulin resistance is a key issue in preterm 
neonates and it is thought that hyperglycaemia is a consequence of relative insulin 
deficiency.  
Aims  
The aims of this research were: to investigate the use of a DBS assay for measuring 
insulin concentrations to improve sampling for pharmacokinetic studies; to describe the 
relationship between C-peptide and insulin secretion in the neonatal population; to 
investigate the relationship between feeding, incretin (GLP-1) and insulin secretion in 
neonates. Finally, to compare these results with neonates treated with insulin for 





Blood samples, DBS and urine samples were obtained from euglycaemic and 
hyperglycaemic insulin-treated preterm neonates admitted into the Dunedin Hospital 
Neonatal Intensive Care Unit (NICU) for this research project.  
DBS of varying haematocrit (0.25-0.65) were prepared at three insulin plasma 
concentrations (10, 25 and 50mU/L) and were analysed for insulin using the method 
developed by Butter et al (2001). DBS and paired plasma samples were obtained from 
neonates. 
Standard addition and direct measurement from the kit standard curve were compared 
for measurement of urinary C-peptide. Insulin concentrations in plasma, along with    
C-peptide concentrations in plasma and urine (diluted to 40%) were measured in 20 
neonates. Urine volume and time of collection were recorded and used to calculate     
C-peptide urinary excretion rate (UER) and clearance (Cl).  
Samples for 102 euglycaemic neonates were obtained from leftover blood from routine 
tests. Samples were obtained for 10 hyperglycaemic insulin-treated neonates and there 
were 9 for which additional blood was collected at the same time as the patients’ 
routine four hourly blood glucose test over a 24-hour period (6 samples).  
Data were collected from clinical notes for gestational age (GA), postmenstrual age 
(PMA), postnatal age, birth weight, current weight, birth length, birth head 
circumference, oral intake, and intravenous fluids at time of samples. Insulin and C-
peptide concentrations from the hyperglycaemic insulin-treated neonates were 
compared with a group of age-matched (PMA <30 weeks) euglycaemic neonates. 
Plasma was analysed for insulin and C-peptide using chemiluminescent kits (Invitron, 
UK), GLP-1 and glucagon using ELISA kits (BioCore Pty Ltd, Australia). Statistical 
analyses were performed using Stata/IC (Version 11.2). 
Results  
Insulin chemiluminescence responses were significantly lower at higher haematocrit 
values (p <0.05). All results showed high variability (CV% = 9 to 61%). Calculated 
whole blood concentrations were plotted against chemiluminescence and an 
exponential function (𝑦 = 𝑎𝑒%&) fitted. Plasma insulin concentrations from neonatal 
DBS were typically higher than paired plasma samples. 
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There were no significant differences between the standard addition and direct 
measurement concentrations (p >0.05). Direct measurement from kit standards 
produced a more precise and simple method for determining C-peptide concentration. 
The mean (SD) C-peptide Cl was 0.309 (0.329) mL/min/kg and UER was 0.0329 
(0.0342) pmol/min/kg.  Correlations between Cl or UER and gestational age were not 
significant (p >0.05). No significant correlation was shown between UER or Cl and 
blood glucose concentration (BGC). 
Insulin and C-peptide concentrations were elevated in very preterm infants (PMA ≤32 
weeks) and decreased as the neonate approached term.  Data were natural log normally 
distributed and linear regression of ln-transformed data was performed. Linear 
regressions showed that I/CP ratio and insulin/BGC (I/BGC) ratio decreased 
significantly with increasing PMA (p <0.001). ANOVA showed GLP-1 increased 
following initial oral feeds regardless of PMA (p <0.001). 
C-peptide concentrations were significantly lower in the hyperglycaemic neonates 
indicating lower insulin production in hyperglycaemic neonates. Insulin concentrations, 
blood glucose concentrations, C-peptide concentrations and I/CP ratios were all 
significantly affected by PMA (p <0.01) in the hyperglycaemic neonates. As expected 
insulin concentrations were higher in the hyperglycaemic neonates confirming that 
exogenous insulin is reaching these neonates intravenously and not retained in the i.v 
apparatus. 
Conclusions  
Measuring plasma insulin concentrations with DBS in neonates is not an ideal method 
due to high variability. Since GA and BGC did not appear to affect Cl and UER, 
urinary C-peptide may provide a non-invasive method of measuring insulin production 
in neonates. 
Preterm neonates exhibit insulin resistance irrespective of hyperglycaemia. The 
significantly higher GLP-1 concentrations in fed neonates confirm that enteral feeds 
result in an increase in GLP-1. These factors are likely to contribute to the increased 
risk of hyperglycaemia in premature neonates (PMA <32 weeks). C-peptide 
concentrations were significantly lower in the hyperglycaemic neonates indicating 
lower insulin production in hyperglycaemic neonates. Treatment with exogenous 
insulin did not suppress insulin production in these neonates.  
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1 General introduction 
1.1 Neonates 
A neonate is a newborn baby up to the first 28 days after birth (World-Health-
Organization, 2004). The length of a normal pregnancy, or term, is between 37 and 42 
weeks of gestation (World-Health-Organization, 2004). A baby born before 37 weeks 
gestation is known as preterm and after 42 weeks is known as post-term (World-
Health-Organization, 2004). 
1.1.1 The preterm neonate 
Preterm birth is defined as babies born alive before 37 weeks gestation with extremely 
preterm being <28 weeks, very preterm: 28 to <32 weeks and moderate to late preterm: 
32 to <37 weeks gestation (March-of-Dimes et al., 2012). The incidence of preterm 
births is increasing worldwide with approximately 1 in 10 of all births being preterm 
(March-of-Dimes et al., 2012). Neonates born with a birth weight of less than 2500 g 
are classed as low birth weight (LBW), less than 1500 g as very low birth weight 
(VLBW) and less than 1000 g as extremely low birth weight (ELBW) (World-Health-
Organization, 2004). 
The most common cause of mortality in neonates is complications related to preterm 
birth which has been reported by the World Health Organisation (WHO) as causing 
over one million neonatal deaths each year (March-of-Dimes et al., 2012). Preterm 
birth is the second leading cause of death after pneumonia in children under five years 
of age with 40% of deaths in under five year olds being neonates (March-of-Dimes et 
al., 2012). Approximately half of neonates born at 24 weeks gestation in high-income 
countries survive whereas in low-income countries only half survive at 32 weeks 
gestation (March-of-Dimes et al., 2012). Intensive care is required to save the majority 
of neonates born before 28 weeks gestation and this is not available in low-income 
countries (March-of-Dimes et al., 2012). This difference in neonatal survival reflects 
the lack of feasible and cost effective care such as basic care for infections, breathing 
difficulties, warmth and breastfeeding support in the low-income countries (March-of-
Dimes et al., 2012).  
Prematurity is associated with a number of short-term and long-term health problems 
but it is unclear if these health problems are a direct consequence of preterm birth or are 
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due to other associated factors (Harding et al., 2013). For example, a suboptimal 
uterine environment may lead to reduced foetal growth, preterm birth and be 
responsible for the subsequent long-term health problems (Harding et al., 2013). Poor 
maternal nutrition and underweight mothers pre-pregnancy may also increase the risk 
of preterm birth and poor maternal nutrition is also associated with poor long-term 
health in the neonate (Harding et al., 2013). 
At birth preterm neonates are at risk of hypoxia due to a failure to establish a fully 
functioning pulmonary circulation and are also susceptible to intestinal tract infections 
(Beath, 2003). They are also at risk of hypoglycaemia due to reduced adipose tissue and 
glycogen stores, also gluconeogenesis (glucose production from non-carbohydrate 
sources) seems to be ineffective as energy is diverted to heat rather than generating 
glucose (Beath, 2003). 
After birth, preterm neonates require nutrition provided by intravenous and enteral 
routes rather than what would normally be still provided by the placenta (Thureen & 
Hay, 2012). This results in these neonates having unique nutritional requirements 
(Thureen & Hay, 2012). Preterm neonates are exposed to early environmental stress 
and suboptimal nutrition (Harding et al., 2013). This nutritional disruption is caused by 
inadequate nutrient intake is a major contributor to failure to thrive postnatally 
(Harding et al., 2013). Very preterm neonates have high energy requirement (9 to 10 
mg/kg/min compared with 3 to 4 mg/kg/min in term neonates) and require a large 
continuous supply of glucose for energy metabolism as glycogen content is limited 
(Thureen & Hay, 2012). This puts these neonates at risk of hypoglycaemia (Thureen & 
Hay, 2012). Glucose should be provided at a rate of about 30 to 45 kcal/kg/day in very 
preterm neonates (Thureen & Hay, 2012). Intravenous lipids are administered to 
prevent essential fatty acid deficiency but metabolism may be impeded due to 
immaturity of triglyceride and fatty acid metabolism and other clinical conditions such 
as stress, malnutrition and infection (Thureen & Hay, 2012). Consequently 
hyperlipemia can occur particularly in more stressed and unstable preterm neonates 
(Thureen & Hay, 2012). Lipids should be provided at a rate of about 20 to 40 
kcal/kg/day (Thureen & Hay, 2012). Increased protein intake in preterm neonates 
produces a greater gain in protein balance as preterm neonates cannot grow without 
more protein and have to rely on carbohydrate and lipid for energy production when 
amino acid and protein supplies are low (Thureen & Hay, 2012). Early amino acid 
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administration is crucial to avoid protein malnutrition and the target is to achieve foetal 
protein rates of at least 3 g/kg/day (Thureen & Hay, 2012). This rate of postnatal amino 
acid administration appears to be around 3.5 g/kg/day (Thureen & Hay, 2012). Enteral 
feeding usually starts as soon as possible with feeds on day one comprising the 
mother’s colostrum when possible (Thureen & Hay, 2012). 
1.1.2 Glucose homeostasis in neonates 
Glucose concentrations are tightly maintained in healthy humans despite wide 
fluctuations in the consumption, utilisation, and production of insulin (Powers & 
D'Alessio, 2011). Glucose homeostasis involves the integration of major organs in a 
highly developed process (Powers & D'Alessio, 2011). The β-cells of the pancreas are 
crucial to glucose homeostasis, promoting glucose uptake after meals by adjusting the 
amount of insulin secreted and regulating glucose output from the liver in the fasted 
state (Powers & D'Alessio, 2011). 
Glucose passage through cell membranes is mediated by transporters and these 
transporters can be divided into two forms: secondary active transporters and facilitated 
transporters (Brown, 2000). There are four well defined facilitated glucose transporters 
(GLUT 1 - 4) (Brown, 2000) . GLUT-1 is the main transporter found in foetal tissues 
and efficiently transports glucose to the organs and has a high affinity to glucose 
(Mericq, 2006). After birth, GLUT-1 concentrations decrease while the concentrations 
of GLUT-2 in the liver, GLUT-3 in the brain and neurons and GLUT-4 in muscle all 
increase (Mericq, 2006). Concentrations of GLUT-1 are negatively regulated by 
glucose and have an important role in the blood-brain barrier (Mericq, 2006). GLUT-3 
regulates glucose uptake by neurones and GLUT-4 concentrations are not influenced by 
glucose but are positively regulated by insulin in muscle and adipose tissue (Mericq, 
2006). 
Glucose homeostasis is a major clinical issue in both preterm and term neonates. In the 
preterm neonate both hyper- and hypoglycaeamia can occur, while in the term neonate 
the issue is primarily hypoglycaemia. Hypoglycaemia in preterm neonates has been 
associated with adverse neurological outcomes and in term neonates permanent 
neurological damage (Hume et al., 2005). Hyperglycaemia in preterm neonates is 
associated with an increased risk of early death (Hays et al., 2006, Kao et al., 2006), 
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intraventricular haemorrhage (Hays et al., 2006), sepsis (Kao et al., 2006) and an 
increased incidence of retinopathy of prematurity (Blanco et al., 2006). 
The molar insulin/C-peptide (I/CP) ratio gives an indication of fasting hepatic insulin 
clearance in adults (Hilton et al., 2001). In normal healthy adults this ratio does not 
exceed 1.0 unless the patient is receiving exogenous insulin or has liver cirrhosis (Iwase 
et al., 2001). Normal I/CP ratios have not been reported in neonates and I/CP may be 
used as an indicator of both insulin clearance and production. If preterm neonates are 
resistant to insulin it would be expected that the I/CP ratio is affected by gestational age 
(GA). 
 
Figure 1.1 Glucose homeostasis in neonates. 
1.1.2.1 Foetal glucose homeostasis 
Foetal glucose homeostasis depends on placental glucose transfer (Beardsall et al., 
2008, Mitanchez, 2007, Mena et al., 2001). Glucose is the main energy source for the 
development of the foetus and is supplied continuously from the mother (Mitanchez, 
2007, Beardsall et al., 2008). Transport across the placenta is mediated by insulin-
dependent GLUT-1 by facilitated diffusion (Slack, 1995). 
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Early in the second trimester insulin activity is present in the foetus but it is not 
functional until later in the second trimester with the onset of corticosteroid action 
(Mena et al., 2001). The foetal pancreas starts releasing insulin in response to nutrients 
such as glucose and amino acids after 20 weeks gestation (Mena et al., 2001). 
Development of the foetal pancreas is regulated by transcription factors and β-cell 
proliferation and differentiation is dependent on growth factors such as insulin-like 
growth factors (Hill & Duvillie, 2000, Hill et al., 1998). Insulin does not cross the 
placenta so the foetus is dependent on secretion from its own pancreas and increasing 
insulin secretion is required for normal growth towards the end of pregnancy (Beardsall 
et al., 2008). Glucose homeostasis in the foetus is regulated by insulin in the third 
trimester by promoting muscle and liver glucose uptake (Mena et al., 2001, Beardsall et 
al., 2008). This results in glycogen synthesis, decreases breakdown of glycogen, 
enhances fatty acid synthesis in the liver and glucose uptake in adipose tissues leading 
to triglyceride synthesis (Mena et al., 2001). 
Glycogen synthesis also begins in the second trimester and increases until 36 weeks 
when the hepatic glycogen content increases rapidly until full term (Mitanchez, 2007). 
Gluconeogenesis is not functional in utero as it is inhibited by high foetal insulin 
concentrations (Mitanchez, 2007). The placenta is permeable to triglycerides, free fatty 
acids and glycerol which permit fat storage in adipose tissue in the third trimester when 
the foetus stores fat in preparation for birth (Mitanchez, 2007). The stores of glycogen 
and fat are required for numerous adaptations that occur at birth such as an initial 
decrease in glucose and insulin and a surge in glucagon (Beardsall et al., 2008, Platt & 
Deshpande, 2005). 
1.1.2.2 Glucose homeostasis in the term neonate 
At birth maternal nutrients are suddenly discontinued and the neonate is forced to 
activate its own glucose production to preserve fuel supplies for vital functions until the 
first exogenous nutritional intake (Platt & Deshpande, 2005). Plasma insulin 
concentrations in the neonate fall rapidly resulting in a surge in plasma immunoreactive 
glucagon (Mitanchez, 2007, Platt & Deshpande, 2005). The metabolic changes at birth 
induce hepatic glucose production through glycogenolysis for the first few hours and 
then subsequently gluconeogenesis (Beardsall et al., 2008, Hume et al., 2005, Mena et 
al., 2001, Mitanchez, 2007, Mitanchez, 2008). 
Chapter one – General introduction 
 8 
Elevated concentrations in the first day of life of the hormone thyrotropin stimulate 
hydrolysis of fat depots (Beardsall et al., 2008). This provides energy and ketone body 
production (Beardsall et al., 2008, Mitanchez, 2008) as alternative fuel for brain 
metabolism (Mitanchez, 2008). An equilibrium between glucose in tissue, hepatic 
glucose and exogenous glucose supply maintain the blood glucose concentration of a 
neonate and if one mechanism fails hypoglycaemia may occur (Mitanchez, 2008). 
Insulin secretion also becomes coupled with the oral supply of milk and incretin release 
(Beardsall et al., 2008). 
The foetus has a balance between β-cell replication, neogenesis, apoptosis (Beardsall et 
al., 2008) and insulin release from β-cells is poorly responsive to glucose (Hill & 
Duvillie, 2000). After birth β-cell apoptosis appears to occur (Beardsall et al., 2008, 
Hill & Duvillie, 2000) and the β-cells are replaced with new islet cells in a second wave 
of neogenesis (Hill & Duvillie, 2000). These new cells are sensitive to glucose with 
acute, first phase insulin release (Hill & Duvillie, 2000). Any interference with this 
remodelling process may have a critical impact on the pancreas’ ability to meet 
requirements for insulin secretion later in life (Beardsall et al., 2008). As enteral 
feeding increases over the first few days and hepatic gluconeogenesis matures, blood 
glucose concentrations stabilise (Hume et al., 2005). The neonate now has to adjust to 
alternating periods of feeding and fasting (Platt & Deshpande, 2005). 
Maternal diabetes and obesity as risk factors which overlap for complications in term 
neonates (Hildén et al., 2016) Obesity and gestational diabetes have both been shown 
to independently increase the rates of preeclampsia, caesarean section and macrosomia 
(Hildén et al., 2016). Obesity is significantly associated with increased NICU 
admission in term neonates mainly due to an increasing frequency of hypoglycaemia 
(Suk et al., 2016). Infants of diabetic mothers frequently have low blood glucose 
concentrations and hypoglycaemia has the highest incidence at 4 to 6 hours after birth 
(Platt & Deshpande, 2005, Andersen et al., 1986). The risk of neonatal hypoglycaemia 
decreases when maternal plasma glucose concentrations are less than 7.1 mmol/L and 
can therefore be avoided if maternal blood glucose concentrations are kept within the 
normal range (Andersen et al., 1986). 
Studies have reported insulin concentrations of 3 to 20 µU/mL (18 to 120 pmol/L) in 
term neonates (Gesteiro et al., 2009). Gesteiro et al. (2009) found a mean insulin 
concentration of 5.5 µU/mL (33 pmol/L), Mitanchez-Mokhtari et al. (2004) 4.66 mU/L 
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(28 pmol/L) and Mitanchez (2007) 2.5 mU/L (15 pmol/L) in term neonates. The mean 
C-peptide concentrations in term neonates reported are 0.62 nmol/L (620 pmol/L) by 
Mitanchez-Mokhtari et al. (2004) and 0.52 nmol/L (520pmol/L) by Mitanchez (2007). 
Gesteiro et al. (2009) reported a mean glucose concentration of 75.3 mg/dL 
(4.2 mmol/L) and Mitanchez (2007) reported a mean glucagon concentration of 224 
pmol/L in term neonates.  
1.1.2.3 Glucose homeostasis in the preterm neonate 
Preterm birth disrupts normal timing of physiological adaptation of insulin secretion 
(Beardsall et al., 2010). This exposes preterm neonates to the risk of abnormal glucose 
homeostasis (Mericq, 2006). Preterm neonates do not have increased cortisol 
concentrations associated with delivery which is needed for maturation of the enzymes 
required for gluconeogenesis (Beardsall et al., 2008). Immaturities in glucose 
homeostasis mechanisms can result in hypoglycaemia in the first day or 
hyperglycaemia during the first week after birth (Beardsall et al., 2008). Preterm 
neonates have lower glycogen reserves, lower gluconeogenic enzyme activity, and 
initial limited hormone response and lower blood glucose concentrations with a slower 
postnatal rise (Hume et al., 2005). In utero studies suggest that there is an increase in 
insulin concentrations towards term, however neonatal studies have shown that plasma 
glucose and insulin concentrations are higher in preterm that term neonates (Beardsall 
et al., 2008). There is often a delay in the establishment of enteral feeds and the 
delivery of glucose intravenously means that the normal postnatal association of 
nutritional delivery with the stimulation of incretins does not occur (Beardsall et al., 
2008, Beardsall & Dunger, 2008). The role of incretins in neonates had not been well 
studied however in adults incretins augment insulin secretion after meals (Beardsall & 
Dunger, 2008).  
Mitanchez (2007) observed lower plasma glucagon concentrations (mean of 
104 pmol/L) and a higher insulin/glucagon ratio in preterm neonates. The mean insulin 
concentrations in preterm neonates reported are 8.6 mU/L (51.6 pmol/L) by Mitanchez 
(2007) and 11.9 mU/L (71.4 pmol/L) by Mitanchez-Mokhtari et al. (2004). The mean 
C-peptide concentrations in preterm neonates reported are 1.1 nmol/L (1100 pmol/L) 
by Mitanchez (2007) and 1.45 nmol/L (1450 pmol/L) by Mitanchez-Mokhtari et al. 
(2004). Both of these studies found higher insulin and C-peptide concentrations in 
preterm neonates compared with term neonates. 
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1.1.2.4 Hyperglycaemia in the preterm neonate 
There is no clear definition for hyperglycaemia in neonates, however, adverse clinical 
outcomes have been associated with elevated blood glucose concentrations (depending 
on the study, above 8.3 to 12 mmol/L) in neonates (Bottino et al., 2009). Adverse 
outcomes include death (Hays et al., 2006, Kao et al., 2006), intraventricular 
haemorrhage (Hays et al., 2006), late onset bacterial infection, necrotising enterocolitis 
(Kao et al., 2006), fungal infection (Manzoni et al., 2006), and retinopathy of 
prematurity (ROP) (Blanco et al., 2006). 
There is little agreement about what blood glucose concentration defines neonatal 
hyperglycaemia (Alsweiler et al., 2007). Hyperglycaemia in the neonate has been 
defined as blood glucose concentration greater than 7 mmol/L or plasma glucose 
concentration greater than 8.25 mmol/L (Mitanchez, 2007). The threshold for 
hyperglycaemia used in different studies has varied: >8.3 mmol/L, >8.5 mmol/L, 
>10.0 mmol/L or >12.0 mmol/L (Bottino et al., 2009). Blood glucose concentrations 
that are considered clinically elevated range from 7 to 14 mmol/L (Ditzenberger et al., 
1999). A survey conducted in Australasia that included 23 tertiary Neonatal Intensive 
Care Units, reported six different definitions of hyperglycaemia with most units 
defining hyperglycaemia as a blood glucose concentration above 10 mmol/L (Alsweiler 
et al., 2007). 
The incidence of hyperglycaemia in premature infants varies between 20% and 86%, 
depending on the definition and the population studied (Ditzenberger et al., 1999). 
Neonates weighing less than 1000 g are 18 times more likely to develop 
hyperglycaemia than those weighing more than 2000 g (Mitanchez, 2007). The 
increasing survival of preterm neonates and the use of early and aggressive parenteral 
nutrition have resulted in an increased frequency of hyperglycaemia (Bottino et al., 
2009). 
There have been increased risks of death and major morbidities observed among 
neonates who develop hyperglycaemia and it is uncertain whether the hyperglycaemia 
is a cause of the adverse outcomes or whether treatment can reduce the adverse 
outcomes (Bottino et al., 2009). The risk of hyperglycaemia is increased by conditions 
that cause stress, such as asphyxia, respiratory distress, intraventricular haemorrhage, 
sepsis, or surgical procedures (Ditzenberger et al., 1999). Continuous infusion of 
glucose or lipids and the administration of some drugs, such as corticosteroids, 
Chapter one – General introduction 
 11 
aminophylline and caffeine, may also induce hyperglycaemic reactions in neonates 
(Ditzenberger et al., 1999). Alaedeen et al. (2006) showed that total parenteral nutrition 
associated hyperglycaemia in septic very low-birth-weight infants was significantly 
related to morbidity and mortality. The causes of hyperglycaemia in the early neonatal 
period in low birth weight preterm neonates appeared to be multifactorial (Beardsall et 
al., 2007). 
The main treatments for hyperglycaemia include reducing the rate of parenteral glucose 
infusion or treating with intravenous insulin (Bottino et al., 2009). However, there is 
not sufficient evidence to determine whether these treatments reduce mortality and 
morbidity in hyperglycaemic neonates (Bottino et al., 2009). Insulin treatment is 
associated with an increase in energy, glucose intake and greater short-term weight gain 
(Bottino et al., 2009). Insulin is used to manage hyperkalaemia, to control 
hyperglycaemia and to optimize parenteral nutrition for the preterm neonate less than 
1000 g (Ditzenberger et al., 1999). A study by Alsweiler et al. (2012), questioned the 
common use of insulin in managing neonatal hyperglycaemia as few data support its 
use. They found that tight glycaemic control (4 to 6 mmol/L) with insulin in 
hyperglycaemic preterm neonates decreased the rate of linear growth despite an 
increase in weight and head circumference, suggesting that an increase in fat rather than 
lean mass was achieved (Alsweiler et al., 2012). They concluded that the balance of 
risks and benefits of insulin treatment in hyperglycaemic preterm neonates remains 
uncertain (Alsweiler et al., 2012). The Dunedin Hospital Neonatal Intensive Care Unit 
current practice defines clinically significant hyperglycaemia as a blood glucose 
concentration of 10 mmol/L or more, for two consecutive concentrations, four hours 
apart. Treatment involves administration of insulin by continuous intravenous infusion 
and is dosed using a sliding scale (NICU Medication Manual, Appendix 1). 
1.1.2.5 Hypoglycaemia in the preterm neonate 
Neonates who are at an increased risk of hypoglycaemia and require careful monitoring 
are those born preterm, with intrauterine growth restriction, or to diabetic women, and 
those who are unwell (Deshpande & Ward Platt, 2005). The metabolic adaptation that 
occurs after birth enables neonates to maintain adequate circulating glucose 
concentrations to supply the body’s organs and to adapt to a new form of feeding 
(Hawdon et al., 1994). Neonatal hypoglycaemia can occur when the metabolic 
adaptation after birth fails to occur (Hawdon et al., 1994). In healthy term neonates, 
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establishing normal feeding is all that is needed to enable metabolic adaptation 
(Deshpande & Ward Platt, 2005). However in the preterm neonate, the rapid fall in 
blood glucose concentration after birth is more difficult to counter-regulate due to the 
neonate’s reduced stores of glycogen and adipose tissue, and immature hormone and 
enzyme systems (Platt & Hawdon, 1993, Hawdon et al., 1994). This can result in a 
prolonged period of hypoglycaemia in preterm neonates compared with term neonates 
(Platt & Hawdon, 1993). Preterm neonates are also at risk of other neurological 
problems such as cerebral ischaemia and therefore blood glucose monitoring is 
important in these neonates (Hawdon et al., 1994). The ratio of brain to body size is 
higher in preterm neonates and as nearly 90% of glucose is utilized by the brain, the 
brain is left unprotected from hypoglycaemia as alternative fuels are not available 
(Mericq, 2006). Hypoglycaemia may lead to adverse neurological outcomes and it is 
associated with abnormal neurodevelopment and reduced brain growth in growth-
retarded preterm neonates (Hume et al., 2005). 
The definition of hypoglycaemia remains controversial resulting in variations in the 
incidence in preterm neonates being reported at between 7 and 57% (Mericq, 2006). 
Identification of a blood glucose concentration below which there is a likelihood of 
functional impairment is important for prevention and treatment of hypoglycaemia 
(Deshpande & Ward Platt, 2005). It has been shown that when blood glucose 
concentrations fall below 2.6 mmol/L, acute cerebral dysfunction occurs in the majority 
of neonates and the evidence to support a higher concentration than 2.6 mmol/L is 
lacking (Hume et al., 2005). Therefore, monitoring of blood glucose concentrations in 
preterm neonates is important and concentrations below 2.6 mmol/L should be avoided 
(Hawdon et al., 1994). The Dunedin NICU defines clinically significant hypoglycaemia 
as a blood glucose concentration less than 2.6 mmol/L (NICU Medication Manual, 
Appendix 1). 
The key to preventing hypoglycaemia is the early administration of intravenous glucose 
in substantially preterm neonates (Platt & Hawdon, 1993). Preterm neonates have an 
impaired ketogenic response to hypoglycaemia meaning that maintaining euglycaemia 
is important to protect neurological function (Platt & Hawdon, 1993). Administering 
dextrose 10% at 72 mL/kg/day provides glucose at the same rate as the average glucose 
production rate in the healthy neonate, and 100 mL/kg/day is used to prevent 
hypoglycaemia (Platt & Hawdon, 1993). Blood glucose concentrations should be 
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measured to confirm this, and glucose infusion rates should be increased where 
required to maintain stable glucose concentrations (Platt & Hawdon, 1993). 
1.1.3 Pharmacokinetic studies in paediatrics and neonates 
There are many documented challenges in conducting PK studies in neonates and 
paediatrics (Meibohm et al., 2005). These include studies in paediatrics covering a 
much larger range in body size in relation to adults (Meibohm et al., 2005). As size 
parameters such as weight, height and body surface area are often highly correlated 
with other maturation related parameters such as renal function or postnatal age in 
neonates it is difficult to estimate the contribution of individual covariates in neonates 
(Meibohm et al., 2005). This lack of PK data has led to a ‘trial-and-error’ approach to 
finding optimal drug dosing regimens in paediatric medicine (Patel et al., 2010). As a 
result paediatric drug dosing is often based on PK data from adults, with the adult dose 
being adjusted to the child’s body weight (Patel et al., 2010). This approach of weight 
adjusted dosing is reported to more likely lead to overdose and toxicity due to 
developmental changes altering drug PK (Patel et al., 2010). Chloramphenicol is an 
example of a drug that has been prescribed at inappropriately high does in paediatrics 
due to differences in PK (Patel et al., 2010). Conversely, there are case reports of drugs 
being prescribed at sub-therapeutic doses in paediatrics based on adult PK data (Patel et 
al., 2010). An example of a drug that can be used sub-therapeutically if prescribed 
based on adult data is aminophylline, which has been found to require higher doses in 
relation to body weight in children and neonates (Patel et al., 2010). 
Although there is a requirement by regulatory agencies to conduct more PK studies in 
neonates and paediatrics there are many challenges that need to be considered. These 
challenges include the great comparative diversity in different age groups and consent, 
recruitment or ethical implications (Zisowsky et al., 2010). Therefore when planning 
paediatric PK studies some factors that need to be considered include: whether the 
disease affects children; if the disease or disease progression in children is similar to 
adults; and if the therapy outcome is likely to be similar to that in adults (Zisowsky et 
al., 2010). If these can be demonstrated, then PK data in paediatrics may be sufficient 
to support an application for paediatric labelling without extensive efficacy 
trials (Zisowsky et al., 2010). However, often these factors are not all addressed and 
clinical efficacy trials are required (Zisowsky et al., 2010). If the relationship between 
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concentration and response for a particular drug is anticipated to be different than 
adults then PKPD studies would also be necessary (Zisowsky et al., 2010). 
Furthermore, drug absorption, distribution and elimination in neonates are different 
compared to paediatrics and adults (Long et al., 1987). Clinical trials to evaluate drugs 
in neonates require multiple blood sampling which can be potentially harmful (Long et 
al., 1987). The European Medicines Agency guideline "Ethical considerations for 
clinical trials on medicinal products with the paediatric population" states that the blood 
sampling volume related to trials must be minimised. Blood loss should not exceed 3% 
of total blood volume over four weeks, and it should not exceed 1% of total blood 
volume at any single time (Zisowsky et al., 2010). Neonates have a blood volume of 85 
to 110 mL/kg2 meaning that extremely preterm infants may have a blood volume of 
only around 50 mL (Long et al., 1987). This results in approximately only 0.5 mL of 
blood being able to be taken at any single time in extremely preterm infants and only 
1.5 mL over four weeks. This creates a barrier in carrying out clinical research due to 
limitations in the number of blood samples obtained from neonates, especially in those 
studies where multiple blood sampling are required, as it is associated with depleted 
blood volume (Long et al., 1987). PK studies that incorporate sparse sampling 
methodology (population PK approach) and reduce the need for repeated blood 
sampling may be advantageous. This is because only two or three blood samples are 
required from each neonate rather than twelve or more samples obtained for traditional 
PK modelling (Patel et al., 2010). Therefore, the population PK approach has been 
recommended by regulatory agencies as the preferred study approach for 
pharmacokinetic studies in paediatrics (Patel et al., 2010). These limited sampling 
studies are becoming more attractive to researchers due to their ability to determine 
important clinical PK information accurately, without bias and provide convenient 
schedules with minimal blood samples and reduced load on laboratories (Meibohm et 
al., 2005). This is important in paediatrics and neonates where, quite often, limited 
sampling PK studies are the only option (Meibohm et al., 2005). Even where the 
volume of blood does not prevent a PK study from taking place, blood sampling can 
make parents and ethics committees hesitant at agreeing to a PK study with neonate 
participants (Patel et al., 2010). 
Pharmacokinetic and pharmacodynamic (PKPD) processes contribute to differences in 
therapeutic efficacy observed between neonates, infants and adults (Alcorn & 
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McNamara, 2003). Functional immaturity in the neonate leads to different responses in 
neonates relative to adults (Alcorn & McNamara, 2003). As an infant matures 
modifications in drug response and toxicity may occur (Alcorn & McNamara, 2003). 
Premature neonates complicate drug PK further due to immaturities in organs and 
biochemical and physiological processes (Alcorn & McNamara, 2003). Clinical studies 
with neonates within defined age groups are required to improve the understanding of 
the PK of different drugs in neonates (Alcorn & McNamara, 2003). 
1.2 Insulin 
1.2.1 Structure 
Human insulin is a polypeptide hormone consisting of 51 amino acid residues in two 
polypeptide chains (A-chain and B-chain) connected by two disulphide bridges (Brange 
& Langkjœr, 1993, De Meyts, 2004, Fu et al., 2013). The A-chain has 21 amino acids 
with an additional disulphide loop between A6 and A11 and the B-chain has 30 amino 
acids (Brange & Langkjœr, 1993, Dodson & Steiner, 1998, Fu et al., 2013) (Figure 
1.2). The A-chain is formed of two nearly antiparallel α-helices; from A2 to A8 and 
A13 to A20 (Brange & Langkjœr, 1993). The B-chain forms a single α-helix from 
residues B9 to B19 followed by a turn and a β-strand from B21 to B30 (Brange & 
Langkjœr, 1993). The A and B chains are joined at A7 - B7 and A20 - B19 by two 
disulphide bonds (Dodson & Steiner, 1998). Insulin circulates in the serum and binds to 
its receptor as a monomer (De Meyts, 2004, Dodson & Steiner, 1998). At micromolar 
concentrations it forms dimers and then hexamers in the presence of zinc ions (Fu et 
al., 2013, De Meyts, 2004, Dodson & Steiner, 1998). Insulin dimers are maintained by 
antiparallel β –sheets at the carboxy terminus of the B-chains (Fu et al., 2013). 
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Figure 1.2 Human insulin amino acid structure. 
1.2.2 Physiology 
Insulin is synthesised as a precursor (preproinsulin) consisting of 110 amino acids in 
the rough endoplasmic reticulum of the ß-cells of the islets of Langerhans (Dodson & 
Steiner, 1998, Fu et al., 2013). Preproinsulin is translocated across the rough 
endoplasmic reticulum membrane, through the peptide-conducting channel into the 
lumen (Fu et al., 2013). Preproinsulin is immediately cleaved by signal peptidase to 
remove the signal sequence and generate proinsulin (Dodson & Steiner, 1998, Fu et al., 
2013). Proinsulin quickly undergoes folding and formation of three disulphide bonds to 
form its three-dimensional structure and is then transported from the endoplasmic 
retitulum into the Golgi apparatus (Dodson & Steiner, 1998, Fu et al., 2013). Proinsulin 
is then cleaved to insulin and C-peptide and stored in the secretory granules of the ß-
cells (Fu et al., 2013). Insulin is stored in the ß-cells and is packed as crystalline 
hexameric insulin in storage granules (Dodson & Steiner, 1998, Fu et al., 2013). These 
hexamers of insulin consist of 3 insulin dimers (Fu et al., 2013).  
Insulin is an important hormone required for normal metabolism and in healthy subjects 
its release is exact to meet metabolic demand (Fu et al., 2013). The production of 
insulin is regulated at the transcriptional level by numerous transcription factors and 
postranscriptionally by mRNA stability and factors that affect protein translation rates 
(Fu et al., 2013). The pancreatic ß-cells respond to nutrients in the blood such as 
glucose, other monosaccarides, fatty acids and amino acids with the major stimulant for 
insulin release being glucose (Fu et al., 2013). To sense the body’s nutritional state the 
ß-cells are clustered in islets that are connected to the vasculature forming a dense 
network that receives ten times the amount of blood than surrounding cells (Fu et al., 
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2013). The ß-cells detect the amount of insulin stored and secreted and adjust insulin 
synthesis with insulin accumulating in the presence of nutrients and decreasing in 
nutrient deprivation (Fu et al., 2013). The metabolic fuel hypothesis proposes that when 
insulin is released after a meal it is linked to the metabolism of glucose by the ß-cells to 
produce adenosine triphosphate (ATP), which is the biochemical signal that triggers 
insulin secretion (Salway, 2006). Immediate environmental triggers can also cause the 
ß-cells to adjust insulin production by regulating the speed of translation (Fu et al., 
2013). The release of insulin in response to a rise in blood glucose is biphasic (Rang et 
al., 2014). There is an initial rapid phase when stored insulin is released and then a 
slower delayed phase where new synthesis occurs as well as stored insulin being 
released (Figure 1.3) (Rang et al., 2014). 
The discovery of insulin in 1921 was one of the most important biomedical events of 
the twentieth century and was the most dramatic event in the history of the treatment of 
diabetes, resulting in extension of the life-span of diabetic patients (Rosenfeld, 2002). 
As a treatment regimen insulin is difficult to use as it has a narrow therapeutic index, 
has an inconsistent magnitude of effect, has to be injected, has fragile physical stability 
and a limited potency (Mayer et al., 2007). However, insulin remains the most effective 
therapy in the treatment of diabetes and its use exceeds any other peptide or protein 
medicine (Mayer et al., 2007). Insulin therapy is used to ideally mimic a healthy 
pancreas in diabetic patients but conventional insulin does not achieve this (Mayer et 
al., 2007). Recombinant DNA technology has allowed modifications of insulin leading 
to the production of insulin analogues in which one or more amino acids in the original 
sequence are replaced (Agin et al., 2007, Andersen et al., 2001). Of these analogues, 
molecules with maintained pharmacodynamic and modified pharmacokinetic profiles 
are now used in newer treatments (Agin et al., 2007). The long-acting insulin analogues 
are used to replace the basal insulin secretion and enable subjects with diabetes to 
maintain more stable glucose levels with less within-subject variation (Jhee et al., 2004, 
Agin et al., 2007). Whereas, the rapid-acting analogues act as the bolus phase at meal 
times (Mayer et al., 2007). 




Figure 1.3 Insulin response during an intravenous glucose tolerance test. The sharp 
increase in insulin release after glucose administration shows the first phase and then 
the more sustained release shows the second phase of insulin release. Reprinted from 
“Insulin secretion in diabetes mellitus”, The American Journal of Medicine Pfeifer et 




Mammalian C-peptide is typically 31 amino acids in length with four or five acidic 
residues (Steiner, 2004, Hoekstra et al., 1982) (Figure 1.4). After cleavage of 
proinsulin, the 31 amino acid C-peptide is secreted into the portal circulation (Wahren 
et al., 2012). 
 
Figure 1.4 Amino acid structure of Human C-peptide. 
1.3.2 Physiology 
Knowledge on the biosynthesis of insulin was limited until proinsulin was identified in 
1967 and was then shown to be cleaved into insulin and C-peptide (Hoekstra et al., 
1982) (Figure 1.5). C-peptide has been a valuable biomarker in diabetes research as it 
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can be used to evaluate ß-cell function while on insulin treatment (Hoekstra et al., 
1982). 
C-peptide is cleaved from proinsulin during insulin synthesis and is secreted into the 
bloodstream in equimolar amounts to insulin (Wahren et al., 2000). C-peptide links the 
A and B chains of insulin allowing correct folding and the formation of interchain 
disulphide bonds (Wahren et al., 2000). When removed from proinsulin it exposes the 
COOH-terminal of insulin’s B-chain thereby allowing interaction with the insulin 
receptor (Wahren et al., 2000).  
After its discovery, C-peptide was thought to have physiological effects similar to 
insulin but since no influence on glucose or lipid metabolism could be demonstrated it 
was then regarded as a waste product of insulin synthesis (Wahren et al., 2012). The 
purpose of C-peptide was considered to be providing structures for correct folding of 
proinsulin, disulphide bond formation and cleavage (Henriksson et al., 2005). The main 
biological role of C-peptide was originally thought to be to ensure the correct structure 
of insulin (Hoekstra et al., 1982). However, C-peptide was found to be useful as an 
indicator of ß-cell function and has since been used to monitor the course of type 1 and 
2 diabetes (Wahren et al., 2012). This can be done because it is secreted in equimolar 
amounts to insulin and can therefore be used as a measure of insulin secretion rate, 
especially when exogenous insulin is being administered (Steiner, 2004). 
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Figure 1.5 Picture of proinsulin showing how cleavage at the dipeptides (Arg-Arg and 
Lys-Arg) produces insulin and C-peptide (open circles). From Annals of Internal 
Medicine, Hoffman (1997). Copyright © 1997 American College of Physicians. All 
Rights Reserved. Reprinted with the permission of American College of Physicians, 
Inc. 
Current belief is that C-peptide may have important biological roles in its own right 
(Henriksson et al., 2005, Wahren et al., 2012). It binds specifically to cell membranes 
resulting in activation and enhanced expression of endothelial nitric oxide synthase 
(eNOS) and sodium-potassium adenosine triphosphatase (Na+ /K+ -ATPase) (Wahren 
et al., 2012). C-peptide has now been shown to have favourable effects on functional 
and structural changes on the kidneys, peripheral nerves and the brain in diabetic 
patients (Henriksson et al., 2005, Wahren et al., 2012). The lack of C-peptide in 
diabetes may therefore be a factor in long term complications and C-peptide therapy 




Glucagon is a pancreatic hormone that stimulates gluconeogenesis and glycogenolysis 
(Bell, 1986). It is a single chain polypeptide with 29 amino acid residues (Bell, 1986) 
(Figure 1.6). Glucagon is processed from proglucagon which also encodes the 
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sequences of the structurally related proglucagon-derived peptides (glucagon-like 
peptides) (Drucker, 2003). 
 
Figure 1.6 Amino acid structure of glucagon. 
1.4.2 Physiology 
Proglucagon is processed into multiple peptide hormones depending on the specific 
tissue (Jiang & Zhang, 2003). Proglucagon is processed into functional glucagon in the 
pancreatic α-cells through the action of prohormone convertase 2 and into GLP-1 and   
-2 in the L-cells of the intestine (Drucker, 2003, Jiang & Zhang, 2003). Glucagon 
signals through its transmembrane G protein-coupled receptor on the cell surface which 
consists of 485 amino acids (Jiang & Zhang, 2003). The binding to the receptor leads to 
the activation of coupled G proteins and binding sites have been identified in the 
pancreas, liver, adipose tissues, intestine, kidney and brain (Jiang & Zhang, 2003). 
Glucagon is released into the bloodstream when blood glucose concentrations are low 
(Jiang & Zhang, 2003). Its concentrations are used as a measure of α-cell function and 
release of glucagon by α-cells is similar to the release of insulin by β-cells with release 
of a stored pool of peptide initiated by specific stimuli (Sandoval & D'Alessio, 2015). 
The secretion of glucagon from the α-cells is pulsatile resulting in more effective 
hepatic glucose output (Jiang & Zhang, 2003). 
The main recognised function of glucagon is as a counter-regulatory hormone released 
in response to decreased glucose concentrations leading to stimulated hepatic glucose 
production and an increase in glycaemia (Sandoval & D'Alessio, 2015, Jiang & Zhang, 
2003). This increased glycaemia is a major counter-regulatory mechanism to insulin for 
maintaining glucose homeostasis (Jiang & Zhang, 2003). Glucagon interacts with its 
receptor on liver cells to activate adenylate cyclase resulting in an increase in 
intracellular cyclic adenosine monophosphate (cAMP) concentrations which activates 
cAMP-dependant protein kinase A (Unger, 1985, Jiang & Zhang, 2003). The activation 
of protein kinase A induces the major hepatic actions of glucagon: glycogenolysis, 
gluconeongenesis and ketogenesis and inhibition of glycogen synthesis, glycolysis and 
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lipogenesis (Unger, 1985, Jiang & Zhang, 2003). Insulin opposes this action by 
decreasing cAMP protein kinase activity (Unger, 1985). 
The key regulatory hormones for glucose homeostasis are insulin and glucagon with 
glucagon initiating and maintaining hyperglycaemic conditions in diabetes (Jiang & 
Zhang, 2003). The opposing effects of insulin and glucagon can be seen in Figure 1.7 
where insulin concentrations increase and glucagon concentrations decrease with an 
increase in glucose. In diabetes, glucagon concentrations are often elevated but it seems 
that the number of receptors in diabetes are decreased (Jiang & Zhang, 2003). The 
fasting glucagon concentrations of diabetic patients are in the same range as non-
diabetic patients however a difference becomes apparent when the concentration of 
glucagon is related to glucose (Unger, 1971). Response to a carbohydrate meal differs 
between diabetic and non-diabetic patients; non-diabetics respond with a rise in glucose 
and insulin and a decrease in glucagon concentrations (Unger, 1971). However, 
diabetics do not show a decrease in glucagon concentrations due to there being little or 
no rise in insulin concentrations despite increased glucose concentrations (Unger, 
1971). 
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Figure 1.7 Response of insulin, glucose and glucagon to a carbohydrate meal (time 0). 
Reproduced with permission from Unger (1971), Copyright Massachusetts Medical 
Society. 
There is a lack of data on glucagon in preterm neonates, however insulin concentrations 
were found to be high and glucagon concentrations low in the cord blood from full term 
neonates (Hume et al., 2005). Insulin concentrations decreased and glucagon increased 
in response to relative postnatal hypoglycaemia in full term neonates (Hume et al., 
2005). A study by Jackson et al. (2003) reported lower blood glucose and higher lactate 
concentrations 30 minutes after glucagon stimulation in preterm neonates with 
inadequate glycaemic response. The inadequate respose to glucagon in these neonates 
was linked to parameters indicating insulin resistance (Jackson et al., 2003). 
Glucagon and its receptor are potential targets for treatment of diabetes (Jiang & 
Zhang, 2003). It can be administered intravenously, intramuscularly or subcutaneously 
as a treatment for severe hypoglycaemia (Powers & D'Alessio, 2011).Treatment with 
glucagon-neutralising antibodies, peptide glucagon analogues and small-molecule 
glucagon receptor antagonists can normalise hyperglycaemia in type 2 diabetes (Jiang 
& Zhang, 2003). Neutralising glucagon or blocking the action of its receptor 
antagonises its action and may provide an intervention for type 2 diabetes and other 
related metabolic disorders (Jiang & Zhang, 2003). 
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1.5 Glucagon-like peptide-1  
1.5.1 Structure 
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone consisting of 30 amino 
acids residues (Figure 1.8) and is released from the enteroglucagon cells (L-cells) in the 
small intestine (Gallwitz et al., 1994). There are two equipotent forms of GLP-1 in the 
circulation resulting from selective cleavage of proglucagon: GLP-1 (7–37) amide and 
GLP-1 (7–36) amide, with the main form in humans being GLP-1 (7–36) amide 
(Padidela et al., 2009, Janssen et al., 2013). The metabolic actions of glucagon have 
been known for several decades however the structure of the glucagon-like peptides 
was not known until the early 1980s when mammalian DNA and genes were cloned 
(Drucker, 2003). 
 
Figure 1.8 Amino acid structure of GLP-1 (7–36) amide. 
1.5.2 Physiology 
GLP-1 is generated in the small intestine as a result of post-translational processing of 
proglucagon (Gallwitz et al., 1994). Proglucagon contains glucagon and also a C-
terminal sequence of 91 amino acids containing the two glucagon-like peptides GLP-1 
and GLP-2 (Ørskov, 1992). 
GLP-1 is secreted from the enteroendocrine L-cells of the small intestine in response to 
food intake (Gutzwiller et al., 1999, Padidela et al., 2009, Fu et al., 2013). It is an 
incretin hormone which is stimulated by the ingestion of nutrients resulting in secretion 
from the L-cells (Fu et al., 2013). Oral glucose stimulates the release of GLP-1 whereas 
intravenous glucose does not (Gutzwiller et al., 1999). An incretin is a hormone from 
the intestinal tract responsible for augmentation of insulin secretion by either releasing 
insulin or potentiating glucose-induced insulin release to meet the increased demand for 
insulin after a meal (Fu et al., 2013, Ørskov, 1992). Secretion of GLP-1 is biphasic with 
an early peak stimulated by neural and endocrine factors followed by a longer late 
phase stimulated by nutrient digestion (Janssen et al., 2013). Once secreted, GLP-1 is 
cleaved rapidly by dipeptidyl peptidase forming GLP-1 (9-36) amide, a biologically 
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inactive metabolite cleared by the kidney (Padidela et al., 2009). This rapid cleavage 
results in a short half-life of just two minutes in adults (Padidela et al., 2009).  
The most important role of GLP-1 is as an incretin by regulating blood glucose 
concentrations through amplification of post meal insulin synthesis and secretion 
(Janssen et al., 2013). The actions of GLP-1 are mediated by its 463 amino acid G 
protein-coupled receptor (Drucker, 2003). Activation of the GLP-1 receptor on β-cells 
results in the generation of cAMP through the activation of adenylyl cyclase and 
protein kinase A (Drucker, 2003, Fu et al., 2013). The increase in cAMP potentiates 
glucose-induced insulin release (Fu et al., 2013). As well as stimulating insulin 
secretion, GLP-1 also inhibits gastric emptying, gastric acid secretion and glucagon 
secretion, and increases somatostatin (Drucker, 2003, Ørskov, 1992). The inhibition of 
glucagon secretion and stimulation of insulin secretion by GLP-1 is glucose-dependant 
(Campbell & Drucker, 2013). It is also thought that GLP-1 has a growth promoting 
effect on β-cell mass by enhancing β-cell proliferation and inhibiting β-cell apoptosis 
(Campbell & Drucker, 2013, Fu et al., 2013). 
A study by Gutzwiller et al. (1999) showed that peripherally infused GLP-1 decreased 
spontaneous food intake, and therefore indicated that GLP-1 is an endogenous signal 
involved in controlling food intake in humans. Only two studies investigated GLP-1 
concentrations in neonates; Amin et al. (2008) found that premature neonates had 
significantly higher fasting concentrations (14.8 pmol/L) of GLP-1 when compared 
with adults (7 pmol/L) and that feeding increased these concentrations further 
(69 pmol/L in neonates and 42 pmol/L in adults). Padidela et al. (2009) found elevated 
basal and post-feed GLP-1 concentrations in neonates. They found a mean GLP-1 
concentration pre-feeding of 79.1 pmol/L (compared with an adult value of 19 pmol/L) 
and post-feeding of 156.6 pmol/L at 20 minutes and 121.5 pmol/L at 60 minutes (adult 
values of 5 to 10 pmol/L after a meal and 40 to 50 pmol/L after 90 minutes) (Padidela 
et al., 2009).  
GLP-1 and gastric inhibitory peptide analogues have been considered as a potential 
therapy for type 2 diabetes (Fu et al., 2013). Inhibitors and resistant analogues to   
GLP-1 have been investigated due to the short half-life of just two minutes (Janssen et 
al., 2013). Two GLP-1 analogues are commercially available (exanatide and 
liraglutide) for the treatment of type 2 diabetes by improving glycaemic control in 
diabetics insufficiently controlled by oral antidiabetic agents or those who are 
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susceptible to hypoglycaemia (Janssen et al., 2013). The GLP-1 analogue liraglutide 
has an additional 16-carbon fatty acid and small amino acid-based spacer which 
prolongs and enhances the effect of GLP-1 to a half-life of approximately 13 hours 
(Janssen et al., 2013). 
1.6 Analytical techniques 
The following analytical techniques were used in the methods to this thesis and the 
backgrounds to these techniques are described here.	
1.6.1 Chemiluminescence 
Chemiluminescence is the light emission produced when a chemical reaction yields 
chemically excited molecules which decay to the electronic ground state and emit 
photons (Roda et al., 2000, García-Campaña & Lara, 2007). It has become a very 
useful detection technology for immunoassays in clinical diagnostics (Natrajan et al., 
2010). Chemiluminescence has been shown to be a good alternative to 
radioimmunoassays as it has the advantage that light is emitted by a specific reaction 
involving the analyte and avoids the background emission typical of fluorescence, due 
to sample matrix components. (Roda et al., 2000). 
Among the chemiluminescent labels which are frequently used acridinium esters are 
particularly attractive because they have high quantum yields and fast light emission 
with simple chemical triggers (Natrajan et al., 2010). Their small size allows for simple 
labelling of proteins and nucleic acids (Natrajan et al., 2010). Light emission from 
acridium esters lasts only two to five seconds and is triggered with alkaline peroxide in 
the presence of a cationic surfactant (Natrajan et al., 2010). This chemical reaction 
produces an excited state called acridone and emits light with an emission around 
425 nm (Natrajan et al., 2010). Figure 1.9 shows this reaction. 
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Figure 1.9 Chemical Reaction of an Aryl Acridinum Ester. Reprinted from 'Bio- and 
chemiluminescence in bioanalysis', Fresenius' Journal of Analytical Chemistry Roda et 
al. (2000) with kind permission from Springer Science and Business Media. 
To cause a chemiluminescence reaction a number of components are needed: the 
chemiluminescent substrate, oxidants, inorganic ions, cofactors and a catalyst (Baeyens 
et al., 1998). Any of these components can be coupled to an antibody or antigen and the 
labelled reagent can be used in a competitive or non-competitive binding assay, then by 
adding the rest of the components the chemiluminescence can be initiated (Baeyens et 
al., 1998). Since the reaction rate is concentration dependent and the light output 
intensity is directly related to the concentration, it is well suited for quantitative 
analysis. Factors such as temperature, pH, ionic strength and composition of solvent 
affect the reaction rate and therefore have to be standardised when performing the assay 
(Roda et al., 2000, García-Campaña & Lara, 2007). 
The light emitted from chemiluminescence reactions is measured by a luminometer 
which is a relatively simple and inexpensive instrument that measures the overall light 
output from a sample (Roda et al., 2000). A luminometer consists of sample chamber, a 
detector and a signal processing apparatus. The sample chamber geometry is designed 
to collect as much light as possible on the detector, therefore increasing sensitivity 
(Roda et al., 2000). The high collection efficiency of a luminometer is achieved by 
using appropriate reflecting surfaces (Roda et al., 2000). One of the advantages of 
chemiluminescence is its high detection sensitivity which is partly caused by a low 
intrinsic background that is not as greatly affected by interference from light scattering 
as in other light methods (Roda et al., 2000). 
1.6.2 ELISA 
Enzyme-linked immunosorbent assay (ELISA) is a versatile and sensitive analytical 
test to detect antibodies (Paulie et al., 2001). This is used as a diagnostic tool in 
medicine, quality control in industry and as analytical tools in biomedical research to 
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detect and quantify specific antigens or antibodies in samples (Gan & Patel, 2013). 
ELISAs are immunoassays in which a reactant is immobilised on a solid phase and they 
include enzyme immunoassay (EIA) which is a competitive ELISA (Butler, 2000). The 
purpose of ELISA is to use an enzyme to deliver a signal that a specific antigen-
antibody reaction has occurred (Butler, 2000). ELISAs always involve the specific 
interaction between antibody and antigen with one of the reactants immobilised to a 
solid support (Paulie et al., 2001). Immobilisation of an antigen means that binding of 
specific antibodies can be measured and detection and quantification of the antigen can 
be achieved by attachment of antibodies to the solid phase (Paulie et al., 2001).  
The immobilised antigen or antigen-specific capture antibody is usually adhered 
directly onto the well surface of a 96-well microtiter plate (Gan & Patel, 2013). With 
the competitive ELISA, the analyte and a competitor molecule compete for limited 
numbers of binding sites (Figure 1.10) (Griffin & Stratis-Cullum, 2009). There is a 
competitive reaction between the sample antigen and antigen bound to the plate’s wells 
with the primary antibody (Gan & Patel, 2013). The process involves incubation of the 
primary antibody with the sample antigen and resulting antibody-antigen complexes are 
added to wells coated with the same antigen (Gan & Patel, 2013). The plate is 
incubated and then the unbound antibody is washed off and the more primary antibody 
that is bound to the sample antigen indicates more antigen in the sample (Gan & Patel, 
2013). This means that there is a smaller amount of primary antibody available to the 
antigen coated to the well (Gan & Patel, 2013). Secondary antibody conjugated to 
enzyme is added followed by a substrate that produces a colour result, the absence of 
colour indicates antigen is present in the sample (Gan & Patel, 2013). The most 
common enzymes used for ELISA are alkaline phosphatase, horseradish peroxidase 
and β-galactosidase (Paulie et al., 2001). Many serologically based diagnostic assays 
use indirect competitive ELISA which is used for screening biological fluids and results 
are usually positive or negative (Paulie et al., 2001). Quantitation can be achieved by 
comparing the sample with a standard curve obtained by serial dilutions of known 
concentrations of an antigen solution (Paulie et al., 2001).  
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Figure 1.10 Diagram of an indirect assay with competitive binding. Reprinted from 
'Biosensors', Encyclopedia of Microbiology (Third Edition) (Griffin & Stratis-Cullum, 
2009) Copyright, with permission from Elsevier. 
Indirect ELISAs can be limited by a varying degree of nonspecific binding, this can 
increase the variability in assay results and therefore increases the need to process 
many samples (Crowther, 2000). Limitations of ELISAs are that the colour change can 
react indefinitely so over a long period of time can inaccurately reflect the amount of 
primary antibody, a known reciprocal antigen or antibody must be generated to allow 
for detection and nonspecific binding can lead to a falsely high positive result (Gan & 
Patel, 2013). 
The main advantage of using a competitive ELISA is its high sensitivity to 
compositional differences in complex antigen mixtures (Gan & Patel, 2013). 
Competitive ELISAs are useful for analysis of smaller molecules which cannot be 
analysed by the more sensitive sandwich ELISA (Paulie et al., 2001). Indirect 
competitive ELISAs are versatile and sensitive for determining antibodies and an 
antigenic substance (Paulie et al., 2001). Since ELISA/EIA uses basic antigen-antibody 
immunology, very small quantities of proteins, peptides, hormones or antibodies can be 
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detected in a fluid sample (Gan & Patel, 2013). Advantages of ELISAs are that they are 
simple; can analyse small volumes and are readily available, can be performed in a few 
hours, reading of results is rapid, they are sensitive and fully standardised ELISAs are 
now accepted as “gold-standard” assays (Crowther, 2000). In summary, the advantages 
of being able to analyse small volumes and detect very small quantities of the target 
analyte in a fluid sample make ELISA a good technique for analysing biological 
samples from neonates. 
1.6.3 Dried blood spot assays 
Dried blood spots (DBS) is a blood sampling technique in which peripheral blood is 
spotted onto filter paper and left to dry (Obroin, 1993). Samples are then taken as small 
discs (typically 3 mm) from the filter paper and eluted from the disc and analysed with 
a specific assay (Holub et al., 2006). The first reported use of DBS for blood sampling 
was by Robert Guthrie in the early 1960s, for detection of phenylketonuria in large 
populations of newborns (Evans, 2010). Guthrie & Susi (1963) reported a new method 
in 1963 for rapid and economical screening of large numbers of neonates for elevation 
of phenylalanine in the blood. An assay using 903 filter paper was developed for heel 
pricks in 682 neonates at four days old (Guthrie & Susi, 1963). A heel prick is when 
fresh blood is obtained from puncturing the neonate’s heel with a lancet and 
immediately applying the filter paper to absorb the blood (Guthrie & Susi, 1963). 
Robert Guthrie’s application of DBS has led to population screening of inherited 
metabolic diseases in neonates (Skopp, 2007). The sampling and storage methods of 
DBS has gained popularity and spread to the detection of a variety of other disorders in 
neonates (Evans, 2010).   
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1.7 Overall study aim 
The main overall aim of this research was to form a better understanding of the 
maturation of glucose homeostasis in the preterm neonate and more specifically the 
hyperglycaemic preterm neonate. Chapters 3 to 6 investigate the following thesis aims 
in more detail to gain a more complete understanding of glucose homeostasis in the 
preterm neonate. The research hypothesis for this thesis was that the relationship 
between neonatal feeding, glucose regulatory hormones and insulin secretion indicate 
insulin resistance in preterm neonates. The thesis aims were designed to test this 
hypothesis and confirm if insulin resistance is a major factor in neonatal 
hyperglycaemia. 
1.7.1 Thesis aims 
• To investigate the use of a dried blood spot assay for measuring insulin 
concentrations in order to improve sampling for PK studies. 
• To describe the relationship between C-peptide and insulin secretion in the 
neonatal population. 
• To investigate the relationship between neonatal feeding and incretin (GLP-1) 
as well as insulin secretion to understand glucose homeostasis in the 
euglycaemic neonate. 
• To compare the results from euglycaemic preterm neonates and neonates treated 
with insulin for hyperglycaemia to investigate alterations in glucose 
homeostasis in hyperglycaemic preterm neonates. 
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The research in this thesis relates to a clinical research project conducted in Dunedin 
Hospital Neonatal Intensive Care Unit (NICU) from January 2011 to November 2012. 
This project was titled “Insulin pharmacokinetics and pharmacodynamics (PKPD) in 
neonates”.  
The main project included two studies (part one: “Insulin/C-Peptide Ratio in Babies” 
and part two: “High Blood Glucose in Babies”) and produced four datasets. The four 
datasets are described over four chapters and are titled: “The effect of haematocrit on 
the measured insulin concentration in dried blood spots using a chemiluminescent 
immunoassay”(Chapter 3), “The effect of gestational age and blood glucose on C-
peptide excretion rate and clearance calculated from urinary C-peptide measured by 
chemiluminescence in twenty neonates” (Chapter 4), “Insulin resistance, glucagon like 
peptide 1 (GLP-1) and other factors influencing glucose homeostasis in preterm and 
term neonates” (Chapter 5) and “Glucose homeostasis in hyperglycaemic neonates 
compared with euglycaemic neonates” (Chapter 6). General methodologies that apply 
to all datasets are described in this chapter. Then, subsequent chapters give details 
relevant to each dataset.  
2.2 Materials 
Insulin chemiluminescent IV2-101 kits and C-peptide chemiluminescent IV2-004 kits 
were obtained from Invitron (Monmouth, UK). The kits contained: microtitre plates 
coated with a specific polyclonal antibody, labelled antibody concentrate, labelled 
antibody diluent, standards in a serum matrix and wash buffer concentrate (phosphate 
buffered saline containing a detergent and preservative). Chemiluminescence detection 
reagent kit IV1-001 (detection reagent 1: 0.5% hydrogen peroxide, 0.1M nitric acid, 
detection reagent 2: 0.25M sodium hydroxide, 0.2% surfactant) was also obtained from 
Invitron (Monmouth, UK). An automated ASYS Atlantis Microplate washer, 
(Cambridge, UK) was used. A BMG LABTECH, POLARstar Omega microplate reader 
was used. GLP-1 and glucagon BioVendor ELISA kits (RSCYK160R and 
RSCYK090R) were obtained from BioCore Pty Limited (Sydney, Australia). A BMG 
LABTECH, POLARstar Omega microplate reader was used for chemiluminescent 
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plates and a Molecular Devices SpectraMax 340 plate reader was used for absorbent 
plates with SoftMax Pro 4.3.1 LS software.  
Leftover plasma samples, from routine blood samples taken as part of normal clinical 
care, were obtained from Southern Community Laboratories at Dunedin Public 
Hospital. 
2.3 Study protocol 
Ethical approval for the research described in this thesis was obtained from the Lower 
South Regional Ethics Committee, New Zealand. 
Study participants were identified through the NICU at Dunedin Public Hospital. 
Medical staff treating potential participants made the initial approach to the parents or 
caregivers then gained informed consent from those agreeing to participate in the study. 
There were no changes to the standard medical care for the study participants. Some 
additional blood (<1.5 mL) was sampled as a consequence of the study. The normal 
NICU protocols for pain were followed for any extra blood sampling. 
Both euglycaemic and hyperglycaemic neonates were included in the main clinical 
study and are described below. The sample size was determined by the need to obtain 
estimates of standard deviation and standard error for the population. To construct a 
population pharmacokinetic model 100 participants are typically required and therefore 
our target sample size for part one was 100. A minimum sample size of six is required 
to obtain mean and SD for future studies, therefore this was the minimum target sample 
size for part two. Prior data were not available because similar studies had not been 
previously performed. 
Study protocol (Appendix 2), information sheets (Appendix 3), consent forms 
(Appendix 4) and case report forms (Appendix 5) are all contained in the Appendices. 
2.3.1 Part one: euglycaemic neonates 
The target sample size for part one of the main clinical study was 100 euglycaemic 
neonates admitted to NICU. At completion of the study 102 euglycaemic neonates were 
recruited. In addition to leftover plasma samples being collected 20 urine samples and 
20 bloodspots from individual neonates were collected. These were obtained at the 
discretion of the NICU medical staff when appropriate and paired with a plasma 
sample. 
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2.3.1.1 Inclusion criteria 
• Euglycaemic (i.e. were not hypo- or hyperglycaemic). 
• Pre-term or term neonates admitted to neonatal intensive care unit. 
• Undergoing blood tests as part of normal clinical management. 
• Ability to obtain written informed consent from parents/caregivers. 
2.3.1.2 Exclusion criteria 
• Hyperglycaemia (BGC of 10mmol/L or more, for two consecutive levels, four 
hours apart) or hypoglycaemia (BGC <2.6 mmol/L). 
• Current treatment with insulin or oral hyperglycaemic agents or other 
medications that alter glucose homeostasis (eg. Corticosteroids). 
2.3.1.3 Part one methodology 
Patients: pre-term or term neonates admitted to NICU, who were undergoing routine 
blood tests. 
Blood sampling was prospective and used leftover samples from routine blood tests to 
measure insulin, C-peptide, blood glucose and incretin concentrations. 
Blood samples were collected in light green BD Vacutainer plasma separator (lithium 
heparin coated and inert polymer gel for plasma separation) tubes or BD Vacutainer 
Ethylenediaminetetraacetic acid (EDTA) tubes as well as a paired blood glucose 
concentration on at least one occasion. A separate heel prick sample was spotted onto 
blotting paper (Guthrie card) in twenty participants. Urine was also collected from 
twenty participants on a single occasion into some cotton wool for measurement of C-
peptide in urine. For this a time was chosen for urine collection when at least one blood 
sample would be sent to the lab (for additional analysis). Nappies and cotton wool were 
weighed at the start of the time period, the time was recorded, then at the next nappy 
change if a good sample was obtained the nappy was reweighed and the urine volume 
calculated. Urine soaked cotton wool balls were stored in a urine container for 
collection and once collected then squeezed out into eppendorf tubes for analyses. All 
plasma, blood spot and urine samples were stored at -20°C until analysis. All samples 
were frozen immediately after collection. 
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Gestational age, chronological age, time and volume of last feed, birth weight, current 
weight and whether intravenous (IV) or total parenteral nutrition (TPN) feeding around 
the time each sample was taken were recorded. 
Participants from part one contributed to all four datasets in this thesis as described in 
Chapters 3 to 6. 
2.3.2 Part two: hyperglycaemic neonates 
For part two the target sample size was 6 to 12 hyperglycaemic premature neonates 
admitted NICU. At the completion of the study 9 hyperglycaemic premature neonates 
were recruited. For this part six small venous blood samples (150 µL) per neonate and 
six blood spots from heel pricks per neonate were collected.  
2.3.2.1 Inclusion criteria 
• Hyperglycaemic (BGC of 10mmol/L or more, for two consecutive levels, four 
hours apart). 
• Birth weight of <1500g. 
• Gestational age at birth of <32 weeks. 
• Require insulin infusion as part of NICU protocol (blood sugar >10mmol/L at 
two consecutive readings at four hours apart). 
• Ability to obtain written informed consent from parents/caregivers. 
2.3.2.2 Exclusion criteria 
• Infants of diabetic mothers. 
• Suspected metabolic disorder. 
• Suspected growth hormone deficiency or pituitary insufficiency. 
• Current treatment with exogenous steroids. 
• Current treatment with diazoxide. 
• Maternal hyperthyroidism. 
• Maternal oral hyperglycaemic agents eg. biguanides, sulphonylureas, 
thiazolidinediones. 
• Maternal exanatide or liraglutide. 
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2.3.2.3 Part two methodology 
Patients: hyperglycaemic low birth weight (<1500 g) premature (<32 weeks) neonates 
who required insulin infusion as part of NICU protocol. 
Blood (150 µL) was collected in light green BD Vacutainer plasma separator (lithium 
heparin coated and inert polymer gel for plasma separation) tubes at the same time as 
the patients’ routine four hourly blood glucose test, a blood spot from a heel prick was 
also taken at the same time.  
Blood taken was used to measure insulin, C-peptide and incretin concentrations and 
was paired with the routine blood glucose concentration. Each patient was monitored 
over 24 hours (6 samples). Blood samples were taken to the laboratory where they were 
centrifuged to separate the plasma which was then stored at -20°C until analysis along 
with the blood spots. 
Gestational age, chronological age, time and volume of last feed, birth weight, current 
weight and whether IV or TPN feeding around the time each sample was taken were 
recorded. 
Participants from part two contributed to two of the four datasets in this thesis as 
described in Chapters 3 and 6. 
2.4 Assays 
Assay kits were used according to the manufacturer’s instructions and brief details are 
given in the following sections. 
2.4.1 Insulin and C-peptide chemiluminescent kits 
2.4.1.1 Specificity 
The manufacturers determined specificities of the Invitron assays by calculating cross 
reactivity. Cross reactivity of related proteins were investigated by the manufacturers, 
at concentrations of 100 pmol/L and results were expressed as percentages of the 
reactivity of an identical concentration of insulin or C-peptide. The insulin kit had a 
specificity of: insulin 100%, proinsulin 1.2%, C-peptide 0% and the C-peptide kit had a 
specificity of: C-peptide 100%, insulin 0%, proinsulin 2.0%. 
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2.4.1.2 Sensitivity 
Sensitivity was estimated, by the manufacturers, as two standard deviations from the 
mean of 20 replicates of a zero standard. Calculated in this way, analytical sensitivity of 
the insulin assay was 1.2 pmol/L and of the C-peptide assay was 5.0 pmol/L. The 
working range for the insulin assay was 0 to 1500 pmol/L and C-peptide 
0 to 5000 pmol/L. 
2.4.1.3 Kit procedure 
All kit components were brought to room temperature before use. Kit standards were 
reconstituted by adding 1 mL of deionised water to each standard and after 5 minutes 
the standards were mixed gently to ensure that all solids were dissolved. 900 µL of 
labelled antibody concentrate was transferred to a bottle of labelled antibody diluent 
and mixed thoroughly. Into each well, 100 µL of labelled antibody solution was 
pipetted and then 25 µL of standard or sample. The plate sealer was then attached to the 
plate and it was incubated for 2 hours at 37°C. Wash buffer was made by diluting 1 part 
of wash buffer concentrate from the kit with 29 parts of deionised water. After 
incubation the plate sealer was removed and the plate was washed three times with 
wash buffer using an automated plate washer (ASYS Atlantis Microplate washer). The 
plate was then transferred to the luminometer. During the measurement process 100 µL 
of each of the two detection reagents were added. The light output from each well was 
measured in a POLARstar Omega Plate reader.  
2.4.2 GLP-1 ELISA 
2.4.2.1 Specificity 
The manufacturers determined specificities of this assay by calculating cross reactivity. 
The GLP-1 ELISA kit had high specificity to rat/mouse/human GLP-1 and showed 
cross reactivity for neither rat/human/mouse glucagons, human glicentin nor 
rat/mouse/human GLP-2. 
The kit specificity was reported to be: GLP-1 (7-36) amide 100%, GLP-1 (9-36) amide 
100%, GLP-1 (1-36) amide 0.3%, GLP-1 (7-37) <0.1%, GLP-1 (1-37) <0.1%. 
2.4.2.2 Sensitivity 
The detection limit of this kit was reported to be 0.206 ng/mL. The assay kit could 
measure rat, mouse and human GLP-1 in the range of 0.206 to 50 ng/mL. 
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2.4.2.3 Kit procedure 
All kit components were brought to room temperature. The plate was washed three 
times with washing solution (concentrated saline, 350 µL per well) using an automated 
plate washer (ASYS Atlantis Microplate washer) and then the plate was inverted and 
tapped to remove excess washing solution. Into each well, 40 µl of labelled antibody 
solution was pipetted and then 30 µl of standard solutions and samples. Then 40 µL of 
GLP-1 antibody was pipetted into each well. The plate was then covered with adhesive 
foil and left to incubate at 4°C for 18 hours. After incubation, the plate sealer was 
removed and the plate was washed four times with washing solution using an 
automated plate washer. HRP labelled streptoavidin (SA-HRP) solution was prepared 
by adding 120 µL of SA-HRP to one bottle of diluent for SA-HRP (phosphate buffer) 
and mixed well. Into each well 100 µL of SA-HRP solution was pipetted and then the 
plate was again covered with adhesive foil and left to incubate for 1 hour at room 
temperature with gentle orbital shaking. After incubation, the plate sealer was removed 
and the plate was washed five times with washing solution using the automated plate 
washer. One o-Phenylenediamine hydrochloride (OPD) tablet was dissolved with 
12 mL of substrate buffer (citrate buffer containing 0.015% hydrogen peroxide) and 
then 100 µL was pipetted into each well, covered with adhesive foil and left for 30 
minutes at room temperature to achieve a colour reaction. After 30 minutes, 100 µL of 
stopping solution (1M H2 SO4) was pipetted into each well and the optical absorbance 
was read at 490 nm in a SpectraMax 340 plate reader.  
2.4.3 Glucagon ELISA  
2.4.3.1 Specificity 
The manufacturers determined specificities of this assay by calculating cross reactivity. 
The glucagon ELISA kit had high specificity to pancreatic glucagon and showed no 
cross reactivity with intestinal glucagon, GLP-1 and GLP-2. 
2.4.3.2 Sensitivity 
The detection limit of this kit was reported to be 50 pg/mL. The assay kit could 
measure rat, mouse or human pancreatic glucagon in plasma samples in the range of 
50 to 10 000 pg/mL. 
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2.4.3.3 Kit procedure 
All kit components were brought to room temperature. Into each well of the 96 well 
plate, 50 µL of standard solutions and samples were pipetted followed by 50 µL of 
labelled antigen solution. The plates were then covered with adhesive foil and left to 
incubate at 4°C for 48 hours. After incubation, plate sealers were removed and the 
plates were washed three times with washing solution (concentrated saline, 350 µL per 
well) using an automated plate washer (ASYS Atlantis Microplate washer) and then 
plates were inverted and tapped to remove excess washing solution. Into each well, 
100 µL of SA-HRP solution was pipetted and then the plate was again covered with 
adhesive foil and left to incubate for 1 hour at room temperature with gentle orbital 
shaking. After the incubation plate sealers were removed and the plates were washed 
three times with washing solution using an automated plate washer. One OPD tablet 
was dissolved with 12 mL of substrate buffer (0.015% hydrogen peroxide) and then 
100 µL was pipetted into each well, covered with adhesive foil and left for 20 minutes 
at room temperature to achieve a colour reaction. After 20 minutes, 100 µL of stopping 
solution (2N H2 SO4) was pipetted into each well and the optical absorbance was read 
at 490 nm in a SpectraMax 340 plate reader.  
2.5 Data analyses 
2.5.1 Sample analysis 
All recorded information (demographics, sample times, feeding times etc) and sample 
results were entered into a Microsoft Excel 2011 spreadsheet as the NICU study 
progressed. At conclusion of the study, the information and results from this 
spreadsheet were transformed into various Stata datasets for analysis with Stata/IC 
version 11.2 (StataCorpLP, TX, USA). 
2.5.1.1 Data below limit of detection 
There are methods for imputing data below the limit of assay detection with the most 
recommended being the maximum likelihood method (Beal, 2001). There are other 
common replacement methods such as replacing all the data under lower limit of 
detection (LOD) with zero or LOD/2 (Beal, 2001). For the data in this thesis it was 
decided to use the LOD divided by two (LOD/2). There were 30 (12%) non-insulin-
treated and 26 (46% due to the hyperglycaemic neonates having low insulin 
production) insulin-treated concentrations of C-peptide that produced concentrations 
Chapter two - Methods 
 43 
below the LOD and required imputing. The LOD for the C-peptide assay was 5 pmol/L, 
therefore all concentrations below 5 pmol/L were replaced with 2.5 pmol/L (LOD/2) 
for analysis. It was decided that LOD/2 was the most appropriate method for this study 
as the missing data were less than LOD, it is a commonly accepted method and 
maximum likelihood methods would use covariate data, which was not appropriate for 
this study. 
2.5.2 Data transformation 
The frequency distributions of participant demographics and sample results were 
investigated in Stata/IC (version 11.2) for Chapters 5 and 6 for each dataset and all the 
datasets combined. Participant demographics were all normally distributed and all 
concentrations of glucose regulatory hormones were found to be natural log (ln) normal 
distributed except for BGC, which was normally distributed.  
2.5.3 Pairwise correlations 
Pairwise correlations were determined using Stata/IC (version 11.2) to identify data that 
were significantly correlated. Gestational age (GA), postmenstrual age (PMA), birth 
weight, current weight, length, and head circumference were all highly correlated with 
each other (r >0.75) and could therefore not be included in the same statistical models. 
PMA was chosen as the main demographic for comparison as it was the most highly 
correlated (Appendix 8) with the glucose regulatory hormones data (insulin, C-peptide, 
GLP-1 and glucagon). Pairwise correlations confirmed which data to analyse for the 
study and that PMA was the most important demographic for comparison.  
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Blood Spots. Journal of Maternal-Fetal and Neonatal Medicine. Nov 13:1-15.   
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3 The effect of haematocrit on the measured insulin 
concentration in dried blood spots using a 
chemiluminescent immunoassay 
3.1 Introduction 
A major barrier to conducting pharmacokinetic (PK) trials in neonates is the relatively 
large volumes of blood required by most drug assays which is problematic in preterm 
neonates because of their comparatively small circulatory volume (Patel et al., 2010). 
The circulatory volume in term neonates has been reported to be around 88 mL/kg 
(Sisson & Whalen, 1960) and higher in preterm neonates at around 98 mL/kg (Usher & 
Lind, 1965). Dried blood spots (DBS) have the potential to facilitate studies in neonates 
(Patel et al., 2013) as smaller volumes of blood can be used which may help in patient 
recruitment and enable serial sampling (Evans, 2010). Using a DBS assay such as the 
one developed by Butter et al. (2001) is expected to be a convenient method for 
estimating insulin levels in neonates and evaluating the delivery of insulin to 
hyperglycaemic preterm neonates.  
3.1.1 Dried blood spots 
The collection of whole blood onto filter paper is used for screening of metabolic errors 
in neonates, therapeutic drug monitoring and more recently PK studies (Spooner et al., 
2009). There are many advantages but also some disadvantages to using DBS as a 
sample collection tool in clinical studies. 
3.1.1.1 Advantages of dried blood spots 
There are numerous benefits of using DBS assays including speed and ease of 
collection, minimal invasiveness, small volumes of blood required and easier 
transportation and storage of specimens (Butter et al., 2001). A growing number of 
studies are adding DBS to data-collection protocols (McDade et al., 2007). DBS allows 
for field-based research where DBS can be collected in participants’ homes and even 
posted to investigators improving the ease of sample collection, storage and transport 
(McDade et al., 2007). The main advantages for using DBS in adult pharmacokinetic 
studies are around simplicity of study design and sample processing in that the 
requirements of centrifuging and freezing are removed and the small sample volume 
required for finger-prick sampling improving recruitment (Evans, 2010). There is also 
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cost saving involved with no requirements for sample shipment and/or storage under 
frozen conditions (Evans, 2010).  
The large blood volume sampling requirements of traditional PK studies are 
unacceptable in neonates, therefore DBS has the potential to facilitate these studies in 
neonates (Patel et al., 2013) as sample volumes less than 100 µL are possible (Evans, 
2010, Stokes et al., 2011). The benefit of the smaller sample volume obtained may also 
result in improved patient recruitment and facilitate serial sampling (Evans, 2010). 
Using a DBS assay such as the one developed by Butter et al. (2001) should be a 
convenient method for the estimation of circulating insulin in neonates (Butter et al., 
2001). The current data suggests that DBS sampling has the ability to provide high-
quality PK information using substantially reduced sampling volumes and handling 
costs (Evans, 2010). 
3.1.1.2 Disadvantages of dried blood spots 
There are a few sources of potential error with DBS sampling. Whole blood must be 
placed onto the blood spot correctly or the blood may not be absorbed uniformly into 
the filter paper, this can be an issue if the blood is blotted or smeared onto the paper or 
a drop is placed on top of another drop of blood (McDade & Shell-Duncan, 2002). The 
volume of blood in a DBS can influence the volume of serum contained within a single 
punched disc (McDade & Shell-Duncan, 2002). Uneven spread of the blood across a 
DBS can also be a potential source of error (McDade & Shell-Duncan, 2002). DBS 
samples are not always comparable with samples from plasma or serum as the results 
from DBS samples represent the concentration in whole blood (McDade et al., 2007). 
This results in the concentration in DBS being lower than that in plasma or serum and a 
correction factor is therefore required to compare concentrations from DBS to plasma 
samples (from which the normal reference range of analyte concentrations is usually 
known) (McDade et al., 2007). 
3.1.2 Haematocrit 
Haematocrit or packed cell volume is the ratio of volume occupied by the red blood 
cells in whole blood which is measured by centrifuging a capillary tube of blood and 
measuring the volume of red blood cells packed in the bottom of the tube (Walker & 
Whittlesea, 2011). 
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Haematocrit has a considerable effect on blood viscosity (Figure 3.1), which may affect 
mass transport of the blood put on filter paper affecting the spreading of blood when 
applied to a card (Patel et al., 2010, Holub et al., 2006). The size of a DBS will 
potentially vary in proportion to the blood volume applied and inversely with blood 
viscosity (Patel et al., 2013). Haematocrit is reported to be the most important 
contributor to blood viscosity (Patel et al., 2013). If the haematocrit value is high, blood 
spreading is reduced, and the concentration of blood components per unit area of filter 
paper is expected to be higher (Patel et al., 2010). Studies with caffeine show that 
haematocrit can reduce the accuracy of a target analyte’s quantification when using 
DBS (Patel et al., 2013). In vitro experiments by Patel et al. (2013) showed a 30% 
positive bias in concentration measurements when haematocrit decreased from 0.45 to 
0.20. A study by Arends (1987) found that a decreasing area of paper was covered by 
the same volume of blood as haematocrit increased (Obroin, 1993). Concentrations of 
metabolites may also vary between plasma and cellular compartment within a blood 
spot and therefore can be affected by changes in haematocrit (Holub et al., 2006). 
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Figure 3.1 The relationship of absolute viscosity and haematocrit. Republished with 
permission of American Society for Clinical Investigation, from (Pirofsky, 1953); 
permission conveyed through Copyright Clearance Center, Inc. 
3.1.3 Haematocrit levels in neonates 
Haematocrit levels in neonates vary significantly and often are different from the 
assumed neonatal values of 0.50 or 0.53 (Holub et al., 2006). “Normal ranges” are not 
available for neonatal haematocrit values and instead, “reference ranges” are used 
(Jopling et al., 2009). “Normal ranges” are not available because blood is not drawn on 
healthy, normal neonates to establish these ranges (Jopling et al., 2009). “Reference 
ranges” are compiled from tests performed on neonatal patients who are thought to 
have minimal pathology that would significantly affect the result and should 
approximate normal values (Jopling et al., 2009). A reference range of 0.42 to 0.65 was 
observed by Jopling et al. (2009) among term neonates at birth. Haematocrit levels in 
premature neonates can increase to 0.70 or more (Holub et al., 2006, Dacombe et al., 
1981) and can decrease to less than 0.30 in neonates less than 29 weeks (Jopling et al., 
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2009). The variability in haematocrit is due to various influences such as phlebotomy 
losses, blood transfusions and administration of intravenous fluids (Jopling et al., 
2009). This variability in haematocrit is therefore likely to influence the accuracy and 
precision of drug concentrations when measured from DBS (Patel et al., 2013). 
3.1.4 Chapter aims 
• To determine the effect of haematocrit on insulin concentrations in dried blood 
spots using a chemiluminescent immunoassay. 
• To determine the variability of blood spot collection for measuring insulin 
levels by chemiluminescence. 
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3.2 Materials and Methods 
3.2.1 Materials 
Material details for assay kits and plate readers used for this study are listed in 
Chapter 2. Red blood cells (human, blank) were obtained from the New Zealand Blood 
Service (written approval obtained). Whatman filter paper sheets (grade 0903) were 
obtained from Global Science & Technology Ltd. A Harris 3 mm micro-punch was 
obtained from Sigma-Aldrich NZ Ltd. A Gilson Microman (M100) positive 
displacement pipette was obtained from John Morris Pty Ltd, NZ.  
3.2.2 Methods 
Whole blood standards were prepared by mixing packed red blood cells (measured 
haematocrit 0.83, Haematocrit of the red blood cells was measured in NICU) with 
reconstituted insulin standards (serum matrix) provided with the chemiluminescent 
immunoassay kit in proportions 50:50 (v/v) (Haematocrit = 0.42: 50% of red blood 
cells at a haematocrit of 0.83) (Table 3.1). Onto filter paper, 50 µL of each whole blood 
standard was individually spotted using a Gilson Microman positive displacement 
pipette. The filter paper used was the same paper used in blood spot cards with 903 
paper being a FDA listed class II medical device used in newborn screening 
programmes worldwide (Skopp, 2007). 









Volume (µL) red 





0.00 0.42 200 200 0.00 
4.30 0.42 200 200 2.50 
22.0 0.42 200 200 12.8 
82.4 0.42 200 200 48.0 
208 0.42 200 200 121 
 
Samples of varying haematocrit (0.25 to 0.65) were prepared by mixing red blood cells 
with insulin kit standards in different proportions. Fresh blood samples were not used at 
this stage, as the insulin concentration in the sample needed to be known to see the 
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effect of haematocrit. The zero insulin kit standard was used to adjust the insulin 
concentration to give the desired plasma insulin concentrations of 10 mU/L, 25 mU/L 
and 50 mU/L (Table 3.2). The volume of red blood cells contained in the red blood cell 
suspension (83.3%) was allowed for in the calculations (0.83 x whole blood volume = 
rbc, Table 3.2). All samples were spotted (50 µL) onto filter paper in six replicates and 
then left to dry at room temperature.  



















10 mU/L 0.25 117 163 120 (100 µL rbc) 7.49 
(std= 25.60 mU/L) 0.35 102 130 168 (140 µL rbc) 6.53 
 0.45 86 98 216 (180 µL rbc) 5.50 
 0.55 70 66 264 (220 µL rbc) 4.48 
 0.65 55 33 312 (260 µL rbc) 3.52 
25 mU/L 0.25 78 202 120 (100 µL rbc) 18.68 
(std= 95.8 mU/L) 0.35 68 164 168 (140 µL rbc) 16.29 
 0.45 57 127 216 (180 µL rbc) 13.65 
 0.55 47 89 264 (220 µL rbc) 11.26 
 0.65 37 51 312 (260 µL rbc) 8.86 
50 mU/L 0.25 62 218 120 (100 µL rbc) 37.60 
(std= 242.6 mU/L) 0.35 54 178 168 (140 µL rbc) 32.75 
 0.45 45 139 216 (180 µL rbc) 27.29 
 0.55 37 99 264 (220 µL rbc) 22.44 
 0.65 29 59 312 (260 µL rbc) 17.59 
 
3.2.2.1 Assay procedure 
A previously developed method (Butter et al., 2001) was used to measure insulin 
concentration from DBS. All kit components were prepared according to the 
manufacturer’s instructions except that soluble labelled antibody with high insulin 
specificity was used instead of the normal kit antibody.  
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All kit components were brought to room temperature. Kit standards were reconstituted 
by adding 1 mL of deionised water to each standard and after 5 minutes the standards 
were mixed gently to ensure that all solids were dissolved. Next 900 µL of high insulin 
specificity labelled antibody concentrate was transferred to a bottle of labelled antibody 
diluent and mixed thoroughly. Two 3 mm filter paper discs were punched from each 
DBS using a Harris 3 mm micro-punch (into each well of an Invitron insulin 
chemiluminescent immunoassay) (Figure 3.2). Labelled antibody solution (100 µL) 
was pipetted into the wells of the 96 well plate. The plate was sealed with a plate sealer 
and incubated for 2 hours at 37°C with shaking. Wash buffer was made by diluting 
1 part of wash buffer concentrate from the kit with 29 parts of deionised water. After 
incubation the plate sealer was removed and the contents of the wells were then 
removed (including all blood spot discs). The plate was washed 4 times with working 
strength wash buffer using an automated plate washer. The light output from each well 
was measured in a POLARstar Omega Plate reader (BMG Labtech). During the 
measurement process 100 µL of each of the two detection reagents were added.  
 
 
Figure 3.2 An Invitron insulin chemiluminescent plate with two punched out discs 
from each blood spot contained in the wells. The punch and a typical blood spot are 
shown to the right of the photo. 
 
3 mm 
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Whole blood insulin concentration (B) was calculated from the haematocrit (HCT) and 
plasma insulin concentration (P) using Equation 3.1. 
𝑩 = 𝟏 −𝑯𝑪𝑻 𝑷 
Equation 3.1 
An exponential function (Equation 3.2) was fitted by least squares regression of 
chemiluminescence versus whole blood insulin concentration using Origin Pro 8.5 
(OriginLab Corporation, MA, USA) (Figure 3.5). 
𝒚 = 𝒂𝒆𝒃𝒙 
Equation 3.2 
The effect of haematocrit on chemiluminescence signals was analysed with a two-way 
ANOVA using Stata/IC 11.2 (StataCorpLP, TX, USA). 
3.2.2.2 Clinical Study: the effect of haematocrit on insulin concentrations from 
dried blood spots of neonates 
Blood spot samples were obtained from twenty euglycaemic neonates (one per neonate) 
and nine hyperglycaemic neonates (six per neonate) admitted to Dunedin Hospital 
NICU as part of the larger clinical study (Chapter 2). Neonates with hyperglycaemia 
were receiving an insulin infusion as per NICU protocol (Appendix 1). Paired leftover 
plasma samples were analysed with the same insulin kit but used in the conventional 
way to allow comparison with concentration determined from DBS. The ethical 
approval described in Chapter 2 allowed collection of filter paper samples plus the use 
of leftover plasma from other blood tests: when clinical blood tests were indicated, 
nurses collected them and at the same time collected the filter paper specimens, thus 
producing paired specimens. 
Plasma insulin concentration was determined for each blood spot by using the 
exponential function to determine whole blood insulin concentration and then Equation 
3.3 to calculate the plasma concentration. 
𝑷 =
𝑩
𝟏 −𝑯𝑪𝑻  
Equation 3.3 
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3.3 Results 
3.3.1 Statistical analyses 
Mean chemiluminescent signals (± SD) at each plasma insulin concentration and 
haematocrit value are shown in Figure 3.3. Variation coefficients (CV%) were also 
calculated and compared at each plasma insulin concentration and haematocrit value 
(Table 3.3). Haematocrit significantly affected chemiluminescence output at all levels 
(p <0.05) as shown by a two-way ANOVA (Figure 3.3). Various functions were fitted 
and residuals showed the best fit was represented by an exponential graph, however this 
over-predicted whole blood concentrations less than 5 mU/L (Figure 3.4). The 
exponential function (Equation 3.2) of chemiluminescence versus whole blood insulin 
concentration allowed for the effect of haematocrit on plasma insulin concentration 
(Figure 3.4). Plasma insulin concentrations were then calculated from this curve using 
Equation 3.3. 
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Figure 3.3 The effect of haematocrit on insulin chemiluminescence response from 
extracted blood spot samples. Means are shown and error bars represent the standard 
deviation (n = 6). Hypothesis testing with ANOVA produced p-values. 
Table 3.3 Effect of haematocrit on the variability of plasma insulin concentration in 
blood spots (n = 6) 
Haematocrit CV% (10 mU/L) CV% (25 mU/L) CV% (50 mU/L) 
0.25 32.0% 14.4% 33.3% 
0.35 22.8% 9.1% 19.7% 
0.45 23.6% 20.6% 12.0% 
0.55 43.3% 60.9% 56.6% 
0.65 36.0% 43.1% 24.1% 
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Figure 3.4 Chemiluminescence relative light units (RLU) versus whole blood 
concentration. An exponential function (y = aebx) was fitted in (A) where a = 350 ± 24 
and b = 0.05 ± 0.001, R2 = 0.891. Residuals are shown in (B) and show over-prediction 
of whole blood concentrations less than 5 mU/L. 
  
Chapter three - Haematocrit effect on insulin in DBS 
 59 
3.3.2 Clinical study: the effect of haematocrit on insulin concentrations from 
dried blood spots of neonates 
Paired samples were obtained from eleven neonates (5 males, 6 females). Neonates in 
the study had a mean (SD) gestational age of 27.1 (3.2) weeks, and mean birth weight 
of 1.08 (0.58) kg. Of the nine hyperglycaemic neonates, eight had paired blood samples 
and haematocrit levels (46 samples). Three out of the twenty euglycaemic neonates had 
a paired leftover blood sample and a corresponding haematocrit level. Paired samples 
were plotted using Origin Pro 8.5 (OriginLab Corporation, MA, USA) and weighted 
linear regressions were investigated. A weighting of variance (Equation 3.4) was 
applied as this produced the highest adjusted R-squared value (Table 3.4) and a p-value 
of < 0.01 (Figure 3.5).  




Table 3.4 Table of the various weighted variances applied to the linear regression of 
paired plasma and blood spot samples and their adjusted R-squared values 
 Adjusted R2 
Linear regression 0.167 
Variance ~ yfit^2 (Wi=1/(ŷi)2) 0.388 
Variance ~ yfit (Wi=1/ŷi) 0.267 
Variance ~ y^2 (W=1/Yi2) 0.138 
Direct Weighting (Wji=Cji) 0.193 
Arbitrary Dataset (Wji=1/C2ji) 0.138 
Statistical (Wji=1/Yji) 0.178 
 
The ratio of blood spot/paired sample plasma insulin concentrations had a high 
variability (ranged from a percentage of blood spot/paired sample of 7.7 to 1143%) and 
showed that the calculated plasma concentrations from the blood spots were generally 
higher than their paired directly measured plasma samples. 
Figure 3.5 shows the samples can be divided into three groups with two potential 
outliers and two samples that had high leverage on the linear regression. As can be seen 
by the axes on the figure, the two samples that are potential outliers are more accurately 
matched than all the other samples on this plot; these two samples also came from the 
same neonate and were taken just four hours apart. When the high leverage samples 
were removed, the adjusted R-squared value did increase slightly but the linear 
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regression was no longer successfully fitted in Origin Pro, this did however 
demonstrate that these two samples do have leverage on the regression. 
 
Figure 3.5 Weighted (𝑾𝒊 =
𝟏
ŷ𝒊 𝟐
) least squares linear regression (𝒚 = 𝑨 + 𝑩𝒙) of 
calculated plasma concentration from blood spots with paired laboratory plasma 
concentrations. A = 6.09 ± 2.04, B = 0.42 ± 0.07, adjusted R2 = 0.388, ● euglycaemic 
neonates and ○ hyperglycaemic neonates. 
  
Potential outliers 
Data points with 
high leverage 
 (1-HCT) (mU/L) 
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3.4 Discussion 
The use of DBS for pharmacokinetic studies in neonates has a number of potential 
advantages over conventional plasma sampling (Spooner et al., 2009, Patel et al., 
2013). The smaller blood volumes required for DBS samples make this an attractive 
method for neonates, where the larger blood volume sampling requirements of 
traditional PK studies are unacceptable (Spooner et al., 2009, Patel et al., 2013). 
However, the variability in haematocrit observed in neonates could influence the 
accuracy and precision of drug concentrations determined from DBS (Patel et al., 
2013). As haematocrit is the most important contributor to blood viscosity, analysis 
based on a ‘fixed’ disc of blood sub-sampled from a DBS may be affected by variations 
in haematocrit (Patel et al., 2013). These variations may reduce the accuracy of analyte 
quantification and affect PK parameter estimation (Patel et al., 2013). 
Chemiluminescence signals were significantly lower at higher haematocrit values, at all 
three plasma concentrations (Table 3.3). Therefore, haematocrit has a significant effect 
on plasma insulin concentration from blood spots as measured by chemiluminescence. 
Analysis of residuals from multiple functions showed the best fit was represented by an 
exponential graph (Figure 3.4), however it over-predicts whole blood concentrations 
less than 5 mU/L which is important at low insulin concentrations. Plasma insulin 
concentrations from the clinical study were calculated using this exponential function 
to allow for the effect haematocrit has on concentration. The calculated plasma insulin 
concentrations were compared to corresponding paired plasma samples. 
Although Butter et al. (2001) determined that haematocrit did not have a significant 
effect, they only tested values of 0.50 and 0.55. Where this assay may have its use in 
healthy term neonates with “normal” haematocrit levels, it is potentially not ideal for 
neonates admitted to NICU, especially those who are preterm. This finding is relevant 
as haematocrit values in the neonate may increase to 0.70 or more and critically ill 
premature infants may have significantly lower haematocrit levels (Holub et al., 2006, 
Dacombe et al., 1981). The neonates in this study had haematocrit levels ranging from 
from 0.28 to 0.45. 
A high variability in chemiluminescence response was observed at all plasma 
concentrations and haematocrit values (CV% = 9 to 61%) (Table 3.3). This variability 
carried through to the samples collected from neonates. As the extreme variability 
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demonstrates, the plasma insulin concentrations calculated from blood spots did not 
accurately match the paired plasma sample concentrations. This shows that blood spots 
are not an accurate way of measuring insulin levels in neonates due to the effect of 
haematocrit and the apparent high variability of extraction. The concentrations 
calculated from the blood spots were in most cases higher than the laboratory plasma 
value, which might indicate insulin being present in the red blood cells. Studies have 
reported that human erythrocytes have highly specific insulin receptors (Murali et al., 
2003, Gambhir et al., 1978). If insulin is bound to these receptors it may be increasing 
the inaccuracy of the calculated plasma concentration due to red blood cells being 
present in the blood spots. This binding would need to be accounted for to calculate an 
accurate and comparable plasma insulin level. This binding could be calculated using a 
separation technique such as a dialysis membrane with a high cut off of around 
8000 MW to calculate fraction unbound.  
One way to improve this assay, as described by Patel et al. (2013), could be to collect a 
“fixed volume” DBS sample then quantify the analyte using the whole sample rather 
than collecting the DBS and using a “fixed punch size”. This technique would require 
significant training due to the difficulty of collecting a precise volume from neonates 
on every occasion (Patel et al., 2013). Another option suggested by Patel et al. (2013) 
is to use DBS cards that reduce or eliminate haematocrit effects. Blood spot cards have 
been reported to have consistent spot homogeneity and minimal changes in spot size 
with haematocrit changes in the range of 0.20 to 0.80 (Patel et al., 2013). These options 
would be worth investigating for future use where intensive PK sampling is required. 
However, since the chemiluminescent insulin assay only requires 25 µL of plasma or 
serum (requiring approximately 100 microlitres of whole blood), insulin levels in 
neonates can be measured accurately without the use of DBS. The promising 
combination of DBS convenience and a DBS analytical method for insulin has variable 
results when looked at in the laboratory and in the newborn clinic with widely varying 
haematocrit levels. Nevertheless the DBS method does have advantages in terms of 
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3.5 Conclusions 
This study shows that haematocrit had a significant effect on measured plasma insulin 
concentration when samples were collected as blood spots. Caution is advised for this 
sampling method in pharmacokinetic studies in neonates. Further work to reduce the 
variability of this sampling technique is required before it should be used to evaluate 
insulin delivery in preterm neonates. 
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4 The effect of gestational age and blood glucose on             
C-peptide excretion rate and clearance calculated from 
urinary C-peptide measured by chemiluminescence in 
twenty neonates 
4.1 Introduction 
As discussed in Chapter 3, the relatively large volume of blood required by most drug 
assays is problematic in preterm neonates because of their comparatively small 
circulatory volume and is therefore a major barrier to conducting pharmacokinetic (PK) 
trials in neonates (Patel et al., 2010). Measuring urinary C-peptide is another 
noninvasive measure to calculate insulin production (Hoogwerf et al., 1983) making it 
an especially attractive method in neonates. 
Although there is some evidence that preterm neonates are relatively resistant to 
insulin, these data are sparse (Mitanchez-Mokhtari et al., 2004). Hence the 
management of neonatal hyperglycaemia is controversial, as to whether the treatment 
should be focussed on insulin administration or caloric restriction (Beardsall & Dunger, 
2008). Understanding the rate of production of insulin in both hyper- and 
hypoglycaemia would aid the understanding of these conditions. 
4.1.1 Urinary C-peptide; excretion rate and clearance 
Measurement of C-peptide clearance is proposed as a potential surrogate marker for 
endogenous insulin production. Insulin and C-peptide are secreted in equimolar 
amounts from the pancreas (Galgani et al., 2010, Rebsomen et al., 2008). Hepatic 
metabolism of insulin is rapid with approximately 50% undergoing extraction by the 
liver (Galgani et al., 2010, Hoogwerf et al., 1983). However since C-peptide is not 
metabolised by the liver and undergoes partial renal clearance, it may be possible to 
estimate insulin secretion from the urinary C-peptide excretion rate (Galgani et al., 
2010). C-peptide renal clearance is influenced by glomerular filtration, tubular 
reabsorption and enzymatic degradation following peritubular uptake (Zavaroni et al., 
1987, Jones & Hattersley, 2013). Of the C-peptide, 5–10% is excreted unchanged in the 
urine, (Gacs et al., 1985, Horwitz et al., 1977, Sherry & Ellison, 2007, Thomas et al., 
2012, Wasada et al., 1995), as compared with 0.1% of insulin (Horwitz et al., 1977). 
The concentration of C-peptide in urine is usually ten to twenty times higher than 
plasma (Jones & Hattersley, 2013, Wasada et al., 1995) and is more chemically stable 
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due to the low proteases concentrations in urine (Jones & Hattersley, 2013, McDonald 
et al., 2009). This makes it feasible to measure C-peptide in urine even when the 
production rate is low.  
Both insulin and C-peptide plasma concentrations have been shown to increase with 
age in children (Gacs et al., 1985), therefore it is expected that neonates would have 
lower plasma insulin and C-peptide concentrations than adults. Insulin-resistant 
individuals have been found to have an increased urinary excretion of C-peptide per 
unit of energy ingested when compared to insulin-sensitive individuals (Galgani et al., 
2010). 
4.1.2 Analysis of analyte concentrations using standard addition 
Standard addition is a commonly used method to calculate the concentration of an 
analyte in a sample when the constituents of the sample are not known, as in complex 
matrices such as biological fluids (Gorazda et al., 2013). Using this method, known 
volumes of analytical standards are added to a known volume of the unknown analyte, 
the response (e.g. chemiluminescence) is then plotted against the concentration of an 
analytical standard. The concentration of the unknown analyte concentration is then 
found by fitting a linear model to the data and determining the x-intercept as shown in 
Figure 4.1 (Saxberg & Kowalski, 1979).  
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Figure 4.1 Method for determining analyte concentration using standard addition. 
Assay response and analyte standard concentrations are given in arbitrary concentration 
units. 
Current chemiluminescent assays are available for C-peptide plasma or serum samples, 
but have not been validated for urine. Previous work (Soelbeck, 2012) determined that 
urine required dilution to between 20 and 40% with bovine serum albumin (BSA) 1% 
in phosphate buffer saline (PBS) to produce concentrations within the range of the 
plasma/serum chemiluminescence standard curve provided by Invitron.  
In this chapter direct measurement and standard addition using the supplied plasma kit 
standards were compared. This comparison was required, as the Invitron kits have not 
been validated for use with urine and C-peptide free urine was not available to produce 
standard solutions for assay calibration. Once the kit was validated for urine, urinary C-
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4.1.3 Chapter aims 
• To investigate direct measurement and standard addition for determination of 
urinary C-peptide concentrations using a plasma/serum chemiluminescent 
immunoassay.  
• To measure urinary C-peptide concentrations using a chemiluminescent 
immunoassay in neonates and calculate C-peptide clearance (Cl) and excretion 
rate (UER). 
• To investigate the effect of gestational age (GA) and blood glucose 
concentrations (BGC) on these two measures. 
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4.2 Materials and Methods 
4.2.1 Materials 
Material details for assay kits and plate readers used for this study are given in Chapter 
2. Bovine serum albumin was obtained from Sigma Aldrich (St Louis, MO, USA). A 
pH 7.4 phosphate buffer solution was prepared using sodium chloride (NaCl), 
potassium chloride (KCl), disodium hydrogen phosphate (Na2HPO4), potassium 
dihydrogen phosphate (KH2PO4) and hydrogen chloride (HCl) purchased from Sigma 
Aldrich (St Louis, MO, USA). 
4.2.2 Methods 
4.2.2.1 Analysis of C-peptide in urine – comparison of standard addition and direct 
measurement 
The insulin and C-peptide assay kit procedures for plasma samples are described in 
Chapter 2. 
Urine was obtained from a non-fasting adult and neonate on two occasions. Urine 
samples (adult and neonate) were diluted by mixing 50 µL or 100 µL with either 
200 µL or 150 µL PBS 1% BSA to give final dilutions of 20% urine and 40% urine 
respectively. Dilution was necessary to produce concentrations within the usual range 
of the plasma assay. Each dilution was repeated six times. Then 100 µL of each kit 
standard was mixed with 100µL of each urine dilution. These dilutions were also 
repeated six times. Standard addition curves were created by mixing diluted urine with 
C-peptide kit standards (six concentrations; 0 to 5045 pmol/L) (1:1 v/v). Urinary        
C-peptide concentration was determined by linear regression analysis and extrapolation 
back to the concentration axis for each standard addition curve. Alternatively, the kit 
standard curve was used to directly estimate C-peptide in diluted urine samples. The 
two measurement methods were compared and t-tests were performed using Stata/IC 
version 11.2 (StataCorpLP, TX, USA). Precision was calculated using CV% (SD/mean 
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4.2.2.2 Clinical study - C-peptide excretion rate and clearance in twenty neonates 
Plasma and urine samples were obtained from 20 euglycaemic neonates (6 females and 
14 males), at Dunedin Hospital NICU. The neonates were included if they were 
euglycaemic, were undergoing blood tests as part of normal clinical care, and written 
informed consent had been obtained from parents or caregivers. The exclusion criteria 
were: hyperglycaemia, hypoglycaemia, or treatment with insulin, oral hypoglycaemic 
agents or other medicines that alter glucose homeostasis (e.g. corticosteroids). Plasma 
was obtained from leftover blood samples taken during routine blood sampling. Urine 
was concurrently collected via cotton wool placement in nappies when it was known 
that routine blood samples would be taken within the same time interval. Urine volume 
was estimated by the weight change of the nappy (assumed urine density was 1g/mL) 
and duration of collection was recorded. Insulin and C-peptide were measured using 
chemiluminescent assays (Invitron, Monmouth, UK). Urine was diluted to 40% with 
BSA 1% in PBS prior to analysis.  
Each urine sample was paired with a plasma sample collected in the same time period 
that urine collection had occurred. The following equations were used to calculate C-
peptide excretion rate (UER) (Equation 4.2) and clearance (Cl) (Equation 4.3). 









Both C-peptide UER and Cl were calculated per kg total body weight (BW), urine FR = 
urine flow rate in mL/min = ( _`abcd	`e	bfghd	(ci)
jgcd	`e	k`aadkjg`h	(lmn)
). Curine = urine concentration in 
pmol/L and Cplasma = plasma concentration in pmol/L. 
Pairwise correlations and analysis of covariance (ANCOVA) were performed using 
Stata/IC (Version 11.2, StataCorpLP, TX, USA).  
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4.3 Results 
4.3.1 Analysis of C-peptide in urine – comparison of standard addition and 
direct measurement 
A typical standard curve for direct measurement of C-peptide in plasma is shown in 
Figure 4.2 (CV% = 2.1 to 5.6%; accuracy = 89 ± 4% to 100 ± 8.6%, Table 4.1). 
Standard addition curves are given for determination of C-peptide in the adult and 
neonate urine samples following initial dilutions to 20 and 40% urine (Figure 4.3 to  
Figure 4.6).  
Table 4.1 Standard curve precision (coefficient of variation: CV%) and accuracy of a 
typical kit standard curve 
Standards Mean 
(RLU) 
SD CV%  
(SD/mean 
*100%) 
Mean accuracy  
(calculated concentration/ 
actual concentration *100%) 
SD of 
accuracy 
1 4456 166 3.7% 99.9% 10.8% 
2 25633 1437 5.6% 100.1% 9.7% 
3 57979 2260 3.9% 100.1% 8.6% 
4 84034 1762 2.1% 100.6% 14.6% 
5 121975 6465 5.3% 88.9% 4.4% 
 
Urine was obtained from two neonates for each occasion of urine dilution. On the first 
occasion urine was obtained from a male neonate who was 34 weeks gestation and 
weighed 2960 g at birth. The second neonate was also male, 31.6 weeks gestation and 
had a birth weight of 2190 g. Urine was obtained on two occasions from a 34 year old 
female for the adult urine used in this analysis. All diluted samples from the adult and 
neonate urine were directly measured from the standard curve (Table 4.2, Figure 4.2) 
and also calculated using standard addition curves. A summary of concentrations 
calculated using both methods is shown in Table 4.2. Results suggested urine diluted to	
20% was sufficient for measuring C-peptide in adult urine (CV% = 3.7 to 11.5%) 
(Table 4.2, Figure 4.3 and Figure 4.4). Whereas urine diluted to	 40% was required for 
measuring C-peptide in neonate urine to produce the best standard curve (CV% = 3.0 to 
13.0%) (Table 4.2, Figure 4.5 and  
Figure 4.6). It was confirmed by t-tests that there were no significant differences 
between the C-peptide concentrations calculated using standard addition and direct 
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measurement (p >0.05, Table 4.2), therefore the direct measurement method was 
chosen for the clinical study.  
Table 4.2 Mean calculated C-peptide concentrations in adult and neonate urine from 
standard addition and direct measurement using C-peptide chemiluminescence kits  
 Occasion Urine 
concentration 
% (v/v) 




curve (pmol/L)  









Adult  1 20% 3557 (676) 2658 (259) 0.067 
 2 40% 11590 (3387) 12485 (318) 0.557 
Neonate  1 20% 440 (283) 279 (7.6) 0.375 
 2 40% 718 (51) 678 (33) 0.179 




Figure 4.2 Typical kit standard curve for direct measurement of C-peptide (second 
order polynomial was fitted (y = a + bx + cx2): a = –1498 ± 714, b = 23.23 ± 0.97, c = –
0.0015 ± 0.0002, R2 = 0.996. Dashed lines represent the 95th percentile upper (UCL) 
and lower (LCL) confidence limits and dotted lines the 95th percentile upper (UPL) and 
lower (LPL) prediction limits.  
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Figure 4.3 Standard addition curve of C-peptide in adult urine, 20% dilution (fitted line 
is a linear function: y = a + bx): a = 9702 ± 1558, b = 16.6 ± 0.60, R2 = 0.949. 
 
Figure 4.4 Standard addition curve of C-peptide in adult urine, 40% dilution (y = a + 
bx): a = 46727 ± 1654, b = 9.78 ± 0.70, R2 = 0.919. 
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Figure 4.5 Standard addition curve of C-peptide in neonate urine, 20% dilution (y = a + 
bx): a = 1589 ± 946, b = 18.05 ± 0.36, R2 = 0.984. 
 
Figure 4.6 Standard addition curve of C-peptide in neonate urine, 40% dilution (y = a + 
bx): a = 4156 ± 915, b = 14.45 ± 0.35, R2 = 0.988. 
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4.3.2 Clinical study of C-peptide excretion rate and clearance in twenty neonates 
There were 14 males and 6 females in the study with a mean (SD) gestational age of 
32.6 (3.43) weeks, and mean (SD) weight of 2110 (735) g. All neonates were 
appropriate size for their gestational age. A summary of the demographic 
characteristics of these neonates is presented in Table 4.3. 
Table 4.3 Participant demographics for neonates included in the study 
 Mean (SD) Median (range) 
Gestational age (weeks) (n = 20) 32.6 (3.4) 33.7 (27.7 - 41.4) 
Postmenstrual age (weeks) (n = 20) 34.4 (3.1) 34.4 (29.6 - 41.7) 
Birth weight (g) (n = 20) 2110 (735) 2200 (515 -4260) 
Weight (g) (n = 10) 2220 (875) 2230 (630 - 3940) 
Birth length (cm) (n = 17) 44.5 (4.7) 46 (30 - 50) 
Birth head circumference (cm) (n = 19) 30.6 (3.4) 31 (22 - 36.4) 
Note some data were missing, as not everything was recorded in patient notes. 
 
The mean (SD) plasma insulin concentration was 71.3 (58.2) pmol/L, and the mean 
(SD) C-peptide concentration was 182 (184)	 pmol/L, resulting in a mean (SD) non-
fasting insulin/C-peptide (I/CP) ratio of 1.29 (2.62) in these neonates. Two potential 
outliers were identified as having unusually high C-peptide urine concentrations 
causing higher C-peptide UER and Cl and were excluded from analysis (Table 4.4). 
The mean (SD) C-peptide UER was 0.0329 (0.0342) pmol/min/kg, and Cl was 0.309 
(0.329) mL/min/kg. The individual C-peptide UER and Cl for each neonate are shown 
in Appendix 6. 
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Table 4.4 Details of two neonates with high C-peptide urine concentrations causing 
higher C-peptide UER and Cl. These two neonates were excluded from the analysis 
 Neonate 1* Neonate 2* 
Gestational age (weeks) 28.6 27.7 
Age (days) 22 31 
Birth weight (g) 1220 515 
Weight (g) 1615 630 
C-peptide plasma concentration (pmol/L) 34.4 442 
C-peptide urine concentration (pmol/L) 2430 2525 
BGC (mmol/L) 4.40 3.90 
C-peptide UER (pmol/min/kg) 0.23 0.86 
C-peptide Cl (mL/min/kg) 6.80 1.94 
*Neonate 1: male and was appropriate size for gestational age (50th percentile). 
*Neonate 2: male but was extremely small for gestational age (0.4th percentile) and 
failed to thrive. 
 
Five neonates (seven observations) had BGC measured during the urine collection 
period with a mean (SD) of 5.36 (1.14) mmol/L, indicating that these subjects had 
normal BGC (normal fasting venous plasma in adults <6.1 mmol/L(Kahn, 2003)) 
during the study.  
Scatter plots for C-peptide clearance and UER compared with blood glucose and GA 
are shown in Figure 4.7. Pairwise correlations were not statistically significant (p 
>0.05, Table 4.5). Analysis of Covariance (ANCOVA) also showed that there was no 
significant effect of GA and BGC on C-peptide Cl and UER (Table 4.5). However, it 
was noted that a negative correlation (r = -0.686, p = 0.132) was observed between C-
peptide Cl and BGC in this small sample.  
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Figure 4.7 Scatter plots of C-peptide Cl versus BGC (A), UER versus BGC (B), C-
peptide Cl versus GA (C), UER versus GA (D) excluding two outliers. 












C-peptide UER -0.326  0.187  -0.318 0.602 
C-peptide CL 0.0066  0.979  -0.686 0.132 
 
All neonates in this study received similar caloric intake with 16 receiving breast milk, 
eight receiving formula (of which five were also receiving breast milk) and one 
received total parenteral nutrition (TPN) alone. Five of the neonates received TPN, four 
also received dextrose, three lipids and two human milk fortifier (HMF). 
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4.4 Discussion 
The main findings in this Chapter were that for neonates GA does not appear to directly 
affect C-peptide UER and Cl. This lack of dependency means that urinary C-peptide 
could have potential as a biomarker of insulin production in neonates. Additionally, 
BGC did not appear to affect C-peptide UER and Cl (p >0.05), making predicting 
insulin production more straightforward. Kruszynska et al. (1987) found that urinary C-
peptide was significantly correlated (r = 0.74) with 24 hour C-peptide secretion (and 
therefore insulin secretion). This would indicate that the C-peptide UER gives an 
indication of insulin secretion. Therefore, since GA and BGC do not seem to directly 
affect C-peptide UER and Cl, urinary C-peptide could be used as a direct indicator of 
insulin secretion in neonates. 
C-peptide concentrations were determined in neonatal urine samples following dilution 
with PBS containing 1% BSA. Addition of BSA to solutions of insulin and other 
hormones in used to reduce analyte loss by adsorption to plasticware during analytical 
procedures (Goebel-Stengel et al., 2011). Standard addition is often used to determine 
the concentration of an analyte in a complex matrix such as biological fluids (Gorazda 
et al., 2013), and can overcome problems caused by matrix effects that modify 
sensitivity (affect the slope of the calibration function) (Andrade et al., 2013). It is also 
used to optimise precision of results and avoid causes of bias that can occur when the 
matrix of the test solution varies unpredictably (Andrade et al., 2013). In this study, the 
standard addition method was compared with a direct measurement method, as the 
chemiluminescent immunoassay in question had not been validated for use in urine. 
Direct measurement produced a more precise estimate (smaller standard deviations) of 
C-peptide concentration and was simpler to perform than the standard addition method, 
which had other factors (for example extra dilution steps) adding to an increase in 
variability. Dilution of urine samples was required to achieve concentrations in the 
range of the chemiluminescence assay kit because concentrations of C-peptide in urine 
are ten to twenty times higher than plasma. A dilution to 40% urine was needed for 
neonate samples whereas greater dilution (final urine concentration of 20%) was 
needed for the adult urine samples. The higher concentration of urinary C-peptide in 
adults is consistent with the work of Gacs et al. (1985) who showed that plasma and 
urine C-peptide concentrations were higher in adults than in children (Gacs et al., 
1985). They showed that urinary C-peptide increased with age from birth until 14 years 
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of age (r = 0.64, p <0.001) when urinary C-peptide was comparable with adults 
(30 µg/day in 14 year olds compared with 36 to 63 µg/day in adults) (Gacs et al., 
1985). This same work showed a four-fold higher urinary C-peptide excretion rate in 
older children (C-peptide to weight ratio (µg/kg): 0.85 ± 0.48, 10 to 14 years) compared 
to neonates (C-peptide to weight ratio (µg/kg): 0.19 ± 0.09, 3 to 3.9 kg) (Gacs et al., 
1985). 
The neonates in the study described in this Chapter had a mean (SD) non-fasting molar 
insulin/C-peptide (I/CP) ratio of 1.29 (2.62), which is higher than that usually seen in 
adults. In healthy adults, the plasma I/CP ratio gives an indication of fasting hepatic 
insulin clearance (Hilton et al., 2001), and does not normally exceed 1.0, whether 
fasting or fed, unless the patient is receiving exogenous insulin or has liver cirrhosis 
(Iwase et al., 2001, Lebowitz & Blumenthal, 1993). Normal ranges for plasma I/CP 
ratios have not been reported in neonates. Therefore, despite their non-fasting status, a 
mean ratio greater than 1 suggests either the hepatic insulin clearance in these neonates 
is reduced (higher insulin concentration) or the C-peptide renal clearance was higher 
(lower C-peptide concentration) when compared with adults. 
C-peptide UER and Cl were highly variable in the neonates studied. A number of 
mechanisms could account for this, and further investigation may be needed to better 
understand the sources of variability. From the data collected for this Chapter there 
were no significant correlations between BGC and C-peptide UER and Cl but this may 
be due to the small sample size (n= 7) and the small range of BGCs (3.9 to 
7.4 mmol/L). Urinary C-peptide has been shown to change due to diet (Gacs et al., 
1985) in adults and children, so it is possible energy intake of these neonates was 
relatively higher in comparison leading to elevated results. Differences in renal function 
can also influence blood concentrations of C-peptide (Henriksen et al., 1987, Zavaroni 
et al., 1987), a potential issue in the premature neonatal population. Premature and 
small for gestational age neonates have been shown to have smaller kidneys and lower 
glomerular filtration rates (GFR) than term neonates (Aperia et al., 1981, Schmidt et 
al., 2005). Another source of variability in UER, could be that even though urinary 
output was timed, there may be discrepancy between the last bladder emptying and the 
time of the last nappy change. While every effort was made to document the last 
bladder emptying, the exact timing remains unknown and may have occurred before the 
last nappy change. A final issue could be evaporation or loss of urine from the cotton 
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wool and/or nappies causing variability in the urinary C-peptide concentrations. This 
was minimised by transferring the urine containing cotton wool into airtight containers 
immediately at each nappy change. There was also no evidence of bulk leakage of urine 
from nappies as all neonate clothing and bedding was dry at the time of urine 
collection. 
Serum insulin concentrations represent a balance between insulin secretion, cellular 
uptake, metabolism and renal elimination and are therefore not a true reflection of beta 
cell secretion (Polonsky & Rubenstein, 1986). C-peptide peripheral kinetics of 
distribution have been described by a two-compartment pharmacokinetic model 
(Polonsky & Rubenstein, 1986). Parameters (C-peptide concentration, C-peptide 
volume of distribution, quantity of C-peptide in a bolus dose and fractional rate 
constants describing movement of C-peptide from the two compartments) (Polonsky & 
Rubenstein, 1986) were derived by analysing C-peptide decay curves and then using 
this information to determine insulin secretion. However, this model requires fasting 
peripheral C-peptide concentrations, which cannot be determined for neonates. Studies 
have shown that urinary C-peptide concentrations reflect changes in insulin production 
due to body size, diet, drug administration and exercise and are an indicator of residual 
β-cell capacity in diabetes (Gacs et al., 1985, Hoogwerf et al., 1983, Meistas et al., 
1981). Since urinary C-peptide clearance parallels the rate of production, urinary C-
peptide may give a non-invasive way of measuring insulin production in neonates 
(Sherry & Ellison, 2007).  
4.5 Conclusions 
C-peptide concentrations in urine were measured directly using a chemiluminescent 
immunoassay and were used to calculate C-peptide clearance and excretion rate in 
neonates. Since GA does not appear to affect C-peptide UER and Cl, urinary C-peptide 
may give a non-invasive method of measuring insulin production in neonates.  
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5 Insulin resistance, glucagon-like peptide-1 and other 
factors influencing glucose homeostasis in preterm and 
term neonates 
5.1 Introduction 
Neonates are at risk of both hypo- and hyperglycaemia. In utero a foetus receives a 
constant supply of glucose across the placenta (Hume et al., 2005, Mena et al., 2001, 
Mitanchez, 2007), but soon after birth, the neonate then must undergo rapid metabolic 
adaptation to establish glucose homeostasis (Beardsall et al., 2008). This cessation of 
maternal glucose supply causes a drop in the neonate’s glucose concentration (Mena et 
al., 2001) producing a surge of plasma catecholamines, glucagon, glucagon receptor 
expression, and cortisol levels (Beardsall et al., 2008, Hume et al., 2005, Mitanchez, 
2007, Mitanchez, 2008), with a corresponding decrease in insulin concentrations 
(Mitanchez, 2008). These changes induce hepatic glucose production through 
glycogenolysis for the first few hours and then subsequently gluconeogenesis 
(Beardsall et al., 2008, Hume et al., 2005, Mena et al., 2001, Mitanchez, 2007, 
Mitanchez, 2008). This allows maintenance of plasma glucose, with hepatic glucose 
production estimated to be 4 to 6 mg/kg/min in term neonates until feeding is 
established (Mitanchez, 2007, Platt & Deshpande, 2005). Once feeding is established 
insulin concentrations in the range of 3 to 20 µU/mL (18 to 120 pmol/L, 1 µU/mL = 
6 pmol/L) have been reported in term neonates (Gesteiro et al., 2009).  
Preterm neonates are particularly susceptible to hypoglycaemia in the first 24 hours 
after birth, and hyperglycaemia in subsequent weeks (Beardsall et al., 2008, Beardsall 
& Dunger, 2008, Mericq, 2006). Hypoglycaemia is thought to be due to multiple 
factors, including: lower glycogen reserves; lower gluconeogenic enzyme activity; 
initial limited counter-regulatory hormone response; and overall lower blood glucose 
concentrations with a slower postnatal rise (Hume et al., 2005). Neonatal 
hyperglycaemia is also reported to be due to a combination of factors. Firstly, it appears 
that while pancreatic β-cells in preterm neonates are sensitive to changes in blood 
glucose, and proinsulin is secreted, the rate of subsequent processing to insulin appears 
slower than in term neonates (Beardsall et al., 2008, Mericq, 2006, Mitanchez-
Mokhtari et al., 2004). Insulin resistance is the other key factor reported for preterm 
neonates (Mitanchez-Mokhtari et al., 2004). Elevated C-peptide concentrations in 
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preterm neonates suggest that insulin production is higher than in term neonates, adding 
support to the concept that preterm neonates are relatively resistant to insulin 
(Mitanchez-Mokhtari et al., 2004).  
The main data supporting these traditional concepts contain some important gaps. Data 
were limited to gestational ages 23 to 29 weeks, and 38 to 41 weeks inclusive, with no 
neonates between 29 and 38 weeks gestation. Insulin and C-peptide concentrations 
were not related to glucose concentrations, and over half the population of preterm 
neonates from whom these data were derived had been exposed to postnatal 
glucocorticoids, which are known to affect glucose homeostasis (Mitanchez-Mokhtari 
et al., 2004).  
In addition to the above limitations, there are few data investigating the role of other 
hormones and their response to first enteral feed in the maturation of neonatal 
glycaemic control. GLP-1 which is excreted in response to oral feeding may be an 
important factor, as glucose control in the neonate appears to improve once enteral 
feeds are established (Beardsall et al., 2008). There are previous data in neonates 
relating to enteroglucagon, a superseded term referring to a number of peptides that 
cross-reacted with glucagon (Aynsley-Green et al., 1977, Lucas et al., 1978). In term 
infants, enteroglucagon concentrations have been shown to rise after the first feed, but 
this response has not been demonstrated in preterm infants. Also, the neonates in these 
studies were seriously ill term infants, so that the effect of enteroglucagon is unknown 
in healthy term infants. Animal studies do, however, support the hypothesis that 
postnatal feeding is important for increasing β-cell function in the postnatal period 
(Asplund, 1972, Beardsall et al., 2008).  
Other measures that may give insight into the maturation of glucose homeostasis 
include glucagon, the relationship between insulin and C-peptide, and the relationship 
between insulin concentrations and blood glucose concentrations. Glucagon 
concentrations do not appear to be affected by feeding or by blood glucose 
concentrations, in euglycaemic neonates (Aynsley-Green et al., 1977, Lucas et al., 
1978). The I/CP ratio gives an indication of insulin clearance in adults (Hilton et al., 
2001) but normal ranges of I/CP ratios have not been reported in neonates. I/CP may be 
an indicator of both insulin clearance and production in neonates. Insulin 
concentrations rise in response to blood glucose concentrations, and in preterm 
neonates who are given a high glucose load it would be expected that insulin 
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concentrations would be greater than in term neonates. Finally, the insulin/blood 
glucose (I/BGC) ratio may give greater insight into insulin resistance than insulin 
concentrations alone. 
5.1.1 Chapter aims 
• To explore the relationships between postmenstrual age and insulin, C-peptide, 
glucagon, and glucose concentrations in preterm and term neonates.  
• To determine the concentrations of GLP-1 in never fed versus fed neonates. 
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5.2 Materials and Methods 
5.2.1 Materials 
Materials used for this study are described in Chapter 2. 
5.2.2 Methods 
The patients recruited into the study were term or preterm neonates admitted into the 
Dunedin Hospital NICU. The neonates were included if they were euglycaemic (i.e. 
were not hypo- or hyperglycaemic), were undergoing blood tests as part of normal 
management, and written informed consent from parents had been obtained. The 
exclusion criteria were: hyperglycaemia, hypoglycaemia, or treatment with insulin, oral 
hypoglycaemic agents or other medicines that alter glucose homeostasis (e.g. 
corticosteroids). Plasma samples were obtained from leftover blood samples taken 
during routine clinical care. The plasma samples were analysed for insulin, C-peptide, 
GLP-1 and glucagon concentrations on the basis of the availability of samples. The 
samples were analysed for insulin, C-peptide, GLP-1 and glucagon using 
chemiluminescence and ELISA as described in Chapter 2. 
BGCs taken at the same time as blood samples were recorded from patient notes. 
Dunedin hospital NICU defines clinically significant hyperglycaemia as BGC of 
10 mmol/L or more, for two consecutive levels, four hours apart. A survey in 
Australasia found that most units defined hyperglycaemia as BGC above 10 mmol/L 
(Alsweiler et al., 2007). Dunedin hospital NICU defines clinically significant 
hypoglycaemia as a blood glucose concentration less than 2.6 mmol/L. It has been 
shown that BGCs below 2.6 mmol/L should be avoided (Hawdon et al., 1994).  
Data were collected from clinical notes for gestational age (GA), age from birth, birth 
weight, current weight, length, head circumference, oral intake (including fed versus 
never fed by mouth), and intravenous fluids. Preterm neonates received dextrose 10% 
as part of their standard treatment regimen. Postmenstrual age (PMA) was calculated 
for each neonate by correcting GA for the age at the time of the study (PMA = GA at 
birth + age from birth). PMA was categorized into three age groups: ≤32 weeks, >32 to 
≤36 weeks and then >36 weeks. Statistical analyses were performed using Stata/IC 
(Version 11.2, StataCorpLP, TX, USA). The data were analysed using summary 
statistics and distributions, pairwise correlations, linear regression for variables 
showing significant correlations (p >0.05), t-tests and ANOVA of categorical PMA 
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versus I/CP and I/BGC ratios were performed on this dataset. The distribution of data 
was tested for normality (Appendix 7). Where the data were log-normally distributed, 
the hypothesis tests were performed on log-transformed data. Non-linear regression 
was also performed to explore the relationships of I/CP and I/BGC with PMA. 
Decreasing exponential functions (𝑦	 = 	𝐴1	×		𝑒 T
p
qr + 	𝑦s)	were fitted using Origin 
Pro 8.5 (OriginLab Corporation, MA, USA) (Figure 5.1 and Figure 5.2). 
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5.3 Results 
5.3.1 Participant demographics 
Plasma samples were obtained from 102 non-insulin-treated neonates. There were 67 
males and 35 females with a mean (SD) PMA of 33.7 (4.36) weeks and mean birth 
weight of 2071 (932) g. A summary of the demographic characteristics of these 
neonates is presented in Table 5.1. The subgroups of neonates that had glucagon and/or 
GLP-1 serum concentrations measured were similar in demographic characteristics to 
the complete dataset. The glucagon group had a mean (SD) PMA of 33.4 (5.0) weeks 
and mean (SD) birth weight of 2000 (963) g; and the GLP-1 group had a mean (SD) 
PMA of 33.4 (5.01) weeks and mean (SD) birth weight of 2014 (1026) g (Table 5.1). 
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5.3.2 Summary of glucose regulatory hormone concentrations 
Plasma insulin concentrations were higher in the preterm neonates: mean (SD) 81.6 
(65.1) pmol/L in the PMA ≤32 week group, 56.0 (97.3) pmol/L in the >32 to ≤36 week 
group and 41.4 (45.6) pmol/L in the >36 week group (ANOVA, p <0.0001) (Table 5.2). 
Plasma C-peptide concentrations were higher in the very preterm infants compared to 
the other groups: mean (SD) 202 (199) pmol/L in the PMA ≤32 week group, 124 (151) 
pmol/L in the >32 to ≤36 week group and 154 (165) pmol/L in the >36 week group 
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(ANOVA, p <0.05). Plasma glucagon concentrations increased with increasing PMA: 
mean (SD) 67.8 (49.0) pmol/L in the PMA ≤32 week group, 98.5 (78.7) pmol/L in the 
>32 to ≤36 week group and 111 (101) pmol/L in the >36 week group (ANOVA, p = 
0.09). Plasma GLP-1 concentrations increased with increasing PMA: mean (SD) 580 
(455) pmol/L in the PMA ≤32 week group, 664 (428) pmol/L in the >32 to ≤36 week 
group and 749 (467) pmol/L in the >36 week group (ANOVA, p = 0.11). Blood 
glucose concentrations were higher in the very preterm infants compared to the other 
groups: mean (SD) 5.35 (2.22) mmol/L in the PMA ≤32 week group, 4.17 (1.57) 
mmol/L in the >32 to ≤36 week group and 4.37 (1.10) pmol/L in the >36 week group 
(ANOVA, p <0.01). The I/CP ratio decreased with increasing PMA: mean (SD) 1.53 
(2.43) in the PMA ≤32 week group, 1.27 (1.98) in the >32 to ≤36 week group and 0.68 
(1.14) in the >36 week group (ANOVA, p <0.05). The I/BGC ratio decreased with 
increasing PMA: mean (SD) 15.2 (13.1) in the PMA ≤32 week group, 13.2 (18.3) in the 
>32 to ≤36 week group and 6.70 (3.73) in the >36 week group (ANOVA, p <0.001).  
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Table 5.2 Concentrations of glucose regulatory hormones by PMA 
 All ages (PMA)  
mean (SD, n) 
PMA  
≤32 weeks  
mean (SD, n) 
PMA  
>32 to ≤36 
weeks 
 mean (SD, n) 
PMA  
>36 weeks  






63.5 (78.4, 343) 
 
81.6 (65.1, 138)  
 
56.0 (97.3, 138) 
 








164 (179, 258)  
 
202 (199, 113)  
 
124 (151, 95) 
 








87.6 (73.9, 107) 
 
67.8 (49.0, 46) 
 
98.5 (78.7, 42) 
 








645 (448, 140) 
 
580 (455, 58) 
 
664 (428, 56) 
 








4.82 (1.96, 247) 
 
5.35 (2.22, 129) 
 
4.17 (1.57, 78) 
 







1.27 (2.09, 251) 
 
1.53 (2.43, 110) 
 
1.27 (1.98, 95) 
 







13.2 (14.2, 171) 
 
15.2 (13.1, 90) 
 
13.2 (18.3, 52) 
 







220 (602, 93) 
 
126.2 (119, 46) 
 
340 (952, 36) 
 




PMA = post-menstrual age 
 
5.3.3 The effect of postmenstrual age on glucose regulatory hormone 
concentrations 
Linear regression was performed to explore the relationships of I/CP and I/BGC with 
PMA. GA, PMA, birth weight, current weight, length, and head circumference were all 
highly correlated with each other (r >0.75) and could therefore not be included in the 
same statistical models. A matrix scatterplot of participant demographics and ln 
concentrations is shown in Appendix 8. PMA was chosen as the main demographic for 
comparison as it was the most highly correlated with I/CP and I/BGC. Insulin 
concentration was negatively correlated (r = -0.38, p <0.01) and glucagon concentration 
was positively correlated (r = 0.21, p <0.05) with increasing PMA. I/CP and I/BGC 
Chapter five - Factors influencing neonatal glucose homeostasis 
 95 
ratios were significantly affected by PMA (p <0.01). Correlation coefficients showed 
negative correlations (r = -0.21 and -0.35 for I/CP and I/BGC with PMA respectively, 
p <0.01). Linear regression of ln-transformed data was performed on all significant 
correlations (Table 5.3). Scatter plots and least squares non-linear regressions are 
shown in Figure 5.1 and Figure 5.2. The age at which I/CP approximated that of term 
neonates appeared to be around 34 weeks (Figure 5.1). The residuals for the non-linear 
regressions were similar to the linear regressions, consequently the non-linear 
regressions were used, even though the evidence for choosing non-linear analysis was 
limited, as neither ratio would be expected to reach zero and should level out at some 
point (Figure 5.3). 




ln (Insulin concentration)  -0.082 (0.011) 0.144 <0.001 
ln (Glucagon concentration)  0.036 (0.016) 0.045 <0.05 
ln (Insulin/C-peptide ratio) -0.065 (0.019) 0.046 <0.001 
ln (Insulin/blood glucose 
ratio) -0.065 (0.013) 0.123 <0.0001 
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Figure 5.1 Scatter plot of ln(I/CP) versus PMA (r = -0.21). A decreasing exponential 
function (y = A1*exp(-x/t1) + y0) was fitted (best fit according to residuals) where 
A1 = 55.3 ± 174 t1 = 6.94 ± 6.09 and y0 = -1.20 ± 0.472, R2 = 0.042. 
 
Figure 5.2 Scatter plot of ln(I/BGC) versus PMA (r = -0.35). A decreasing exponential 
function (y = A1*exp(-x/t1) + y0) was fitted (best fit according to residuals) where 
A1 = 10.3 ± 56.1, t1 = 119 ± 908 and y0 = -5.63 ± 59.0, R2 = 0.112.  




Figure 5.3 Residuals of plot of ln(I/CP) versus PMA for a decreasing exponential 
function plot (A) and a linear plot (B). Residuals of plot of ln(I/BGC) versus PMA for a 
decreasing exponential function plot (C) and a linear plot (D). 
 
One-way ANOVA was performed to determine the influence of age categories on 
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Figure 5.4 Box plot of ln(I/CP)   and ln(I/BGC)   in three age group categories for 
PMA (<32, 32 to 36 and >36 weeks). Medians are shown with boxes representing the 
interquartile range and error bars show upper and lower values. Outside values: values 
outside 1.5x interquartile range. 
5.3.4 Fed versus never fed neonates 
GLP-1 concentrations were significantly higher in fed when compared with never fed 
neonates regardless of PMA (Table 5.4 and Figure 5.5). This was statistically 
significant for the overall groups (p <0.001) and also for the ≤32 weeks PMA subgroup 
(p <0.05). There were no significant differences in glucagon concentrations between 
fed and never fed neonates (Table 5.4).  
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Table 5.4 Concentrations of GLP-1 and glucagon in never fed and fed neonates with 
different postmenstrual age (PMA) 
 All ages  
mean (SD, n) 
PMA  
≤32 weeks  
mean (SD, n) 
PMA  
>32 ≤36 weeks 
mean (SD, n) 
PMA  
>36 weeks  
mean (SD, n) 









735 (460, 79) 697 (469, 32) 730 (419, 33) 831 (549, 14) 
p-value <0.001 <0.05 0.09 0.33 









90.3 (80.8, 60) 76.3 (58.6, 27) 93.7 (77.1, 25) 127 (140, 8) 
p-value 0.94 0.43 0.53 0.90 




Figure 5.5 Box plot of ln(GLP-1 concentration) in never fed versus fed neonates 
(p <0.001). Medians are shown with boxes representing the interquartile range and 
error bars show upper and lower adjacent values. Outside values: values outside 1.5x 
interquartile range.  
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5.4 Discussion 
The main findings of this chapter were that insulin and C-peptide concentrations were 
elevated in very preterm infants and decreased to term. This relationship persisted when 
blood glucose concentrations were accounted for. GLP-1 was higher in fed compared 
with never fed neonates, regardless of postmenstrual age. There was also no significant 
change in glucagon concentrations with feeds or PMA. Higher C-peptide 
concentrations in preterm neonates suggest that insulin production is higher and 
therefore support the hypothesis of insulin resistance (Mitanchez-Mokhtari et al., 
2004). The neonates in this study did not receive corticosteroids, giving new support 
for the insulin resistance hypothesis of prematurity. Changes in GLP-1 concentrations 
following the first feed have not previously been reported in preterm or term neonates. 
The findings are not unexpected, but confirm that enteral feeds are important in 
modulating insulin secretion in preterm and term neonates, in part via GLP-1, which is 
consistent with its known mechanism of action in older age groups (Sandoval & 
D'Alessio, 2015). While previous studies have reported an increase in enteroglucagon 
(a superseded term referring to a number of peptides that cross-reacted with glucagon, 
including GLP-1and GLP-2) after feeding compared with fasting neonates, this study 
shows that GLP-1 specifically increases in fed compared with never-fed neonates 
(Aynsley-Green et al., 1977, Lucas et al., 1978). Lucas et al. (1978) measured 
enteroglucagon concentrations following feeds in preterm and term infants and 
although term infants had an increase in concentration following feeds, preterm 
neonates did not have a significant increase. In the present study PMA did not have a 
significant effect on GLP-1 concentrations. Data from animal studies also indicate that 
enteric feeds are necessary to induce the maturation of insulin secretion in response to 
blood glucose (Asplund, 1972). The clinical relevance of this finding relates to the 
observation that extremely premature neonates commonly have delayed introduction of 
enteral feeds, but at the same time are having parenteral nutrition and/or dextrose 
infusions, which in combination may increase the risk of hyperglycaemia in these 
patients.  
The study described in this chapter also showed a significant decrease in insulin 
concentrations and a significant increase in glucagon concentrations with increasing 
PMA. The mean (SD) insulin concentration in this study of 63.5 (78.4) pmol/L was 
consistent with other studies that have reported insulin concentrations of 3 to 20 µU/mL 
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(18 to 120 pmol/L) (Gesteiro et al., 2009). Mitanchez (2007) observed lower plasma 
glucagon concentrations and a higher insulin/glucagon ratio in preterm neonates. This 
finding is consistent with, but also builds on these findings, as a complete spectrum of 
PMA was investigated, and is the first to avoid the important confounder of postnatal 
corticosteroids. By looking at the intermediate PMA group as shown in Figure 5.4 it 
can be seen that I/CP ratio appears to change between 32 and 36 weeks PMA. The 
change in I/CP at around 34 weeks shows that the insulin resistance is most pronounced 
in extremely premature neonates, but reduces with increased gestation. Mitanchez-
Mokhtari et al. (2004) demonstrated that defective processing of proinsulin in β-cells 
and partial resistance to insulin were present in hyperglycemic extremely premature 
neonates and that these defects were likely responsible for altered glucose homeostasis. 
The present study indicates that insulin resistance is also present in extremely 
premature neonates without hyperglycaemia.  
I/CP ratios have not been previously reported in neonates and in the study described in 
this chapter the I/CP ratio was found to be significantly affected by PMA. Fasting 
insulin, homeostasis model assessment (HOMA), I/BGC ratio, and the Bennett index 
have all been used to predict insulin sensitivity (McAuley et al., 2001). However, in 
neonates it is impractical to measure fasting values because of the risk of 
hypoglycaemia. The I/BGC ratio reported in this chapter represents a practical 
alternative and was shown to decrease significantly with increasing PMA. A previous 
study by Gesteiro et al. (2009) reported a blood glucose to insulin ratio of 33.6 ± 
49.0 ((mg/dL)/(µUI/mL)) in term normal weight neonates which when converted to the 
same units as in this chapter is an I/BGC of 9.14 ((pmol/L)/(mmol/L)). This is 
consistent with the mean (SD) of 13.2 (14.2) and median of 9.3 reported in this chapter. 
Although the relationship between ln(I/BGC) and PMA was approximately linear 
(PMA 23 – 42 weeks), this relationship is likely to reach an asymptote at a PMA when 
I/BGC stops decreasing, which is likely to be soon after full term (i.e. PMA ≥42 
weeks).  
The main strengths of the study described in this chapter are the inclusion of a 
population of neonates across a broad range of PMA; a larger sample size than previous 
studies (12 preterm and 19 term in Mitanchez (2007) and 12 preterm and 21 term in 
Mitanchez-Mokhtari et al. (2004)), and the collection of samples prior to, and 
following the first feed. The use of leftover plasma samples limited the intrusiveness of 
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the study on the neonates and their parents and families, and took account of the small 
blood volume in these patients. However, this did lead to limitations due to limited 
plasma volume, and difficulty in pairing observations of different hormones and blood 
glucose measurements. Hence not all compounds were measured in each patient, and 
there was not always a paired BGC for each insulin/C-peptide measurement. The study 
population did not include neonates with hyperglycaemia, so it is not possible to 
exclude impaired secretion of insulin, in addition to insulin resistance, as a contributor 
to the hyperglycaemia in that specific patient population. This will be investigated in 
Chapter 6. 
5.5 Conclusions 
This study supports the conclusion that preterm neonates exhibit insulin resistance even 
in the absence of hyperglycaemia. Enteral feeds result in an increase in plasma GLP-1. 
Both of these factors are likely to contribute to, and are also interrelated, with the 
increased risk of hyperglycaemia in neonates born prematurely (PMA <32 weeks). The 
data help to explain the reduced risk of neonatal hyperglycaemia seen at postmenstrual 
ages of more than 32 to 34 weeks and beyond compared with lower PMA neonates. 
These findings, therefore, add to a more complete understanding of the maturation of 
glucose homeostasis in the preterm neonate. 
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6 Glucose homeostasis in hyperglycaemic neonates 
compared with euglycaemic neonates 
6.1 Introduction 
The previous chapter (Chapter 5) demonstrated that preterm neonates exhibit insulin 
resistance in the absence of hyperglycaemia. Insulin and C-peptide concentrations were 
elevated in very preterm infants and decreased to term and this relationship persisted 
when blood glucose concentrations were accounted for. The change in I/CP at around 
34 weeks demonstrated that insulin resistance is most pronounced in extremely 
premature neonates, but reduces with increased gestation. However, the study reported 
in Chapter 5 did not include neonates with hyperglycaemia, and therefore did not 
examine the potential contribution of impaired secretion of insulin, in addition to 
insulin resistance, to the development of hyperglycaemia. 
Hyperglycaemia is common in extremely premature neonates (gestation <28 weeks), 
and in those with a birth-weight less than 1000 g has an estimated incidence of over 
50% (Hays et al., 2006). Severe persistent hyperglycemia over the first week of life has 
been associated with increased mortality and severe hyperglycemia is associated with 
adverse outcomes in extremely low birth weight neonates (Kao et al., 2006). It is not 
known if the increase in morbidity and mortality is just a reflection of illness severity, 
or a direct causal relationship (Alsweiler et al., 2007).  
It is thought that hyperglycaemia in preterm neonates is a consequence of relative 
insulin deficiency and glucose homeostasis in neonates is poorly understood 
(Mitanchez, 2007). In preterm neonates the sensitivity and hepatocyte reaction to 
changes in glucose and insulin concentrations is limited due to immature processing of 
insulin with an elevated GLUT-1/GLUT-2 ratio in tissue (Mericq, 2006). It is believed 
that preterm neonates are not able to suppress glucose production within a large range 
of glucose and insulin concentrations (Mericq, 2006).  
A number of factors have been shown to influence hyperglycaemia, Mitanchez-
Mokhtari et al. (2004) showed that hyperglycaemic premature neonates have impaired 
pancreatic β-cell secretion and that these neonates are also relatively resistant to insulin. 
They reported that insulin and C-peptide concentrations were similar in hyperglycaemic 
and control preterm neonates but these were significantly higher than in term neonates 
(Mitanchez-Mokhtari et al., 2004). Proinsulin concentrations were higher in 
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hyperglycaemic neonates than control preterm neonates and term neonates suggesting 
defective processing of proinsulin to mature insulin in hyperglycaemic preterm 
neonates (Mitanchez-Mokhtari et al., 2004). The higher C-peptide concentrations in 
control and hyperglycaemic preterm neonates compared with term controls suggests 
there is a higher production rate of insulin in preterm neonates (Mitanchez-Mokhtari et 
al., 2004). C-peptide concentrations fell significantly in hyperglycaemic neonates when 
insulin infusion was received (Mitanchez-Mokhtari et al., 2004). The hyperglycaemic 
pre-term neonates were more resistant to insulin as they failed to achieve euglycaemia 
when administered similar amounts of insulin to control preterm neonates (Mitanchez-
Mokhtari et al., 2004). The main limitation of the study by Mitanchez-Mokhtari et al. 
(2004) was that over half of the preterm neonates were exposed to postnatal 
glucocorticoids. It is known that glucose homeostasis can be affected by steroid 
treatment which can cause a rise in blood glucose concentration (Hey, 2005). A study 
by Koivisto et al. (2007) reported that short exposure (<24 hours) to antenatal steroids 
caused a decrease in blood glucose in the neonate and a long exposure time (>7 days) 
increased the risk of hyperglycaemia in neonates during the first three days after birth. 
Therefore, it would be expected that at least half of the neonates in the study by 
Mitanchez-Mokhtari et al. (2004) would have altered glucose homeostasis as they 
received hydrocortisone (0.5 mg/kg/every 6 hours). 
A contradictory study by Farrag et al. (1997) found that preterm neonates had a greater 
insulin sensitivity than adults but suggested that this may be due to higher insulin 
receptor concentration or receptor affinity for insulin in neonates. They could not 
achieve complete suppression of glucose production with a euglycemic 
hyperinsulinemic clamp in neonates concluding this could be due to a component of the 
glucose production response to insulin being unresponsive (Farrag et al., 1997). 
Sunehag et al. (1994) also reported that preterm neonates responded to glucose infusion 
with incomplete suppression of glucose production. They found that insulin 
concentrations seemed to be more important than glucose in regulating the glucose 
homeostasis in preterm neonates (Sunehag et al., 1994). 
Meetze et al. (1998) reported hyperglycaemic neonates were either insulin resistant or 
insulin deficient. Insulin resistant neonates increased their insulin concentrations in 
response to hyperglycaemia while insulin deficient neonates did not (Meetze et al., 
1998). They concluded that insulin infusion was a safe and effective method of treating 
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hyperglycaemia as caloric intake did not need to be reduced and in their study neonates 
did not develop hypoglycaemia as a result of the insulin infusion (Meetze et al., 1998). 
Another study by Collins et al. (1991) demonstrated that insulin infusion stabilised 
plasma glucose concentrations and allowed for the provision of calories in non-
hyperglycaemic extremely premature neonates indicating the advantage of insulin 
treatment in premature neonates who are not hyperglycaemic.  
As discussed previously, the I/CP ratio gives an indication of insulin clearance in adults 
(Hilton et al., 2001). In normal healthy adults this ratio does not exceed 1.0 unless the 
patient is receiving exogenous insulin or has liver cirrhosis (Iwase et al., 2001). 
Therefore, it would be expected that neonates receiving insulin therapy would have an 
increased I/CP ratio when compared to neonates that are not receiving insulin. If the 
neonates in the study described in this chapter received adequate insulin therapy and 
insulin was reaching the neonates, they should have higher insulin concentrations and 
I/CP ratios. Insulin therapy in the newborn is fraught with problems of administration 
because of the low dose required and the potential for adsorption onto IV line 
components, including in-line filters (Hewson et al., 2000). This potential for varying 
degrees for adsorption allows for clinically significant variations in insulin delivery 
especially at low insulin concentrations and flow rates that are commonly used in 
extremely low birth-weight neonates (Hewson et al., 2000). Measuring both C-peptide 
and insulin both before and after insulin treatment allows evaluation of this issue.  
This chapter will investigate markers of glucose homeostasis in hyperglycaemic 
neonates and make a comparison with euglycaemic premature neonates (<30 weeks 
PMA) described in Chapter 5. It was hypothesised that insulin concentrations would be 
higher in the hyperglycaemic (insulin treated) neonates and that insulin treatment 
would suppress endogenous insulin production resulting in a decrease in C-peptide 
concentrations in insulin-treated neonates. 
6.1.1 Chapter aims 
• To investigate differences in blood glucose, insulin and C-peptide 
concentrations between hyperglycaemic preterm neonates and euglycaemic 
preterm neonates. 
• To explore the relationships between postmenstrual age and insulin, C-peptide, 
and blood glucose concentrations in hyperglycaemic preterm neonates.  
Chapter six – Glucose homeostasis in neonatal hyperglycaemia 
 110
6.2 Materials and Methods 
6.2.1 Materials 
Materials used for this study are as listed in Chapter 2. 
6.2.2 Methods 
The participants recruited into the study were hyperglycaemic preterm neonates 
admitted into the Dunedin Hospital NICU during 2011 and 2012. The neonates were 
included if they were hyperglycaemic (two consecutive blood glucose levels, four hours 
apart, of >10 mmol/L as defined by The Dunedin Hospital NICU Medication Manual) 
(Appendix 1), a birth weight of <1500 g, gestational age at birth less than 32 weeks, 
required insulin infusion as part of local NICU protocol (Table 6.1, Appendix 1) and 
written informed consent from parents had been obtained. The exclusion criteria were: 
an infant of a diabetic mother, a suspected metabolic disorder, suspected growth 
hormone deficiency or pituitary insufficiency, receiving treatment with exogenous 
steroids, receiving treatment with diazoxide, infant of a mother with hyperthyroidism, 
maternal treatment with oral anti-diabetic agents eg. biguanides, sulphonylureas, 
thiazolidinediones and maternal treatment with exanatide or liraglutide. Insulin 
treatment was introduced below the filter of the main IV line of these neonates using a 
Y connector placed as close to the baby as possible. This avoided the filter and also 
reduced dead space minimising delays to changes in the rate of infusion.  
Table 6.1 Sliding scale for insulin administration (Actrapid – insulin neutral human) by 
continuous intravenous infusion at Dunedin Hospital NICU. Insulin infusion started at 
0.5 mL/kg/hour (= 0.05 units/kg/hour) and adjusted using the sliding scale below based 
on subsequent blood glucose results 
Blood Glucose 
Concentration (mmol/L)  
Dose  
(units/kg/hour) 
Infusion Rate (0.1 unit/mL) 
(mL/kg/hour) 
>20  0.07  0.7  
15 to 20  0.05  0.5  
10 to 15  0.03  0.3  
7 to 10  0.01  0.1  
<7  Stop infusion Stop infusion 
 
Chapter six – Glucose homeostasis in neonatal hyperglycaemia 
 111 
Data were collected from clinical notes for gestational age (GA) postmenstrual age 
(PMA), age from birth, birth weight, current weight, length, head circumference, oral 
caloric intake, and intravenous fluids. Additional blood (150 µL) was collected into a 
tube at the same time as the patients’ routine four hourly blood glucose test over 24 
hours (6 samples). When each blood sample was collected the sample time, time of last 
feed, volume of last feed, blood glucose concentration and insulin dose were recorded. 
The blood samples were analysed for insulin and C-peptide using chemiluminescence 
as described in Chapter 2. 
The neonates in this study were compared with data obtained from euglycaemic 
neonates described in Chapter 5. Insulin and C-peptide concentrations from the insulin-
treated neonates were compared with a group of age-matched (PMA less than 30 
weeks) euglycaemic neonates (n = 20).  
Statistical analyses were performed using Stata/IC (Version 11.2, StataCorpLP, TX, 
USA). The data were analysed using summary statistics and frequency distributions, 
pairwise correlations and t-tests. Where the data were ln distributed, the hypothesis 
tests were performed on log-transformed data. Pairwise correlations were performed to 
explore the relationships of I/CP and I/BGC with PMA in the insulin treated group. 
GA, PMA, birth weight, current weight, length, and head circumference were all highly 
correlated with each other (r > 0.75) and could therefore not be included in the same 
statistical models (as in Chapter 5). PMA was chosen as the main demographic for 
comparison as it was the most highly correlated with I/CP and I/BGC. As the 
concentration data were ln distributed, ln-transformed data was used (except for BGC 
which was normally distributed).  
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6.3 Results 
6.3.1 Hyperglycaemic neonates 
There were nine hyperglycaemic preterm neonates (6 females and 3 males) with 
additional blood samples taken and their demographics are shown in Table 6.2. Each 
neonate’s BGC, plasma insulin and C-peptide concentrations were measured and 
plotted individually (Appendix 9). Insulin dose received and BGC were also plotted for 
each neonate individually (Appendix 9). Blood glucose concentrations (Figure 6.1) are 
shown over 24 hours for all nine neonates. Insulin dose (Figure 6.2) is also shown over 
24 hours. Five of the nine neonates had very low (2.5 to 9.63 pmol/L) C-peptide 
concentrations and four neonates had comparatively higher (9.97 to 526 pmol/L) 
concentrations of C-peptide (Figure 6.3). One neonate had two significantly higher     
C-peptide and insulin concentrations than the other neonates, producing a very high 
peak (Figure 6.3, Figure 6.4). 
 
Figure 6.1 Blood glucose concentrations of nine hyperglycaemic neonates treated with 
insulin over 24 hours. The shaded area (7 to 10 mmol/L) shows the lower range of the 
insulin sliding scale treatment regimen below which insulin infusion is stopped if 
<7 mmol/L and started if >10 mmol/L on two occasions. Enrolment occurred at time = 
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Figure 6.2 Insulin dose of nine hyperglycaemic neonates treated with insulin over 24 
hours. Enrolment occurred at time = 0 hours with the first blood sample taken four 
hours after. 
 
Figure 6.3 C-peptide concentrations of nine hyperglycaemic neonates treated with 
insulin over 24 hours. Enrolment occurred at time = 0 hours with the first blood sample 
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Figure 6.4 Insulin concentrations of nine hyperglycaemic neonates treated with insulin 
over 24 hours. Enrolment occurred at time = 0 hours with the first blood sample taken 
four hours after. 
 
6.3.2 Comparative study of hyperglycaemic versus euglycaemic premature 
neonates (PMA <30 weeks) 
Plasma samples were obtained from 20 non-insulin-treated neonates and 10 insulin-
treated neonates (including the 9 neonates from section 6.3.1 and 1 more neonate from 
the euglycaemic study who became hyperglycaemic and received insulin). The non-
insulin treated subgroup contained 15 males and 5 females with a mean (SD) PMA of 
28.3 (1.52) weeks and mean (SD) birth weight of 1109 (211) g. The insulin-treated 
group contained four males and six females with a mean (SD) PMA of 26.2 (1.66) 
weeks and mean (SD) birth weight of 800 (174) g. Insulin-treated neonates were 
significantly more premature (lower GA) and smaller than non-insulin-treated neonates 
(Table 6.2). A summary of the demographic characteristics of these neonates is 
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Table 6.2 Participant demographics for non-insulin treated and insulin treated neonates 











































(23.4 - 27.9) <0.01 
Birth weight (g) 1109  (211, 20) 
1118 




(565 - 1040) <0.001 
Weight (g) 1110  (277, 17) 
1040 




(565 - 1050) <0.01 
Birth length (cm) 37.2  (3.6, 17) 
37  














(19.5 - 25.3) <0.001 
Note some data were missing, as not everything was recorded in patient notes. 
 
Plasma insulin concentrations were significantly higher in the insulin-treated neonates: 
mean (SD) 142 (150) pmol/L than in the non-insulin-treated group mean (SD) 93.2 
(63.1) pmol/L (t-test, p <0.0001) (Table 6.3, Figure 6.5). Plasma C-peptide 
concentrations were lower in the insulin-treated neonates: mean (SD) 76.6 (150) 
pmol/L than in the non-insulin-treated group: mean (SD) 200 (208) pmol/L (t-test, 
p <0.0001) (Table 6.3, Figure 6.5). Blood glucose concentrations were higher in the 
insulin-treated neonates: mean (SD) 9.81 (2.19) mmol/L than in the non-insulin-treated 
group: 5.62 (2.20) mmol/L (p <0.01) despite being treated with insulin (Table 6.3, 
Figure 6.5). The I/CP ratio was higher in the insulin-treated neonates: mean (SD) 22.1 
(30.8) than in the non-insulin-treated group: mean (SD) 3.28 (8.61) (t-test, p <0.0001) 
(Table 6.3, Figure 6.5). There was no significant difference between the two groups for 
I/BGC ratio (Table 6.3, Figure 6.5). 
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Table 6.3 Comparison of concentrations of glucose regulatory hormones in non-insulin 
treated and insulin treated neonates with PMA <30 weeks  
 Non-insulin treated 
(<30 weeks PMA) 
mean (SD, n) 
Insulin treated 










200 (208, 79) 76.6 (150, 56) <0.0001 
Blood glucose 
(mmol/L) 5.62 (2.20, 79) 9.81 (2.19, 66) <0.0001 
Insulin/C-peptide 
ratio 3.28 (8.61, 79) 22.1 (30.8, 56) <0.0001 
Insulin/blood glucose 
ratio 16.8 (12.5, 55) 15.4 (17.1, 63) >0.1 
*All t-tests were performed on ln-transformed data except BGC. 





Figure 6.5 Box plots of ln(insulin) (A), 
ln(C-peptide) (B), blood glucose 
concentrations (C), ln(insulin/C-peptide) 
(D), ln(insulin/blood glucose) (E) in non-
insulin-treated and insulin-treated 
neonates. Medians are shown with boxes 
representing the interquartile range and 
error bars show upper and lower adjacent 
values. Outside values: values outside 
1.5x interquartile range. 
Insulin concentration (r = -0.38, p <0.01) (Figure 6.6) and blood glucose (r = -0.38, 
p <0.01) (Figure 6.7) were negatively correlated and C-peptide concentration was 
positively correlated (r = 0.36, p <0.01) with increasing PMA. The I/CP ratio was 
significantly affected by PMA (r = -0.49, p <0.01) (Figure 6.9) however the I/BGC 





Chapter six – Glucose homeostasis in neonatal hyperglycaemia 
 118
 
Figure 6.6 Scatter plot of ln(insulin) versus PMA (r = -0.38 in insulin-treated-neonates) 
in ● non-insulin-treated neonates and ○ insulin-treated neonates. 
 
Figure 6.7 Scatter plot of BGC versus PMA (r = -0.49 in insulin-treated-neonates) in ● 
non-insulin-treated neonates and ○ insulin-treated neonates. 
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Figure 6.8 Scatter plot of ln(C-peptide) versus PMA (r = 0.36 in insulin-treated-
neonates) in ● non-insulin-treated neonates and ○ insulin-treated neonates. 
 
Figure 6.9 Scatter plot of ln(I/CP) versus PMA (r = -0.49 in insulin-treated-neonates) 
in ● non-insulin-treated neonates and ○ insulin-treated neonates. 
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6.3.2.1 Comparative case study of two neonates before and after treatment with 
insulin  
Two neonates from the euglycaemic study (Chapter 5) developed hyperglycaemia 
during their time in the study and they had samples taken before and during insulin 
treatment and were investigated as case studies. One neonate had high C-peptide 
concentrations (290 to 754 pmol/L) while the other had low C-peptide concentrations 
(2.50 to 13.0 pmol/L, Figure 6.10). The C-peptide concentrations did not appear to be 
affected by the commencement of insulin treatment in either neonate. Neonate 1 had 
much higher I/CP ratios and slightly higher I/BGC ratios than neonate 2 (Figure 6.11). 
Figure 6.12 shows each neonate’s individual changes in insulin and C-peptide with 
time. Neonate 1 was only one day old at the start of this study (GA 24, PMA 24 weeks) 
whereas neonate 2 was one month old (GA 28, PMA 32 weeks). 
Table 6.4 Participant demographics for neonates included in the study with the 
neonates from the case study identified 
 Non-insulin treated 
(<30weeks PMA) 
mean (SD, n) 
Insulin treated 








(weeks) 28.0 (1.4, 20) 25.5 (1.7, 10) 24.0 27.7 
Postmenstrual 
age (weeks) 28.3 (1.5, 20) 26.2 (1.7, 10) 24 - 24.4 31.9 – 32.6 
Birth weight 
(g) 1109 (211, 20) 800 (174, 10) 760 515 
Weight (g) 1110 (277, 17) 800 (166, 8) 760 630 
Birth length 




26.0 (1.7, 18) 22.9 (2.0, 9) 22.2 22 
 
  





Figure 6.10 Two participants (neonate 1 ● and neonate 2 ▲) before and during insulin 
treatment: blood glucose concentration (A), insulin concentration (B) and C-peptide 
concentration versus time. Filled symbols are concentrations when not on insulin 
treatment and open symbols are concentrations during insulin treatment. Insulin 




























































































Figure 6.11 Two participants (neonate 1 ● and neonate 2 ▲) before and during insulin 
treatment: Insulin/C-peptide ratio (A) and Insulin/Blood glucose ratio (B) versus time. 
Filled symbols are concentrations when not on insulin treatment and open symbols are 
concentrations during insulin treatment. Insulin treatment started at time = 0 hours, 

















































Figure 6.12 Two participants before and during insulin treatment: insulin concentration 
(●) and C-peptide concentration (▲) versus time in neonate 1 (A) with low C-peptide 
concentrations and in neonate 2 (B) with high C-peptide concentrations. Filled symbols 
are concentrations when not on insulin treatment and open symbols are concentrations 
during insulin treatment. Insulin treatment started at time = 0 hours, insulin treatment 



































































Chapter six – Glucose homeostasis in neonatal hyperglycaemia 
 124
6.4 Discussion 
The main findings of this chapter were that C-peptide concentrations were significantly 
lower in hyperglycaemic neonates than in similar PMA euglycaemic neonates 
indicating lower insulin production in hyperglycaemic neonates both prior to and 
during treatment. Insulin concentrations, blood glucose concentrations, C-peptide 
concentrations and I/CP ratios were all significantly affected by PMA (p <0.01) in the 
hyperglycaemic neonates. This same effect was seen in the non-insulin-treated neonates 
indicating that all the neonates whether hyperglycaemic or not showed insulin 
resistance confirming that insulin resistance was a direct result of prematurity. As 
expected insulin concentrations were higher in the hyperglycaemic neonates confirming 
that exogenous insulin is reaching these neonates intravenously. 
C-peptide concentrations in hyperglycaemic neonates increased with increasing PMA 
(Figure 6.8) and were significantly lower than the concentrations found in euglycaemic 
neonates less than 30 weeks PMA (Figure 6.5). This is a major difference in the 
hyperglycaemic neonates and is different to Chapter 5 where neonates were shown to 
have decreasing C-peptide concentrations to term. The lower C-peptide concentrations 
in the hyperglycaemic neonates are consistent with either suppression of insulin 
production when exogenous insulin is administered or that hyperglycaemic neonates 
have lower production rates of insulin indicating insulin deficiency. The case studies of 
two neonates that were initially euglycaemic, but became hyperglycaemic gave 
evidence to support the latter (i.e. insulin deficiency) as the C-peptide concentrations 
did not decrease in these neonates with the introduction of insulin treatment (Figure 
6.10). The findings that insulin treatment does not suppress insulin production in these 
neonates are two-fold. The hyperglycaemic neonates showed no apparent decrease in 
C-peptide concentrations with increasing insulin dose (Appendix 9), which is supported 
by the case study findings. Since C-peptide concentrations did not appear to decrease, 
the significantly higher I/CP ratios in the insulin-treated neonates are most likely due to 
an increase in insulin concentrations as a direct result of insulin therapy.  
Although all the hyperglycaemic neonates in this study had lower insulin production 
than euglycaemic neonates, the hyperglycaemic neonates can be divided into two 
groups, those with very low insulin production (low C-peptide and comparatively lower 
insulin concentrations) and those with higher insulin production (Figure 6.3). This 
confirms the work of Meetze et al. (1998) which showed the same division into insulin 
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deficient and insulin resistant infants. Three out of the five neonates in the low insulin 
production group had insulin concentration and exogenous doses that followed similar 
profiles related to their BGC whereas two did not. This could indicate that three out of 
the five neonates in this group responded as expected to insulin treatment. All four of 
the higher insulin production group show similar profiles of insulin and C-peptide 
concentrations with exogenous insulin dose that were directly related to BGC showing 
good response in insulin treatment with no apparent insulin suppression. All nine 
neonates had insulin doses consistent with the Dunedin Hospital NICU sliding scale 
(Table 6.1); when BGC increased the insulin dose then increased on the next blood 
sample. The significant effect of PMA on insulin concentrations, blood glucose 
concentrations, C-peptide concentrations and I/CP ratios indicate that hyperglycaemic 
neonates may also exhibit insulin resistance as a direct result to their prematurity as 
shown in Chapter 5. 
The results of this study support the conclusion by Mitanchez-Mokhtari et al. (2004) 
that both defective processing of proinsulin in the pancreatic β-cells and insulin 
resistance are likely to be responsible for altered glucose homeostasis in 
hyperglycaemic neonates. These two factors may be present separately and 
hyperglycaemic neonates may have both defective processing of insulin and insulin 
resistance or just one of these factors. 
The main weakness of the present study is that apart from the extra data from the two 
case study neonates, the hyperglycaemic neonates in the present study were only 
studied while on insulin infusion. This was because the insulin treated cohort was 
recruited once hyperglycaemia had been diagnosed as in the inclusion criteria. This 
limits the study as a lack of samples prior to patients starting insulin treatment and 
possibly after treatment makes it difficult to determine the exact contributors to 
hyperglycaemia in these neonates. Since there were only two case study neonates it is 
difficult to determine if low insulin production is the sole cause of hyperglycaemia in 
these neonates. The two groups of hyperglycaemic neonates found by Meetze et al. 
(1998) may help explain why Mitanchez-Mokhtari et al. (2004) found a significant 
decrease in C-peptide concentrations with insulin infusion and this was not found in 
this study. However, as all the neonates in this study show no sign of insulin 
suppression either with the introduction of insulin treatment (case study neonates) or an 
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increase in insulin dose (hyperglycaemic neonates) it is reasonable to conclude that 
these neonates do not show suppression of insulin secretion. 
A particular strength of the present study is that none of the neonates received steroid 
treatment. This is an important strength over previous studies such as the study by 
Mitanchez-Mokhtari et al. (2004) for which it would be expected that their preterm 
neonates would have altered glucose homeostasis due to steroid treatment which can 
cause a rise in blood glucose concentration (Hey, 2005). Additional strengths of the 
present study are the minimal blood sample size of 150 µL and the collection of six 
samples over 24 hours providing a rich data set with the hyperglycaemic neonates.  
6.5 Conclusions 
This study demonstrates that: preterm neonates exhibit insulin resistance; C-peptide 
concentrations were significantly lower in the hyperglycaemic neonates indicating that 
hyperglycaemic neonates had lower insulin production than euglycaemic neonates; and 
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7 General Discussion 
This thesis adds to the understanding of the maturation of glucose homeostasis in the 
preterm neonate. The overall aim of the work in this thesis was to form a more 
complete understanding of the maturation of glucose homeostasis in the preterm 
neonate and more specifically in the hyperglycaemic preterm neonate.  
The first aim was to investigate the use of a blood spot (DBS) assay for measuring 
insulin concentrations to improve sampling for pharmacokinetic (PK) studies. The use 
of DBS for PK studies in neonates has a number of potential advantages over 
conventional plasma sampling (Spooner et al., 2009, Patel et al., 2013). The accuracy 
and precision of drug concentrations determined from DBS can be influenced by the 
variability in haematocrit observed in neonates (Patel et al., 2013). These variations 
may reduce the accuracy of analyte quantification and affect PK parameter estimation 
(Patel et al., 2013). It was found that haematocrit had a significant effect on plasma 
insulin concentration from DBS as measured by chemiluminescence. Insulin 
chemiluminescence responses were significantly lower at higher haematocrit values at 
all plasma concentrations (p <0.05). An exponential function plot of whole blood 
concentration versus chemiluminescence allowed for the effect of haematocrit on 
concentration when calculating insulin concentrations from DBS. However, all of the 
results showed high variability (CV% = 9 to 61%) and plasma insulin concentrations 
from neonatal DBS were typically higher than paired plasma samples. Consequently 
the usefulness of this sampling technique for glucose homeostasis investigations was 
linited. Conventional blood sampling techniques were used in the remainder of the 
research. 
The second aim was to describe the relationship between C-peptide and insulin 
secretion in the neonatal population. Insulin and C-peptide are secreted in equimolar 
amounts from the pancreas and since C-peptide is not metabolised by the liver and 
undergoes partial renal clearance, it may be possible to estimate insulin secretion from 
the urinary C-peptide excretion rate (UER) (Galgani et al., 2010, Rebsomen et al., 
2008). Direct measurement from Invitron chemiluminescent kit standards produced a 
more precise and simple method than standard addition for determining urinary          
C-peptide concentration when urine was diluted with bovine serum albumin (BSA) 1% 
in phosphate buffered saline (PBS). It was confirmed by t-tests that there were no 
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significant differences between the standard addition and direct measurement 
concentrations (p >0.05). Kruszynska et al. (1987) reported that urinary C-peptide was 
significantly correlated (r = 0.74) with 24 hour C-peptide secretion (and therefore 
insulin secretion). This would suggest that the C-peptide UER gives an indication of 
insulin secretion. In Chapter 4 the correlations between C-peptide clearance (Cl) or 
UER and gestational age (GA) were not significant (p >0.05). Futhermore, BGC did 
not appear to affect C-peptide UER and Cl as no significant correlations were found 
(p >0.05) making predicting insulin production more straightforward. These results 
demonstrated that for neonates GA does not appear to directly affect C-peptide UER 
and Cl. This suggests that urinary C-peptide concentrations may have the potential to 
be used as a biomarker for insulin production in neonates. 
The third aim was to investigate the relationship between neonatal feeding and incretin 
and insulin secretion to understand glucose homeostasis in the euglycaemic neonate. 
Insulin production appears to be higher in preterm neonates than in term neonates as 
indicated by elevated C-peptide concentrations, adding support to the concept that 
preterm neonates are relatively resistant to insulin (Mitanchez-Mokhtari et al., 2004). 
Chapter 5 showed that insulin and C-peptide concentrations were elevated in very 
preterm neonates (postmenstrual age (PMA) ≤32 weeks) and decreased to term. This 
relationship persisted when blood glucose concentrations were accounted for. 
Insulin/C-peptide (I/CP) ratios had not been reported in neonates. Linear regressions 
showed that I/CP ratios and insulin/blood glucose concentration (I/BGC) ratios 
decreased significantly with increasing PMA (p <0.001). Analysis of the intermediate 
PMA group appeared to demonstrate that the I/CP ratio changed between 32 and 36 
weeks PMA. This change showed that the insulin resistance is most pronounced in 
extremely premature neonates, and reduces with increased gestational age. Fasting 
insulin, homeostasis model assessment (HOMA), I/BGC ratio, and the Bennett index, 
which all require fasting have all been used to predict insulin sensitivity (McAuley et 
al., 2001). However, in neonates it is impractical to measure fasting values because of 
the risk of hypoglycaemia. Therefore, the I/BGC ratio represents a practical alternative. 
Glucagon like peptide-1 (GLP-1) is an incretin hormone which is stimulated by the 
ingestion of nutrients (Fu et al., 2013). Incretin hormones are responsible for 
augmentation of insulin secretion by either releasing insulin or potentiating glucose-
induced insulin release to meet the increased demand for insulin after a meal (Fu et al., 
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2013, Ørskov, 1992). Glucose control in the neonate appears to improve once enteral 
feeds are established and therefore GLP-1 which is excreted in response to oral feeding 
may be an important factor (Beardsall et al., 2008). Changes in GLP-1 concentrations 
following the first feed have not previously been reported in preterm or term neonates. 
GLP-1 was higher in fed compared with never fed neonates regardless of PMA 
(p <0.001). These findings are not unexpected, but confirm that enteral feeds are 
important in modulating insulin secretion in preterm and term neonates. There was also 
no significant change in glucagon concentrations with feeds or PMA. Mitanchez-
Mokhtari et al. (2004) demonstrated that defective processing of proinsulin in β-cells 
and partial resistance to insulin were present in hyperglycemic extremely premature 
neonates and this study indicates that insulin resistance is also present in extremely 
premature neonates without hyperglycaemia. These findings provided further evidence 
of insulin resistance in preterm neonates in the absence of postnatal corticosteroid 
treatment, which is an important difference from the key paper by Mitanchez-Mokhtari 
et al. (2004). This adds to a more complete understanding of the maturation of glucose 
homeostasis in the preterm neonate. 
The final specific aim of this research project was to compare the results from 
euglycaemic preterm neonates with neonates treated with insulin for hyperglycaemia to 
investigate alterations in glucose homeostasis in hyperglycaemic preterm neonates. 
Severe persistent hyperglycemia over the first week of life has been associated with 
increased mortality and is associated with worse outcomes in extremely low birth 
weight neonates (Kao et al., 2006). It is not known if the increase in morbidity and 
mortality is a reflection of illness severity, or a direct causal relationship (Alsweiler et 
al., 2007). Mitanchez-Mokhtari et al. (2004) showed that hyperglycaemic premature 
neonates have impaired pancreatic β-cell secretion and that these neonates are also 
relatively resistant to insulin. It was hypothesised that insulin concentrations would be 
higher in the hyperglycaemic (insulin-treated) neonates and that insulin treatment will 
suppress endogenous insulin production resulting in a decrease in C-peptide 
concentrations in insulin treated neonates. The main findings of Chapter 6 were that   
C-peptide concentrations were significantly lower in the hyperglycaemic neonates than 
euglycaemic neonates less than 30 weeks PMA indicating lower insulin production in 
hyperglycaemic neonates. This was a major difference in the hyperglycaemic neonates 
compared with the euglycaemic neonates who were shown to have decreasing             
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C-peptide concentrations to term. The lower C-peptide concentrations in the 
hyperglycaemic neonates were consistent with lower insulin production indicating 
insulin deficiency and that insulin treatment did not appear to suppress insulin 
production in these neonates. Insulin concentrations, blood glucose concentrations, C-
peptide concentrations and I/CP ratios were all significantly affected by PMA (p <0.01) 
in the hyperglycaemic neonates. As expected insulin concentrations were higher in the 
hyperglycaemic neonates confirming that exogenous insulin is reaching these neonates 
intravenously which is an important finding because of the low dose required and the 
potential for adsorption onto intravenous (IV) line components (Hewson et al., 2000).  
This thesis differs from previous literature because it included a population of neonates 
across a broad range of PMA, a larger sample size than previous studies and the 
collection of samples prior to and following the first feed. The use of leftover plasma 
samples limited the intrusiveness of the study on the neonates and their parents and 
families, and took account of the small blood volume in these patients. The 
hyperglycaemic study also had a minimal blood sample size of 150 µL and the 
collection of six samples over 24 hours provided a rich data set. Futhermore, none of 
the neonates in the present study were exposed to corticosteroids making this a crucial 
difference to the main current literature. It is known that glucose homeostasis can be 
affected by steroid treatment which can cause a rise in blood glucose concentration 
(Hey, 2005). Therefore, the preterm neonates in the study by Mitanchez-Mokhtari et al. 
(2004) would be expected to have altered glucose homeostasis due to exposure to 
postnatal corticosteroids.  
The promising combination of DBS convenience and a DBS analytical method for 
insulin had variable results when looked at in the laboratory and in neonates with 
widely varying haematocrit levels. It did have advantages in terms of collection, 
handling and transport and would become viable if its various problems can be 
overcome. There are a few ways this assay could be improved such as collecting a 
“fixed volume” DBS sample then quantify the analyte using the whole sample or use 
DBS cards that reduce or eliminate haematocrit effects (Patel et al., 2013). These blood 
spot cards have been reported to have consistent spot homogeneity and minimal 
changes in spot size with haematocrit changes in the range of 0.20 to 0.80 (Patel et al., 
2013). These options were not investigated for the current project as the 
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chemiluminescent insulin assay only required 25 µL of plasma and insulin levels could 
be measured accurately in neonates without the use DBS.  
The urinary C-peptide assay had a number of possible limitations and causes of 
variability. Urinary C-peptide has been shown to change due to diet (Gacs et al., 1985) 
in adults and children, so it is possible C-peptide UER and Cl were affected by energy 
intake. Premature and small for gestational age neonates have been shown to have 
smaller kidneys and lower glomerular filtration rate (GFR) than term neonates (Aperia 
et al., 1981, Schmidt et al., 2005). This is a potential issue as differences in renal 
function can influence blood levels of C-peptide (Henriksen et al., 1987, Zavaroni et 
al., 1987). Another limitation could be that even though urinary output was timed, there 
may be a discrepancy between the last bladder emptying and the time of the last nappy 
change. While every effort was made to document the last bladder emptying, the exact 
timing remains unknown and may have occurred before the last nappy change. 
Evaporation or loss of urine from the cotton wool and/or nappies was minimised by 
transferring the urine containing cotton wool into airtight containers immediately at 
each nappy change however this could still be an issue causing variability in the urinary 
C-peptide concentrations.  
The use of leftover plasma samples for the euglycaemic neonates facilitated recruitment 
and minimised discomfort in these neonates, but it did lead to limitations due to limited 
plasma volume and difficulty in pairing observations. This resulted in not all 
compounds being measured in each patient and there was not always a paired BGC for 
each measurement. 
A limitation to the statistical analyses of this thesis was the use of standard regressions 
and ANOVA. Due to the high correlations of the demographic data it was not possible 
to include them in the same statistical models and it was decided to use standard 
regressions rather than multivariate regressions. Use of multilevel models could be a 
more appropriate choice for any future analyses to account for intra-individual 
correlation. 
Apart from the two case study neonates, the hyperglycaemic neonates were only 
studied while on insulin infusion. This limits the study as a lack of samples prior to 
patients starting insulin treatment and possibly after makes it difficult to determine the 
exact contributors to hyperglycaemia in these neonates. However, as all the neonates in 
this study show no signs of insulin suppression, either with the introduction of insulin 
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treatment (case study neonates) or an increase in insulin dose (hyperglycaemic 
neonates), it is reasonable to conclude that these neonates do not show suppression of 
insulin secretion during treatment with insulin. 
Further research is needed to determine the effect of different glucose infusion rates on 
insulin production as determined by C-peptide UER and Cl. If neonates with a high 
glucose infusion rate also had a high C-peptide excretion rate, this could mean that they 
were maintaining euglycaemia by producing more insulin. Investigation into the 
variability of C-peptide UER and Cl could determine whether it is due to variable renal 
function in this population and if it varies in parallel with the clearance of other 
molecules. 
Further work is needed to understand how responsive the neonatal pancreas is to 
varying glucose levels. Future research should determine whether changes in C-peptide 
UER and Cl in the neonate could be used to indicate pancreatic beta cell function when 
corrected for weight and energy intake. 
Ultimately the overall aim beyond the scope of this thesis is to use the data obtained for 
this thesis to develop a PKPD model for glucose homeostasis in neonates. This study 
will use the data from this thesis in addition to historical data collected from Dunedin 
Hospital NICU on insulin use in neonates to then develop a model of insulin 
pharmacokinetics and pharmacodynamics in neonates. A simulation model could be 
used to design an optimal dosing model and work out the number of relevant 
covariates. This model will predict the concentration of insulin at different time points 
and determine the effect that insulin has on BGC. This will enable the determination of 
the variables affecting dosage requirements in the treatment of hyperglycaemia in 
preterm neonates and allow optimal dosing criteria and BGC monitoring resulting in 
improved morbidity and mortality. 
Haematocrit was shown to have a significant effect on insulin measurement by 
chemiluminescence when using DBS. Measuring plasma insulin concentrations with 
DBS in neonates was not ideal due to high variability. Kit standards produced a more 
precise and simple method for determining urinary C-peptide concentration. Since GA 
and BGC did not appear to affect Cl and UER, urinary C-peptide may provide a non-
invasive method of measuring insulin production in neonates. The significantly higher 
GLP-1 concentrations in fed neonates confirm that enteral feeds result in an increase in 
GLP-1. C-peptide concentrations were significantly lower in the hyperglycaemic 
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neonates indicating lower insulin production in hyperglycaemic neonates. Treatment 
with exogenous insulin did not suppress insulin production in these neonates. Preterm 
neonates exhibit insulin resistance whether hyperglycaemic or not. These factors are 
likely to contribute to the increased risk of hyperglycaemia in premature neonates 
(PMA <32 weeks). The elevated insulin and C-peptide concentrations in preterm 
neonates which decreased towards term and the significantly higher GLP-1 
concentrations in fed neonates indicate that preterm neonates demonstrate insulin 
resistance (Figure 7.1).  
 
Figure 7.1 Glucose homeostasis in neonates with the findings to this thesis added. 
The significant effect of PMA on insulin and C-peptide concentrations and I/CP 
demonstrated that insulin resistance is a key factor in neonatal hyperglycaemia. The 
increased understanding of glucose homeostasis in preterm neonates and neonatal 
hyperglycaemia gained from this thesis illustrated the importance of developing a 
PKPD model for glucose homeostasis in neonates to ultimately improve the treatment 
of neonatal hyperglycaemia. In conclusion, this thesis adds to a more complete 
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Hyperglycaemia is a common problem in preterm neonates [1]. The incidence of 
hyperglycemia in premature infants can vary between 20% and 86%, depending on the 
definition and the population studied [2].  There is an estimated incidence of 
hyperglycemia in over 50% of babies with a birth-weight less than 1000 g [1]. 
Neonates weighing less than 1000g are 18 times more likely to develop hyperglycemia 
than those weighing more than 2000g [3]. The increasing survival of preterm neonates 
and the use of early and aggressive parenteral nutrition have resulted in an increased 
frequency of hyperglycemia [4]. 
The risk of hyperglycaemia is increased by conditions that cause stress, such as 
asphyxia, respiratory distress, intraventricular haemorrhage, sepsis, or surgical 
procedures [2]. Continuous infusion of glucose, or lipids and the administration of 
some drugs, such as corticosteroids, aminophylline, and caffeine, may also induce 
hyperglycemic reactions in neonates [2]. 
Insulin is used to manage hyperkalemia, to control hyperglycemia, and to optimize 
parenteral nutrition for the preterm neonate less than 1000g [2]. 
Hyperglycaemia is poorly defined in the literature and there is little agreement about 
what blood glucose level defines neonatal hyperglycaemia [1].  Hyperglycemia in the 
neonate can be defined as blood glucose concentration greater than 7 mmol/L or plasma 
glucose concentration greater than 8.25 mmol/l [3]. The threshold for hyperglycemia 
used in different studies varied: > 8.3 mmol/L, > 8.5 mmol/L, > 10.0 mmol/L or > 12.0 
mmol/L [4].  Blood glucose levels that are considered clinically significant range from 
7 to 14 mmol/L [2]. 
 
Neonatal hyperglycaemia has been associated with an increase in morbidity and 
mortality and it is not known if this is a reflection of illness severity or a causal 
relationship [1]. Alaedeen et al showed that TPN-associated hyperglycemia in septic 
very low-birth-weight infants was significantly related to morbidity and mortality [5]. 
Hyperglycemia is an important condition in low birth weight preterm neonates, because 
it is associated with increased morbidity including retinopathy of prematurity(ROP) and 
intra-ventricular haemorrhage as well as with increased mortality [6, 7]. The causes of 
hyperglycemia in the early neonatal period in low birth weight preterm neonates are 
multifactorial [6]. Therefore, severe hyperglycemia is associated with worsened 
outcome in low birth weight preterm neonates [7]. 
 
The perinatal period seems to be a critical time for pancreatic development and 
programming of glucose homeostasis however, this is poorly understood [8]. 
Hyperglycaemia in the preterm neonate can be used as a marker of relative insulin 
deficiency [8]. In utero foetal glucose levels are normally tightly regulated at 4–
6mmol/L by glucose delivery from the mother [3]. However, after birth rapid metabolic 
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adaptation is needed for the newborn to establish independent glucose homeostasis [3]. 
It is thought that immature neonates are unable to secrete enough insulin and are 
relatively resistant to insulin and their pancreatic beta cell secretion is impaired [5].   
Hyperglycemia may also be related to a defective islet β-cell processing of proinsulin 
[3]. 
 
Insulin plays a key role in the regulation of carbohydrate, fat, and protein metabolism 
[9]. It is a polypeptide hormone of complex structure [9] consisting of 51 amino acids 
in two chains connected by two disulphide bridges [10]. Insulin is synthesised in the 
pancreatic ß-cells and its major stimulant for release is glucose [10]. The release of 
insulin is triggered both by the intake of nutrients and also the release of 
gastrointestinal hormones called incretins [10]. Postnatally, insulin secretion is under 
the influence of neural, neuroendocrine and enteroendocrine mechanisms [8]. The 
neonate’s insulin secretion is coupled with the enteric supply of milk and release of 
incretins [8].  In preterm neonates the pancreatic cells may be sensitive to changes in 
blood glucose but might respond by increasing secretion of non processed proinsulin 
[8]. In adults incretins play an important role in augmenting insulin secretion post 
prandially however, the role for incretins in the neonate has not been well studied [8]. 
 
Hyperglycaemia and low birth weight is therefore a unique scenario where the dose 
response and PKPD is unknown. 
 
This study will be used to develop a model of insulin pharmacokinetics (describing the 
time-course of plasma insulin concentrations) and pharmacodynamics (describing the 
time course of effect of insulin in relation to plasma insulin concentrations).  This 
model will be used to determine optimal dosing criteria and glucose monitoring for 
babies with hyperglycaemia and to determine if the PKPD relationships of insulin in 




To determine the PKPD of insulin in premature neonates to determine the variables 
affecting dosage requirements in the treatment of neonatal hyperglycaemia. 
 
To determine if the PKPD relationships of insulin in neonates indicate insulin 
resistance. 
 
To describe the pharmacokinetic and pharmacodynamic (PKPD) relationship of 
endogenous insulin and C-peptide in neonates and determine any differences in the 







2. Pre-term or term neonates admitted to neonatal intensive care unit. 
3. Undergoing blood tests as part of normal management. 







2. Birth weight of <1500g 
3. Gestational age at birth of <32 weeks. 
4. Require insulin infusion as part of NICU protocol (blood sugar >10mmol/L at 
two consecutive readings at four hours apart). 






1. Hyperglycaemia or Hypoglycaemia. 
2. Treated with insulin or oral hyperglycaemic agents or other medications that 




1. Infants of diabetic mothers. 
2. Suspected metabolic disorder. 
3. Suspected growth hormone deficiency or pituitary insufficiency. 
4. Treatment with exogenous steroids. 
5. Treatment with diazoxide. 
6. Maternal hyperthyroidism. 
7. Maternal oral hyperglycaemic agents eg. Biguanides, Sulphonylureas,  
thiazolidinediones. 






1. Patients: pre-term or term neonates admitted to neonatal intensive care unit, 
undergoing routine blood tests. 
2. Prospective sampling: use left over samples of blood from other blood tests to 
test for insulin, c-peptide, blood sugar and incretin levels. 
3. Collect blood sample in a tube and onto blotting paper (Guthrie card) as well as 
a paired blood sugar level on a single occasion. 
4. Urine will also be collected on a single occasion into some cotton wool for 
measurement of C-peptide in urine. 
5. Gestational age, chronological age, timing and volume of last feed, birth weight, 
current weight, whether i.v. or tpn feeding and other relevant risk factors will all 




1. Patients: Hyperglycaemic low birth weight (<1500g) premature (<32 weeks) 
neonates who require insulin infusion as part of NICU protocol. 
Appendix 2 
155 
2. Blood (150µL) will be collected into a tube at the same time as the patients’ 
routine four hourly blood glucose test, a blood spot will also be taken at the 
same time. 
3. Blood taken will be used to measure insulin, c-peptide and incretin and will be 
paired with the routine blood glucose test. 




Plasma will be separated from blood by centrifuging and then stored at -20°C until 
analysis. Plasma insulin concentrations will be measured using chemiluminescence 
immunoassays. The two assays used will be an Invitron Insulin Assay Kit (IV2-
001/101) and an Invitron C-peptide Assay Kit (IV2-004/104) measured with a BMG 
Labtech Polarstar OMEGA luminometer. Blood spots will also be analysed with these 
same kits but with a high specificity antibody provided by the manufacturer. Plasma 
leptin and incretin levels will also be measured with commercially available kits. Urine 
c-peptide levels will be measured using the same invitron C-peptide Assay kit as for 
plasma. 
Blood glucose concentrations will be measured as part of routine care and all other tests 






Number of subjects: 100 euglycaemic neonates admitted to the neonatal intensive care 




Number of subjects: 12 hyperglycaemic premature neonates (minimum of 6). This has 




Pharmacometric analysis will be performed using WinNonLin and NONMEM. 
Comparison of means using Stata. Data from this study will be compared with other 




This study will be cost neutral to the hospital as the neonates will be inpatients and the 
blood samples taken will be left over blood from routine blood sampling. All blood 
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Appendix 3 – Information sheets 
INFORMATION SHEET FOR PARTICIPANTS 
(Insulin/C-Peptide Ratio in Babies) 
Your baby is invited to take part in this research study. Please read this information 
sheet carefully before deciding whether or not you wish for him/her to participate. If 
there is anything that is not clear, or if you would like more information, please do not 
hesitate to ask one of the investigators. 
Participation 
Your participation is entirely voluntary (your choice). Your baby does not have to take 
part in this study, and if you choose for them not to take part they will continue to 
receive the standard treatment/care available. If you do agree for your baby to take part 
in the study, you are free to withdraw him/her from the study at any time. 
About the study 
What are the aims of the study? 
• To determine if there are any differences in the ratio of naturally occurring 
insulin and a related chemical (C-peptide) in babies with respect to birth weight 
and blood glucose levels. 
• To use the results from this study determine how insulin behaves in premature 
babies with high blood glucose. 
How were participants selected for this study, and who selected them? 
Study participants have been identified through the neonatal intensive care unit at 
Dunedin Hospital. 
How many participants will be involved? 
This study will involve 100 babies with normal blood glucose admitted to the neonatal 
intensive care unit at Dunedin Public Hospital. 
Where will the study be held? 
The study will be held at the Neonatal Intensive Care Unit at Dunedin Hospital, where 
your baby will be an inpatient. 
What will happen during the study? 
For babies who participate in this study, blood remaining after routine blood tests 
(“left-over samples”) will be used to test for insulin, related chemicals; c-peptide and 
pro-insulin, related hormones and glucose levels. The left-over blood sample will be 
collected in a tube and a separate heel-prick will be made onto blotting paper (Guthrie 
card). Urine will also be collected on a single occasion into some cotton wool for 
measurement of C-peptide in urine. 
Age, timing and volume of last feed, birth weight and current weight, blood glucose 
level, type of feeding and other relevant risk factors will all be recorded for future 
analysis and comparison. 
What will happen to samples after the study? 
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Serum or plasma will be separated from the blood cells and frozen in storage for later 
analysis. Urine samples will also be frozen for later storage. During the course of this 
study blood and urine will be collected, stored and then discarded as per standard 
laboratory practice. The cultural issues associated with discarding your baby’s samples 
should be discussed with your family/ whānau. To avoid problems at a later stage we 
suggest your family/ whānau is involved with you at all stages of the research. Some 
Iwi disagree with storage of blood and tissue samples citing whakapapa, and advise 
their people to consult prior to participation in research where this occurs.  
What are the benefits of the study? 
Your baby will not necessarily benefit from this study; however participating will help 
improve management and understanding of high blood glucose in newborn babies. 
Therefore this study will improve long-term health outcomes for these babies.  
What are the risks and/or inconveniences of the study?   
Most samples will be left over blood from routine blood samples taken as part of 
normal management for your baby. Therefore risks of the study should be minimal 
except that some extra pain resulting from the separate heel-prick may occur.  
General 
Will my GP be told I am in the study? 
No. The study is a descriptive study. There will be no change to your baby’s normal 
treatment. 
Where can I get more information about the study? 
Further information can be obtained from the researchers. 
You may have a friend, family or whanau support to help you understand the risks 
and/or benefits of this study and any other explanation you may require. 
If you have any queries or concerns regarding your rights as a participant in this study, 
you may wish to contact an independent health and disability advocate: 
Free phone: 0800 555 050  Free fax: 0800 2 SUPPORT (0800 2787 7678) 
Email: advocacy@hdc.org.nz 
If there is a specific Maori issue/concern please contact Linda Grennell at 0800 377 
766. 
Confidentiality 
No material which could personally identify you or your baby will be used in any 
reports on this study. Results of this project may be published but any data included 
will in no way be linked to any specific baby. You are most welcome to request a copy 
of the results of the project should you wish. 
Data will be stored in a locked filing cabinet in the Department of Women’s and 
Children’s Health and the School of Pharmacy and will be stored for 10 years after the 
youngest participant turns 16. Data will only be available to the researchers. 
Results 
The parents/caregivers will be given the option of receiving copies of publications and 
reports arising from the study. 
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Statement of Approval 
This study has received ethical approval from the Lower South Regional Ethics 
Committee; ethics reference number LRS/10/06/017.Contacts 
Associate Professor David Reith 
Associate Professor  
Dunedin School of Medicine  
University of Otago 
Phone: 474 0999 
Dr Natalie Medlicott 
Senior Lecturer 
School of Pharmacy 
University of Otago 
Phone: 479 5919 
Ms Emma Salis 
PhD student  
School of Pharmacy 
University of Otago 
Phone: 479 5285 
   





INFORMATION SHEET FOR PARTICIPANTS 
(High Blood Glucose in Babies) 
Your baby is invited to take part in this research study. Please read this information 
sheet carefully before deciding whether or not you wish for him/her to participate. If 
there is anything that is not clear, or if you would like more information, please do not 
hesitate to ask one of the investigators. 
Participation 
Your participation is entirely voluntary (your choice). Your baby does not have to take 
part in this study, and if you choose for them not to take part they will continue to 
receive the standard treatment/care available. If you do agree for your baby to take part 
in the study, you are free to withdraw him/her from the study at any time. 
About the study 
What are the aims of the study? 
• To determine how insulin behaves in premature babies.  
• To determine what affects dosage requirements of insulin in the treatment of 
high blood glucose in newborn babies. 
How were participants selected for this study, and who selected them? 
Study participants have been identified through the neonatal intensive care unit at 
Dunedin Hospital. 
How many participants will be involved? 
This study will involve 12 premature babies with high blood glucose levels. 
Where will the study be held? 
The study will be held at the Neonatal Intensive Care Unit at Dunedin Hospital, where 
your baby will be an inpatient. 
What will happen during the study? 
A microtube of your baby’s blood (approximately one sixth of a millilitre) will be 
collected into a tube at the same time as your baby’s routine four hourly blood glucose 
test. A blood spot on filter paper will also be taken at the same time. This blood will be 
used to measure insulin, c-peptide, pro-insulin and incretin. Each baby will be 
monitored over 24 hours (6 samples). The amount of blood taken for research purposes 
will be small compared to the amount required for routine clinical care. Urine will also 
be collected on a single occasion into some cotton wool for measurement of C-peptide 
in urine. 
What will happen to samples after the study? 
Serum or plasma will be separated from the blood cells and frozen in storage for later 
analysis. Urine samples will also be frozen for later storage. During the course of this 
study blood and urine will be collected, stored and then discarded as per standard 
laboratory practice. The cultural issues associated with discarding your baby’s samples 
should be discussed with your family/whānau. To avoid problems at a later stage we 
suggest your family/whānau is involved with you at all stages of the research. Some Iwi 
disagree with storage of blood and tissue samples citing whakapapa, and advise their 
people to consult prior to participation in research where this occurs.  
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What are the benefits of the study? 
Your baby will not necessarily benefit from this study; however participating will help 
improve management and understanding of high blood glucose in newborn babies. 
Therefore this study will improve long-term health outcomes for these babies. 
What are the risks and/or inconveniences of the study?   
Six very small samples (less than 1mL in total) will be taken in addition to the blood 
normally taken for clinical testing. It will not be harmful to take this small amount. 
Some extra pain may be felt as a result of these samples but as most babies will already 
have an arterial line this should be rare. 
General 
Will my GP be told I am in the study? 
No. The study is a descriptive study. There will be no change to your baby’s normal 
treatment. 
Where can I get more information about the study? 
Further information can be obtained from the researchers. 
You may have a friend, family or whanau support to help you understand the risks 
and/or benefits of this study and any other explanation you may require. 
If you have any queries or concerns regarding your rights as a participant in this study, 
you may wish to contact an independent health and disability advocate: 
Free phone: 0800 555 050  Free fax: 0800 2 SUPPORT (0800 2787 7678) 
Email: advocacy@hdc.org.nz 
If there is a specific Maori issue/concern please contact Linda Grennell at 0800 377 
766. 
Confidentiality 
No material which could personally identify you or your child will be used in any 
reports on this study. Results of this project may be published but any data included 
will in no way be linked to any specific baby. You are most welcome to request a copy 
of the results of the project should you wish. 
Data will be stored in a locked filing cabinet in the Department of Women’s and 
Children’s Health and the School of Pharmacy and will be stored for 10 years after the 
youngest participant turns 16. Data will only be accessed by the researchers. 
Results 
The parents/caregivers will be given the option of receiving copies of publications and 
reports arising from the study. 
Statement of Approval 
This study has received ethical approval from the Lower South Regional Ethics 





Associate Professor David Reith 
Associate Professor  
Dunedin School of Medicine  
University of Otago 
Phone: 474 0999 
Dr Natalie Medlicott 
Senior Lecturer 
School of Pharmacy 
University of Otago 
Phone: 479 5919 
Ms Emma Salis 
PhD student  
School of Pharmacy 
University of Otago 
Phone: 479 5285 
   






Appendix 4 – Consent form 
STATEMENT BY RELATIVE/FRIEND/WHANAU 
Lay title: Time-course of activity of insulin in neonates 
  
Principal investigator: Associate Professor David Reith. 
  
Participant’s name:       
I have read and I understand the information sheet dated ________ for people taking 
part in the study designed to determine the time-course of activity of insulin in 
neonates.  I have had the opportunity to discuss this study.  I am satisfied with the 
answers I have been given. 
I believe that _________________________(participant’s name) would have chosen 
and consented to participate in this study if he/she had been able to understand the 
information that I have received and understood. 
I understand that taking part in this study is voluntary and that may withdraw my child 
from at any time if Iwish. This will not affect his/her continuing health care. 
I understand that his/her participation in this study is confidential and that no material 
which could identify him/her will be used in any reports on this study. 
I know whom to contact if my baby has any side effects to the study or if anything 
occurs which I think he/she would consider a reason to withdraw from the study. 
This study has been given ethical approval by the Lower South Regional Ethics 
Committee. This means that the Committee may check at any time that the study is 
following appropriate ethical procedures. 
I would like a copy of the results of the study.  Yes  No 
 
 
Signed:  Date:  
  
Printed name:  
  
Relationship to participant:  
  
Address for results:  
  




STATEMENT BY PRINCIPAL INVESTIGATOR 
I ______________________ (name of investigator) declare that this study is in the 
potential health interest of the group of patients of which 
________________________(name of participant) is a member and that participation in 
this study is not adverse to _________________________(name of participant)’s interests. 
 
STATEMENT BY INDEPENDENT CLINICIAN 
I confirm that participation in the study is not adverse to ____________________ 
(participant)’s interests. 
 
Signed:       Date:       
 (Clinician)   
  




Appendix 5 – Case report forms 
Case Report Form 
Insulin pharmacokinetics and pharmacodynamics (PKPD) in neonates - Part One 
(NN01) 
 
Participant’s Name:      Study ID:   
 
Consenting Adult’s Name:      Date:    
 
Inclusion Criteria 
  Yes No 
1 Is the subject euglycaemic?   
2 Is the subject a pre-term or term neonates admitted to neonatal intensive care unit?   
3 Is the subject undergoing blood tests as part of normal management?   
4 Has written informed consent been obtained?   
If any inclusion criteria are ticked no then the patient is not eligible for the study. 
Exclusion Criteria 
  Yes No 
1 Does the subject have either Hyperglycaemia or Hypoglycaemia?   
2 Is the subject treated with insulin or oral hyperglycaemic agents or other medications that alter glucose homeostasis (eg. Corticosteroids)?   
If any exclusion criteria are ticked yes then the patient is not eligible for the study. 
 
Bloodspot taken?          
 






Is informed consent signed? (please attach a copy of the consent to the data collection sheets) 
    Yes   No    
Demographic Data. 
 
Gestational age (m/d):   Chronological age (m/d):    
 
Sex:  Female   Male    
 
Length (cm):     Head circumference (cm):  
  
 
Current weight (g):    Birth weight (g):   
  
 
Time of last feed:    Volume of last feed (mL):  
   
 
Type of feed:   IV:   TPN:   other:  
   
 
Other relevant risk factors:         
            
 
Medications. 
Is the subject currently or previously taking any medication including OTC, vitamins and/or 
supplements?     Yes   No  
  
Record all medication on Concomitant Medications page 
Results: 
Insulin level (tube):    Insulin level (bloodspot):  
  
 
C-peptide level (tube):   C-peptide level (bloodspot):    
 
Blood glucose:    Incretin level:      
 
Haematocrit     
  
  


































































































































































































































































































































































































































Case Report Form 
Insulin pharmacokinetics and pharmacodynamics (PKPD) in neonates - Part Two 
(NN02). 
 
Participant’s Name:       Study ID: 
   
 
Consenting Adult’s Name:       Date:  
   
Inclusion Criteria 
  Yes No 
1 Is the subject hyperglycaemic?   
2 Does the subject have a birth weight of <1500g?   
3 Does the subject have a gestational age at birth of <32 weeks?   
4 Does the subject require insulin infusion as part of NICU protocol (blood sugar >10mmol/L at two consecutive readings at four hours apart)?   
5 Has written informed consent been obtained?   
If any inclusion criteria are ticked no then the patient is not eligible for the study. 
Exclusion Criteria 
  Yes No 
1 Is the subject an infant of a diabetic mother?   
2 Does the subject have a suspected metabolic disorder?   
3 Does the subject have suspected growth hormone deficiency or pituitary insufficiency?   
4 Is the subject receiving treatment with exogenous steroids?   
5 Is the subject receiving treatment with diazoxide?   
6 Does the mother of the subject have hyperthyroidism?   
7 Is the mother of the subject receiving treatment with oral hyperglycaemic agents eg. Biguanides, Sulphonylureas,  thiazolidinediones?   
8 Is the mother of the subject receiving treatment with exanatide or liraglutide   





Informed consent signed? (please attach a copy of the consent to the data collection sheets) 
    Yes   No    
Demographic Data. 
 
Gestational age (m/d):   Chronological age (m/d):    
 
Sex:  Female   Male    
 
Length (cm):     Head circumference (cm):  
  
 
Current weight (g):    Birth weight (g):   
  
 
Type of feed:   IV:   TPN:   other:  
   
 
Other relevant risk factors:        
   
           
   
Medications. 
Is the subject currently or previously taking any medication including OTC, vitamins and/or 
supplements?     Yes   No  
  
 











Blood sample 1: 
Time of sample:   Insulin dose:      
Time of last feed:   Volume of last feed (mL):    
Insulin level (tube):   Insulin level (bloodspot):    
C-peptide level (tube):   C-peptide level (bloodspot):    
Blood glucose:    Incretin level:      
Haematocrit     
Blood sample 2: 
Time of sample:   Insulin dose:      
Time of last feed:   Volume of last feed (mL):    
Insulin level (tube):   Insulin level (bloodspot):    
C-peptide level (tube):   C-peptide level (bloodspot):    
Blood glucose:    Incretin level:      
Haematocrit     
Blood sample 3: 
Time of sample:   Insulin dose:      
Time of last feed:   Volume of last feed (mL):    
Insulin level (tube):   Insulin level (bloodspot):    
C-peptide level (tube):   C-peptide level (bloodspot):    
Blood glucose:    Incretin level:      




Blood sample 4: 
Time of sample:   Insulin dose:      
Time of last feed:   Volume of last feed (mL):    
Insulin level (tube):   Insulin level (bloodspot):    
C-peptide level (tube):   C-peptide level (bloodspot):    
Blood glucose:    Incretin level:      
Haematocrit     
Blood sample 5: 
Time of sample:   Insulin dose:      
Time of last feed:   Volume of last feed (mL):    
Insulin level (tube):   Insulin level (bloodspot):    
C-peptide level (tube):   C-peptide level (bloodspot):    
Blood glucose:    Incretin level:      
Haematocrit     
Blood sample 6: 
Time of sample:   Insulin dose:      
Time of last feed:   Volume of last feed (mL):    
Insulin level (tube):   Insulin level (bloodspot):    
C-peptide level (tube):   C-peptide level (bloodspot):    
Blood glucose:    Incretin level:      

































































































































































































































































































































































































































Appendix 6 - Table with urine calculations for all twenty 
neonates (Chapter 4) 























77 53.43 767.37 0.18 2.58 0.138 1.21 
*83 34.44 2430.10 0.15 *10.93 0.377 *6.77 
84 94.47 162.14 0.16 0.27 0.026 0.11 
85 24.78 157.00 0.17 1.06 0.026 0.45 
86 17.65 163.37 0.10 0.96 0.017 0.43 
88 45.18 154.43 0.16 0.56 0.025 0.22 
89 82.66 189.21 0.10 0.22 0.018 0.07 
92 441.74 2525.36 0.21 1.22 0.540 1.94 
95 98.86 154.51 0.24 0.38 0.037 0.15 
96 90.92 157.76 0.17 0.30 0.027 0.13 
97 52.24 300.34 0.09 0.53 0.028 0.22 
98 267.47 494.31 0.18 0.34 0.091 0.15 
99 196.16 651.16 0.18 0.60 0.117 0.27 
100 349.48 156.71 0.14 0.06 0.023 0.04 
101 448.29 156.82 0.19 0.07 0.029 0.04 
*102 43.31 978.26 0.19 *4.30 0.186 1.09 
105 629.53 1401.16 0.11 0.24 0.152 0.20 
106 18.69 154.90 0.10 0.86 0.016 0.37 
107 432.91 1738.77 0.06 0.24 0.103 0.23 
108 233.72 575.55 0.10 0.24 0.055 0.19 
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Appendix 7 - Data transformations 
 Distributions of: (A) C-peptide normal scale, (B) insulin normal scale, (C) C-peptide 
natural logarithmic scale, and (D) insulin natural logarithmic scale. Data from non-
insulin treated neonates’ dataset. 
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 Distributions of: (A) GLP-1 normal scale, (B) glucagon normal scale, (C) GLP-1 
natural logarithmic scale, and (D) glucagon natural logarithmic scale. Data from non-





Distributions of: (A) I/BGL normal scale, (B) I/CP normal scale, (C) I/BGL natural 




Appendix 8 - Correlation scatterplot 
Matrix scatterplot of participant demographics and natural log concentrations of 







Appendix 9 – Individual blood glucose, plasma insulin and C-
peptide concentrations and insulin dose plots (Chapter 6) 
 
	
Figure 1 Blood glucose, insulin and C-peptide concentrations (A), insulin dose 






























































































Figure 2 Blood glucose, insulin and C-peptide concentrations (A), insulin dose 





























































































Figure 3 Blood glucose, insulin and C-peptide concentrations (A), insulin dose 




























































































Figure 4 Blood glucose, insulin and C-peptide concentrations (A), insulin dose 





























































































Figure 5 Blood glucose, insulin and C-peptide concentrations (A), insulin dose 





























































































Figure 6 Blood glucose, insulin and C-peptide concentrations (A), insulin dose 





























































































Figure 7 Blood glucose, insulin and C-peptide concentrations (A), insulin dose 





























































































Figure 8 Blood glucose, insulin and C-peptide concentrations (A), insulin dose 





























































































Figure 9 Blood glucose, insulin and C-peptide concentrations (A), insulin dose 

























































































(B) blood glucose insulin dose
